<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://onlinelibrarystatic.wiley.com/xslt/wol-journal-rss.xsl"
            type="text/xsl"?><rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"><channel rdf:about="http://onlinelibrary.wiley.com/rss/journal/10.1002/(ISSN)1521-4141" xmlns="http://purl.org/rss/1.0/"><title>European Journal of Immunology</title><description> Wiley Online Library : European Journal of Immunology</description><link>http://dx.doi.org/10.1002%2F%28ISSN%291521-4141</link><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc</dc:publisher><dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">en</dc:language><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Copyright © 2012 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim</dc:rights><prism:issn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">0014-2980</prism:issn><prism:eIssn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1521-4141</prism:eIssn><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><prism:coverDisplayDate xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">February 2012</prism:coverDisplayDate><prism:volume xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">42</prism:volume><prism:number xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">2</prism:number><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">269</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">550</prism:endingPage><image rdf:resource="http://onlinelibrary.wiley.com/store/10.1002/eji.v42.2/asset/cover.gif?v=1&amp;s=08e5df17ed92527b3559621aa134edeaa3fbe0ef"/><items><rdf:Seq><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142125"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142104"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142226"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142004"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141926"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142260"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141690"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141969"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142105"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142071"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141835"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141857"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142086"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142057"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141442"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201041225"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141856"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142045"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141786"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141511"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141519"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201041286"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141965"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141907"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141958"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141613"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141657"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142193"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142035"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142011"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141581"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141950"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201040865"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201041383"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201041291"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201041408"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141931"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141737"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141983"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142024"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141991"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201041950"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141930"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141955"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141921"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141902"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141910"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141800"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142108"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142079"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141748"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142094"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141920"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141798"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141702"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.200939117"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201290004"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201290005"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201290000"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201290001"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201290002"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201290003"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142231"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142223"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142337"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142342"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141801"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141847"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142091"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201142064"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141692"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141787"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141569"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141548"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141903"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141845"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141659"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141871"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141880"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201041303"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141826"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141924"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141915"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201041295"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141758"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141889"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141940"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141987"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201041038"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Feji.201141832"/></rdf:Seq></items></channel><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142125" xmlns="http://purl.org/rss/1.0/"><title>Ankrd17 positively regulates RIG-I-like receptor (RLR)-mediated immune signaling</title><link>http://dx.doi.org/10.1002%2Feji.201142125</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Ankrd17 positively regulates RIG-I-like receptor (RLR)-mediated immune signaling</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yetao Wang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiaomei Tong</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gang Li</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Junhui Li</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Min Deng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xin Ye</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-13T03:32:45.300769-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142125</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142125</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142125</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>RIG-I (retinoic acid-inducible gene-I)-like receptors (RLRs), such as RIG-I, MDA5 (melanoma differentiation-associated gene 5) and VISA (virus-induced signaling adaptor), are intracellular molecules that sense diverse viral RNAs and trigger immune responses. In this study, we demonstrate that the ankyrin repeat protein ankrd17 interacts with RIG-I, MDA5 and VISA and upregulates RLR-mediated immune signaling. Overexpression of ankrd17 enhances RLR-mediated activation of IRF-3 and NF-κB and upregulates the transcription of IFN-β. It also promotes RLR signaling in response to polyI:C, influenza virus RNA and Sandai virus (SeV). Consistently, knockdown of ankrd17 impairs RLR signaling. Furthermore, we demonstrate that ankrd17 enhances the interaction of RIG-I and MDA5 with VISA; the ankyrin repeat domain of ankrd17 is required for its interaction with RIG-I as well as for its function in regulating the RLR pathway. Taken together, our results indicate that ankrd17 is a positive regulator of the RLR signaling pathway.</p></div>]]></content:encoded><description>RIG-I (retinoic acid-inducible gene-I)-like receptors (RLRs), such as RIG-I, MDA5 (melanoma differentiation-associated gene 5) and VISA (virus-induced signaling adaptor), are intracellular molecules that sense diverse viral RNAs and trigger immune responses. In this study, we demonstrate that the ankyrin repeat protein ankrd17 interacts with RIG-I, MDA5 and VISA and upregulates RLR-mediated immune signaling. Overexpression of ankrd17 enhances RLR-mediated activation of IRF-3 and NF-κB and upregulates the transcription of IFN-β. It also promotes RLR signaling in response to polyI:C, influenza virus RNA and Sandai virus (SeV). Consistently, knockdown of ankrd17 impairs RLR signaling. Furthermore, we demonstrate that ankrd17 enhances the interaction of RIG-I and MDA5 with VISA; the ankyrin repeat domain of ankrd17 is required for its interaction with RIG-I as well as for its function in regulating the RLR pathway. Taken together, our results indicate that ankrd17 is a positive regulator of the RLR signaling pathway.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142104" xmlns="http://purl.org/rss/1.0/"><title>Autoimmunity against M2 muscarinic acetylcholine receptor induces myocarditis and leads to a dilated cardiomyopathy-like phenotype</title><link>http://dx.doi.org/10.1002%2Feji.201142104</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Autoimmunity against M2 muscarinic acetylcholine receptor induces myocarditis and leads to a dilated cardiomyopathy-like phenotype</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Akihiro Yoshizawa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shigenori Nagai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yukiko Baba</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Taketo Yamada</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Minoru Matsui</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hikaru Tanaka</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shun-ichiro Miyoshi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Masayuki Amagai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tsutomu Yoshikawa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Keiichi Fukuda</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Satoshi Ogawa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shigeo Koyasu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-13T03:29:38.437115-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142104</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142104</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142104</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Patients with dilated cardiomyopathy (DCM) often have autoantibodies against cardiac antigens including the M<sub>2</sub> muscarinic acetylcholine receptor (M<sub>2</sub>R). To elucidate the role of autoimmunity against M<sub>2</sub>R in disease development, we induced an immune response against M<sub>2</sub>R by adoptive transfer into Rag2<sup>−/–</sup> mice of splenocytes from M<sub>2</sub>R<sup>−/–</sup> mice immunized with a recombinant M<sub>2</sub>R protein. T lymphocytes transiently infiltrated the heart in recipient mice followed by morphological changes in cardiomyocytes. These mice produced IgG antibodies against M<sub>2</sub>R which bound to cardiomyocytes in vivo and decreased the amplitude of calcium signals in isolated rat cardiomyocytes in vitro. Recipient mice showed increased heart weights associated with increased intraventricular diameter, decreased systolic function and increased action potential duration, which are characteristics of DCM. Our results suggest that myocarditis and DCM associated with the presence of anti-M<sub>2</sub>R antibodies are autoimmune diseases with a risk of progressing to the terminal stage. Our mouse model will be useful in the analysis of the molecular mechanisms of disease progression and the development of new therapies for DCM.</p></div>]]></content:encoded><description>Patients with dilated cardiomyopathy (DCM) often have autoantibodies against cardiac antigens including the M2 muscarinic acetylcholine receptor (M2R). To elucidate the role of autoimmunity against M2R in disease development, we induced an immune response against M2R by adoptive transfer into Rag2−/– mice of splenocytes from M2R−/– mice immunized with a recombinant M2R protein. T lymphocytes transiently infiltrated the heart in recipient mice followed by morphological changes in cardiomyocytes. These mice produced IgG antibodies against M2R which bound to cardiomyocytes in vivo and decreased the amplitude of calcium signals in isolated rat cardiomyocytes in vitro. Recipient mice showed increased heart weights associated with increased intraventricular diameter, decreased systolic function and increased action potential duration, which are characteristics of DCM. Our results suggest that myocarditis and DCM associated with the presence of anti-M2R antibodies are autoimmune diseases with a risk of progressing to the terminal stage. Our mouse model will be useful in the analysis of the molecular mechanisms of disease progression and the development of new therapies for DCM.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142226" xmlns="http://purl.org/rss/1.0/"><title>Developmentally regulated expression of MEF2C limits the response to BCR engagement in transitional B cells</title><link>http://dx.doi.org/10.1002%2Feji.201142226</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Developmentally regulated expression of MEF2C limits the response to BCR engagement in transitional B cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sarah F. Andrews</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xuezhi Dai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Byoung Y. Ryu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tod Gulick</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bindu Ramachandran</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David J. Rawlings</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T06:10:14.230297-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142226</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142226</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142226</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Transitional and naïve mature peripheral B cells respond very differently to BCR cross-linking. While transitional B cells undergo apoptosis upon BCR engagement, mature B cells survive and proliferate. This differential response correlates with the capacity of mature, but not transitional B cells to transcribe genes that promote cell survival and proliferation, including those encoding c-Myc and the Bcl-2 family members Bcl-xL and A1. We recently demonstrated that transitional B cells fail to assemble transcriptional machinery at the promoter region of these target genes despite equivalent cytoplasmic signaling and nuclear translocation of key transcription factors including NFĸB and NFAT. The transcription factor MEF2C is regulated by both calcineurin and MAPK signaling pathways, and is essential for proliferation and survival downstream of BCR engagement in mature B cells. In this work, we demonstrate that transitional B cells have intrinsically low levels of MEF2C protein and DNA-binding activity, and that this developmental difference in MEF2C expression is functionally significant. Forced expression of MEF2C in transitional B cells promoted cell survival, proliferation, and up-regulation of pro-survival genes. Thus, low MEF2C expression limits transitional B-cell responsiveness to BCR engagement before these cells reach maturity.</p></div>]]></content:encoded><description>Transitional and naïve mature peripheral B cells respond very differently to BCR cross-linking. While transitional B cells undergo apoptosis upon BCR engagement, mature B cells survive and proliferate. This differential response correlates with the capacity of mature, but not transitional B cells to transcribe genes that promote cell survival and proliferation, including those encoding c-Myc and the Bcl-2 family members Bcl-xL and A1. We recently demonstrated that transitional B cells fail to assemble transcriptional machinery at the promoter region of these target genes despite equivalent cytoplasmic signaling and nuclear translocation of key transcription factors including NFĸB and NFAT. The transcription factor MEF2C is regulated by both calcineurin and MAPK signaling pathways, and is essential for proliferation and survival downstream of BCR engagement in mature B cells. In this work, we demonstrate that transitional B cells have intrinsically low levels of MEF2C protein and DNA-binding activity, and that this developmental difference in MEF2C expression is functionally significant. Forced expression of MEF2C in transitional B cells promoted cell survival, proliferation, and up-regulation of pro-survival genes. Thus, low MEF2C expression limits transitional B-cell responsiveness to BCR engagement before these cells reach maturity.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142004" xmlns="http://purl.org/rss/1.0/"><title>Protein kinase D isoforms are dispensable for integrin-mediated lymphocyte adhesion and homing to lymphoid tissues</title><link>http://dx.doi.org/10.1002%2Feji.201142004</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Protein kinase D isoforms are dispensable for integrin-mediated lymphocyte adhesion and homing to lymphoid tissues</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sharon A. Matthews</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hwee San Lek</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vicky L. Morrison</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Matthew G. Mackenzie</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marouan Zarrouk</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Doreen Cantrell</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Susanna C. Fagerholm</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T06:10:02.427615-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142004</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142004</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142004</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>LFA-1 and VLA-4 integrins are essential for lymphocyte adhesion, trafficking and effector functions. Protein kinase D (PKD) has previously been implicated in lymphocyte integrin regulation through regulation of Rap1 activity. However, the true role of PKD in integrin regulation in primary lymphocytes has not previously been investigated. The major PKD isoform in lymphocytes is PKD2. Here we employed PKD2-deficient mice, a specific PKD kinase inhibitor, as well as PKD-null DT40 B cells to investigate the role of PKD in integrin regulation in lymphocytes. We report that PKD2-deficient lymphocytes bound normally to integrin ligands in static and shear flow adhesion assays. They also homed normally to lymphoid organs after adoptive transfer into wild-type mice. DT40 B cells devoid of any PKD isoforms and primary lymphocytes pretreated with a specific PKD inhibitor bound normally to integrin ligands, indicating that multiple PKD isoforms do not redundantly regulate lymphocyte integrins. In addition, PKD2-deficient lymphocytes, as well as DT40 cells devoid of any PKD isoforms, could activate Rap1 in response to BCR ligation or phorbol ester treatment. Together, these results show that the PKD family does not play a critical role in lymphocyte integrin-mediated cell adhesion or lymphocyte trafficking in vivo.</p></div>]]></content:encoded><description>LFA-1 and VLA-4 integrins are essential for lymphocyte adhesion, trafficking and effector functions. Protein kinase D (PKD) has previously been implicated in lymphocyte integrin regulation through regulation of Rap1 activity. However, the true role of PKD in integrin regulation in primary lymphocytes has not previously been investigated. The major PKD isoform in lymphocytes is PKD2. Here we employed PKD2-deficient mice, a specific PKD kinase inhibitor, as well as PKD-null DT40 B cells to investigate the role of PKD in integrin regulation in lymphocytes. We report that PKD2-deficient lymphocytes bound normally to integrin ligands in static and shear flow adhesion assays. They also homed normally to lymphoid organs after adoptive transfer into wild-type mice. DT40 B cells devoid of any PKD isoforms and primary lymphocytes pretreated with a specific PKD inhibitor bound normally to integrin ligands, indicating that multiple PKD isoforms do not redundantly regulate lymphocyte integrins. In addition, PKD2-deficient lymphocytes, as well as DT40 cells devoid of any PKD isoforms, could activate Rap1 in response to BCR ligation or phorbol ester treatment. Together, these results show that the PKD family does not play a critical role in lymphocyte integrin-mediated cell adhesion or lymphocyte trafficking in vivo.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141926" xmlns="http://purl.org/rss/1.0/"><title>Leishmania amazonensis impairs DC function by inhibiting CD40 expression via A2B adenosine receptor activation</title><link>http://dx.doi.org/10.1002%2Feji.201141926</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Leishmania amazonensis impairs DC function by inhibiting CD40 expression via A2B adenosine receptor activation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Amanda B. Figueiredo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tiago D. Serafim</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eduardo A. Marques-da-Silva</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">José R. Meyer-Fernandes</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luís C. C. Afonso</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T06:09:56.044825-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141926</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141926</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141926</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Dendritic cells (DCs) play an essential role in the modulation of immune responses and several studies have evaluated the interactions between <em>Leishmania</em> parasites and DCs. While extracellular ATP exhibits pro-inflammatory properties, adenosine is an important anti-inflammatory mediator. Here we investigated the effects of <em>Leishmania</em> infection on DC responses and the participation of purinergic signalling in this process. BMDCs from C57BL/6J mice infected with <em>Leishmania amazonensis</em>, <em>Leishmania braziliensis</em> or <em>Leishmania major</em> metacyclic promastigotes showed decreased MHC class II and CD86 expression and increased ectonucleotidase expression as compared with uninfected cells. In addition, <em>L. amazonensis</em>-infected DCs, which had lower CD40 expression, exhibited a decreased ability to induce T-cell proliferation. The presence of MRS1754, a highly selective A<sub>2B</sub> adenosine receptor antagonist at the time of infection increased MHC class II, CD86 and CD40 expression in <em>L. amazonensis</em>-infected DCs and restored the ability of the infected DCs to induce T-cell proliferation. Similar results were obtained through the inhibition of extracellular ATP hydrolysis using suramin. In conclusion, we propose that A<sub>2B</sub> receptor activation may be used by <em>L. amazonensis</em> to inhibit DC function and evade the immune response.</p></div>]]></content:encoded><description>Dendritic cells (DCs) play an essential role in the modulation of immune responses and several studies have evaluated the interactions between Leishmania parasites and DCs. While extracellular ATP exhibits pro-inflammatory properties, adenosine is an important anti-inflammatory mediator. Here we investigated the effects of Leishmania infection on DC responses and the participation of purinergic signalling in this process. BMDCs from C57BL/6J mice infected with Leishmania amazonensis, Leishmania braziliensis or Leishmania major metacyclic promastigotes showed decreased MHC class II and CD86 expression and increased ectonucleotidase expression as compared with uninfected cells. In addition, L. amazonensis-infected DCs, which had lower CD40 expression, exhibited a decreased ability to induce T-cell proliferation. The presence of MRS1754, a highly selective A2B adenosine receptor antagonist at the time of infection increased MHC class II, CD86 and CD40 expression in L. amazonensis-infected DCs and restored the ability of the infected DCs to induce T-cell proliferation. Similar results were obtained through the inhibition of extracellular ATP hydrolysis using suramin. In conclusion, we propose that A2B receptor activation may be used by L. amazonensis to inhibit DC function and evade the immune response.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142260" xmlns="http://purl.org/rss/1.0/"><title>IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1</title><link>http://dx.doi.org/10.1002%2Feji.201142260</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Inessa Schwab</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Markus Biburger</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gerhard Krönke</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Georg Schett</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Falk Nimmerjahn</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-26T05:09:28.533886-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142260</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142260</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142260</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Short Communication</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Intravenous immunoglobulin G (IVIg) therapy is widely used to treat autoimmune and inflammatory diseases. Recent evidence suggests that in mice splenic resident cells might be important for the anti-inflammatory activity of IVIgs in a model of serum transfer arthritis. Splenectomized human immunothrombocytopenia (ITP) patients, however, still respond to IVIg therapy. To investigate whether the requirement of the spleen is essential for mouse ITP we used a passive model of induced ITP and demonstrated that IVIg activity was functional in splenectomized animals. Further analysis showed that the IVIg-mediated amelioration of platelet phagocytosis was fully dependent on terminal sialic acid residues in the IVIg preparation and could be blocked with a SIGNR1 specific antibody. These results suggest that, similar to the human system, a spleen-independent but sialic acid- and SIGNR1- dependent pathway is responsible for IVIg-mediated suppression of autoantibody-dependent platelet depletion in mice.</p></div>]]></content:encoded><description>Intravenous immunoglobulin G (IVIg) therapy is widely used to treat autoimmune and inflammatory diseases. Recent evidence suggests that in mice splenic resident cells might be important for the anti-inflammatory activity of IVIgs in a model of serum transfer arthritis. Splenectomized human immunothrombocytopenia (ITP) patients, however, still respond to IVIg therapy. To investigate whether the requirement of the spleen is essential for mouse ITP we used a passive model of induced ITP and demonstrated that IVIg activity was functional in splenectomized animals. Further analysis showed that the IVIg-mediated amelioration of platelet phagocytosis was fully dependent on terminal sialic acid residues in the IVIg preparation and could be blocked with a SIGNR1 specific antibody. These results suggest that, similar to the human system, a spleen-independent but sialic acid- and SIGNR1- dependent pathway is responsible for IVIg-mediated suppression of autoantibody-dependent platelet depletion in mice.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141690" xmlns="http://purl.org/rss/1.0/"><title>Effective T-cell recall responses require the Taurine transporter Taut</title><link>http://dx.doi.org/10.1002%2Feji.201141690</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Effective T-cell recall responses require the Taurine transporter Taut</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Susanne Kaesler</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Malgorzata Sobiesiak</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Manfred Kneilling</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas Volz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wolfgang E. Kempf</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Philipp A. Lang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Karl S. Lang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas Wieder</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Birgit Heller-Stilb</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ulrich Warskulat</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dieter Häussinger</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Florian Lang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tilo Biedermann</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-17T05:09:10.947436-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141690</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141690</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141690</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>T-cell activation and the subsequent transformation of activated T cells into T-cell blasts require profound changes in cell volume. However, the impact of cell volume regulation for T-cell immunology has not been characterized. Here we studied the role of the cell-volume regulating osmolyte transporter Taut for T-cell activation in Taut-deficient mice. T-cell mediated recall responses were severely impaired in <em>taut<sup>−/−</sup></em> mice as shown with B16 melanoma rejection and hapten-induced contact hypersensitivity. CD4<sup>+</sup> and CD8<sup>+</sup> T cells were unequivocally located within peripheral lymph nodes of unprimed <em>taut<sup>−/−</sup></em> mice but significantly decreased in <em>taut<sup>−/−</sup></em> compared with <em>taut<sup>+/+</sup></em> mice following in vivo activation. Further analysis revealed that Taut is critical for rescuing T cells from activation-induced cell death in vitro and in vivo as shown with TCR, superantigen, and antigen-specific activation. Consequently, reduction of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in <em>taut<sup>−/−</sup></em> mice upon antigen challenge resulted in impaired in vivo generation of T-cell memory. These findings disclose for the first time that volume regulation in T cells is an element in the regulation of adaptive immune responses and that the osmolyte transporter Taut is crucial for T-cell survival and T-cell mediated immune reactions.</p></div>]]></content:encoded><description>T-cell activation and the subsequent transformation of activated T cells into T-cell blasts require profound changes in cell volume. However, the impact of cell volume regulation for T-cell immunology has not been characterized. Here we studied the role of the cell-volume regulating osmolyte transporter Taut for T-cell activation in Taut-deficient mice. T-cell mediated recall responses were severely impaired in taut−/− mice as shown with B16 melanoma rejection and hapten-induced contact hypersensitivity. CD4+ and CD8+ T cells were unequivocally located within peripheral lymph nodes of unprimed taut−/− mice but significantly decreased in taut−/− compared with taut+/+ mice following in vivo activation. Further analysis revealed that Taut is critical for rescuing T cells from activation-induced cell death in vitro and in vivo as shown with TCR, superantigen, and antigen-specific activation. Consequently, reduction of CD4+ and CD8+ T cells in taut−/− mice upon antigen challenge resulted in impaired in vivo generation of T-cell memory. These findings disclose for the first time that volume regulation in T cells is an element in the regulation of adaptive immune responses and that the osmolyte transporter Taut is crucial for T-cell survival and T-cell mediated immune reactions.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141969" xmlns="http://purl.org/rss/1.0/"><title>FOXO3 as a new IKKϵ-controlled check-point of regulation of IFN-β expression</title><link>http://dx.doi.org/10.1002%2Feji.201141969</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">FOXO3 as a new IKKϵ-controlled check-point of regulation of IFN-β expression</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lionel Luron</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David Saliba</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Katrina Blazek</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alessandra Lanfrancotti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Irina A. Udalova</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-17T05:09:10.947436-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141969</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141969</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141969</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Cell survival transcription factor FOXO3 has been recently implicated in moderating pro-inflammatory cytokine production by dendritic cells (DCs), but the molecular mechanisms are unclear. It was suggested that FOXO3 could antagonise NF-κB activity, while IKKβ was demonstrated to inactivate FOXO3, suggesting a cross-talk between the two pathways. Therefore, FOXO3 activity must be tightly regulated to allow for an appropriate inflammatory response. Here we show that in human monocyte derived DCs (MDDCs), FOXO3 is able to antagonise signalling intermediates downstream of the Toll like receptor (TLR) 4, such as NF-κB and Interferon Regulatory Factors (IRFs), resulting in inhibition of interferon (IFN)-β expression. We also demonstrate that activity of FOXO3 itself is regulated by IKKϵ, a kinase involved in IFN-β production, which phosphorylates and inactivates FOXO3 in response to TLR4 agonists. Thus, we identify FOXO3 as a new IKKϵ-controlled check-point of IRF activation and regulation of IFN-β expression, providing new insight into the role of FOXO3 in immune response control.</p></div>]]></content:encoded><description>Cell survival transcription factor FOXO3 has been recently implicated in moderating pro-inflammatory cytokine production by dendritic cells (DCs), but the molecular mechanisms are unclear. It was suggested that FOXO3 could antagonise NF-κB activity, while IKKβ was demonstrated to inactivate FOXO3, suggesting a cross-talk between the two pathways. Therefore, FOXO3 activity must be tightly regulated to allow for an appropriate inflammatory response. Here we show that in human monocyte derived DCs (MDDCs), FOXO3 is able to antagonise signalling intermediates downstream of the Toll like receptor (TLR) 4, such as NF-κB and Interferon Regulatory Factors (IRFs), resulting in inhibition of interferon (IFN)-β expression. We also demonstrate that activity of FOXO3 itself is regulated by IKKϵ, a kinase involved in IFN-β production, which phosphorylates and inactivates FOXO3 in response to TLR4 agonists. Thus, we identify FOXO3 as a new IKKϵ-controlled check-point of IRF activation and regulation of IFN-β expression, providing new insight into the role of FOXO3 in immune response control.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142105" xmlns="http://purl.org/rss/1.0/"><title>NOD2 enhances the innate response of alveolar macrophages to Mycobacterium tuberculosis in humans</title><link>http://dx.doi.org/10.1002%2Feji.201142105</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">NOD2 enhances the innate response of alveolar macrophages to Mycobacterium tuberculosis in humans</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Esmeralda Juárez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Claudia Carranza</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fernando Hernández-Sánchez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Juan C. León-Contreras</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rogelio Hernández-Pando</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dante Escobedo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Martha Torres</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eduardo Sada</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142105</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142105</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142105</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>A role for the nucleotide-binding oligomerization domain 2 receptor (NOD2) in pulmonary innate immune responses has recently been explored. In the present study, we investigated the role that NOD2 plays in human alveolar macrophage innate responses and determined its involvement in the response to infection with virulent <em>Mycobacterium tuberculosis</em>. Our results showed that NOD2 was expressed in human alveolar macrophages, and significant amounts of IL-1β, IL-6 and TNF-α were produced upon ligand recognition with muramyldipeptide (MDP). NOD2 ligation induced the transcription and protein expression of the antimicrobial peptide LL37 and the autophagy enzyme IRGM in alveolar macrophages, demonstrating a novel function for this receptor in these cells. MDP treatment of alveolar macrophages improved the intracellular growth control of virulent <em>M. tuberculosis</em>; this was associated with a significant release of TNF-α and IL-6 and overexpression of bactericidal LL37. In addition, the autophagy proteins IRGM, LC3 and ATG16L1 were recruited to the bacteria-containing autophagosome after treatment with MDP. In conclusion, our results suggest that NOD2 can modulate the innate immune response of alveolar macrophages and play a role in the initial control of respiratory <em>M. tuberculosis</em> infections.</p></div>]]></content:encoded><description>A role for the nucleotide-binding oligomerization domain 2 receptor (NOD2) in pulmonary innate immune responses has recently been explored. In the present study, we investigated the role that NOD2 plays in human alveolar macrophage innate responses and determined its involvement in the response to infection with virulent Mycobacterium tuberculosis. Our results showed that NOD2 was expressed in human alveolar macrophages, and significant amounts of IL-1β, IL-6 and TNF-α were produced upon ligand recognition with muramyldipeptide (MDP). NOD2 ligation induced the transcription and protein expression of the antimicrobial peptide LL37 and the autophagy enzyme IRGM in alveolar macrophages, demonstrating a novel function for this receptor in these cells. MDP treatment of alveolar macrophages improved the intracellular growth control of virulent M. tuberculosis; this was associated with a significant release of TNF-α and IL-6 and overexpression of bactericidal LL37. In addition, the autophagy proteins IRGM, LC3 and ATG16L1 were recruited to the bacteria-containing autophagosome after treatment with MDP. In conclusion, our results suggest that NOD2 can modulate the innate immune response of alveolar macrophages and play a role in the initial control of respiratory M. tuberculosis infections.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142071" xmlns="http://purl.org/rss/1.0/"><title>T cells interact with T cells via CD40-CD154 to promote autoimmunity in T1D</title><link>http://dx.doi.org/10.1002%2Feji.201142071</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">T cells interact with T cells via CD40-CD154 to promote autoimmunity in T1D</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rocky L. Baker</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thierry Mallevaey</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laurent Gapin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kathryn Haskins</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142071</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142071</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142071</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>We have investigated the role of CD40 signaling in islet-reactive, diabetogenic CD4<sup>+</sup> Th1 T-cell clones. Using multispectral flow cytometry, we showed that CD40 and CD154 are co-expressed and form complexes on the surface of activated T cells. We also demonstrate that activated T cells can transactivate CD4<sup>+</sup>CD40<sup>+</sup> T cells through the CD40-CD154 pathway. To investigate the role of CD40 signaling on Th1 cells, we used the diabetogenic clone BDC-5.2.9 retrovirally transduced with a truncated form of the CD40 molecule to produce a CD40 dominant-negative T-cell clone. Upon challenge with antigen in vitro, the production of IFN-γ by BDC-5.2.9 CD40DN was greatly reduced and in vivo, the dominant-negative variant was unable to induce diabetes. Transduction with the CD40DN vector was also effective in preventing transfer of disease by primary NOD CD4<sup>+</sup> T cells. Ex vivo analysis of pancreatic infiltrates after transfer of BDC-5.2.9 CD40DN cells revealed an overall reduction of cell numbers and cytokine production by both T cells and macrophages. These data indicate that CD40 is an important signaling molecule on autoreactive CD4<sup>+</sup> T cells and contributes to their pathogenic effector function.</p></div>]]></content:encoded><description>We have investigated the role of CD40 signaling in islet-reactive, diabetogenic CD4+ Th1 T-cell clones. Using multispectral flow cytometry, we showed that CD40 and CD154 are co-expressed and form complexes on the surface of activated T cells. We also demonstrate that activated T cells can transactivate CD4+CD40+ T cells through the CD40-CD154 pathway. To investigate the role of CD40 signaling on Th1 cells, we used the diabetogenic clone BDC-5.2.9 retrovirally transduced with a truncated form of the CD40 molecule to produce a CD40 dominant-negative T-cell clone. Upon challenge with antigen in vitro, the production of IFN-γ by BDC-5.2.9 CD40DN was greatly reduced and in vivo, the dominant-negative variant was unable to induce diabetes. Transduction with the CD40DN vector was also effective in preventing transfer of disease by primary NOD CD4+ T cells. Ex vivo analysis of pancreatic infiltrates after transfer of BDC-5.2.9 CD40DN cells revealed an overall reduction of cell numbers and cytokine production by both T cells and macrophages. These data indicate that CD40 is an important signaling molecule on autoreactive CD4+ T cells and contributes to their pathogenic effector function.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141835" xmlns="http://purl.org/rss/1.0/"><title>Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients</title><link>http://dx.doi.org/10.1002%2Feji.201141835</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dàlia Raïch-Regué</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laia Grau-López</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mar Naranjo-Gómez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cristina Ramo-Tello</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ricardo Pujol-Borrell</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eva Martínez-Cáceres</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Francesc E. Borràs</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141835</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141835</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141835</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Multiple sclerosis (MS) is a chronic demyelinating autoimmune disease of the central nervous system. Current therapies decrease the frequency of relapses and limit, to some extent, but do not prevent disease progression. Hence, new therapeutic approaches that modify the natural course of MS need to be identified. Tolerance induction to self-antigens using monocyte-derived dendritic cells (MDDCs) is a promising therapeutic strategy in autoimmunity. In this work we sought to generate and characterize tolerogenic MDDCs (tolDCs) from relapsing-remitting (RR) MS patients, loaded with myelin peptides as specific antigen, with the aim of developing immunotherapeutics for MS. MDDCs were generated from both healthy-blood donors and RR-MS patients, and MDDC maturation was induced with a proinflammatory cytokine cocktail in the absence or presence of 1α,25-dihydroxyvitamin-D<sub>3</sub>, a tolerogenicity inducing agent. TolDCs were generated from monocytes of RR-MS patients as efficiently as from monocytes of healthy subjects. The RR-MS tolDCs expressed a stable semi-mature phenotype and an anti-inflammatory profile as compared with untreated MDDCs. Importantly, myelin peptide-loaded tolDCs induced stable antigen-specific hyporesponsiveness in myelin-reactive T cells from RR-MS patients. These results suggest that myelin peptide-loaded tolDCs may be a powerful tool for inducing myelin-specific tolerance in RR-MS patients.</p></div>]]></content:encoded><description>Multiple sclerosis (MS) is a chronic demyelinating autoimmune disease of the central nervous system. Current therapies decrease the frequency of relapses and limit, to some extent, but do not prevent disease progression. Hence, new therapeutic approaches that modify the natural course of MS need to be identified. Tolerance induction to self-antigens using monocyte-derived dendritic cells (MDDCs) is a promising therapeutic strategy in autoimmunity. In this work we sought to generate and characterize tolerogenic MDDCs (tolDCs) from relapsing-remitting (RR) MS patients, loaded with myelin peptides as specific antigen, with the aim of developing immunotherapeutics for MS. MDDCs were generated from both healthy-blood donors and RR-MS patients, and MDDC maturation was induced with a proinflammatory cytokine cocktail in the absence or presence of 1α,25-dihydroxyvitamin-D3, a tolerogenicity inducing agent. TolDCs were generated from monocytes of RR-MS patients as efficiently as from monocytes of healthy subjects. The RR-MS tolDCs expressed a stable semi-mature phenotype and an anti-inflammatory profile as compared with untreated MDDCs. Importantly, myelin peptide-loaded tolDCs induced stable antigen-specific hyporesponsiveness in myelin-reactive T cells from RR-MS patients. These results suggest that myelin peptide-loaded tolDCs may be a powerful tool for inducing myelin-specific tolerance in RR-MS patients.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141857" xmlns="http://purl.org/rss/1.0/"><title>Immunoglobulin class switching appears to be regulated by B cell antigen receptor-specific T-cell action</title><link>http://dx.doi.org/10.1002%2Feji.201141857</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Immunoglobulin class switching appears to be regulated by B cell antigen receptor-specific T-cell action</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hans Lange</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Oliver Hecht</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Zemlin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ahmad Trad</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Radu I. Tanasa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Harry W. Schroeder</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hilmar Lemke</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141857</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141857</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141857</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Frontline: Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Antigen affinity is commonly viewed as the driving force behind the selection for dominant clonotypes that can occur during the T cell-dependent processes of class switch recombination (CSR) and immune maturation. To test this view, we analyzed the variable gene repertoires of natural monoclonal antibodies to the hapten 2-phenyloxazolone (phOx) as well as those generated after phOx protein carrier-induced thymus-dependent or Ficoll-induced thymus independent antigen stimulation. In contrast to expectations, the extent of IgM heterogeneity proved similar and many IgM from these three populations exhibited similar or even greater affinities than the classic Ox1 clonotype that dominates only after CSR among primary and memory IgG. The population of clones that were selected during CSR exhibited a reduced VH/VL repertoire that was enriched for variable domains with shorter and more uniform CDR-H3 lengths and almost completely stripped of variable domains encoded by the large VH1 family. Thus, contrary to the current paradigm, T-cell dependent clonal selection during CSR appeared to select for VH family and CDR-H3 loop content even when the affinity provided by alternative clones exhibited similar to increased affinity for antigen.</p></div>]]></content:encoded><description>Antigen affinity is commonly viewed as the driving force behind the selection for dominant clonotypes that can occur during the T cell-dependent processes of class switch recombination (CSR) and immune maturation. To test this view, we analyzed the variable gene repertoires of natural monoclonal antibodies to the hapten 2-phenyloxazolone (phOx) as well as those generated after phOx protein carrier-induced thymus-dependent or Ficoll-induced thymus independent antigen stimulation. In contrast to expectations, the extent of IgM heterogeneity proved similar and many IgM from these three populations exhibited similar or even greater affinities than the classic Ox1 clonotype that dominates only after CSR among primary and memory IgG. The population of clones that were selected during CSR exhibited a reduced VH/VL repertoire that was enriched for variable domains with shorter and more uniform CDR-H3 lengths and almost completely stripped of variable domains encoded by the large VH1 family. Thus, contrary to the current paradigm, T-cell dependent clonal selection during CSR appeared to select for VH family and CDR-H3 loop content even when the affinity provided by alternative clones exhibited similar to increased affinity for antigen.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142086" xmlns="http://purl.org/rss/1.0/"><title>Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation</title><link>http://dx.doi.org/10.1002%2Feji.201142086</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chiara Napoletano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ilaria G. Zizzari</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Aurelia Rughetti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hassan Rahimi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tatsuro Irimura</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Henrik Clausen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hans H. Wandall</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Francesca Belleudi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Filippo Bellati</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luca Pierelli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luigi Frati</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marianna Nuti</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142086</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142086</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142086</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>DCs sense the microenvironment through several types of receptors recognizing pathogen-associated-molecular patterns. In particular, C-type lectins, expressed by distinct subsets of DCs, recognise and internalize specific carbohydrate antigen in a Ca<sup>2+</sup>-dependent manner. Targeting of these receptors is becoming an efficient strategy of delivering antigens in DC-based anticancer immunotherapy. Here we investigated the role of the macrophage galactose type C-lectin receptor (MGL), expressed by immature (i) DCs, as a molecular target for GalNAc (Tn)-carrying tumor-associated antigens to improve DC performance.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>MGL expressed by ex vivo-generated iDCs from healthy donors was engaged by a 60-mer MUC1 9Tn-glycopeptide as a Tn-carrying TAA, and an anti-MGL antibody, as a specific MGL binder. We demonstrated that MGL engagement induced homo-trimers and homo-dimers, triggering the phosphorylation of ERK1,2 and NF-κB activation. Analysis of DC phenotype and function demonstrated that MGL engagement improved DC performance as APCs, promoting the up-regulation of maturation markers, a decrease in phagocytosis, an enhancement of motility and most importantly an increase in antigen-specific CD8<sup>+</sup> T-cell activation. These results demonstrate that targeting the MGL receptor on human DCs has an adjuvant effect and this strategy can be used to design novel anti-cancer vaccines.</p></div>]]></content:encoded><description>DCs sense the microenvironment through several types of receptors recognizing pathogen-associated-molecular patterns. In particular, C-type lectins, expressed by distinct subsets of DCs, recognise and internalize specific carbohydrate antigen in a Ca2+-dependent manner. Targeting of these receptors is becoming an efficient strategy of delivering antigens in DC-based anticancer immunotherapy. Here we investigated the role of the macrophage galactose type C-lectin receptor (MGL), expressed by immature (i) DCs, as a molecular target for GalNAc (Tn)-carrying tumor-associated antigens to improve DC performance.MGL expressed by ex vivo-generated iDCs from healthy donors was engaged by a 60-mer MUC1 9Tn-glycopeptide as a Tn-carrying TAA, and an anti-MGL antibody, as a specific MGL binder. We demonstrated that MGL engagement induced homo-trimers and homo-dimers, triggering the phosphorylation of ERK1,2 and NF-κB activation. Analysis of DC phenotype and function demonstrated that MGL engagement improved DC performance as APCs, promoting the up-regulation of maturation markers, a decrease in phagocytosis, an enhancement of motility and most importantly an increase in antigen-specific CD8+ T-cell activation. These results demonstrate that targeting the MGL receptor on human DCs has an adjuvant effect and this strategy can be used to design novel anti-cancer vaccines.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142057" xmlns="http://purl.org/rss/1.0/"><title>Complement plays a central role in Candida albicans-induced cytokine production by human PBMCs</title><link>http://dx.doi.org/10.1002%2Feji.201142057</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Complement plays a central role in Candida albicans-induced cytokine production by human PBMCs</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shih-Chin Cheng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tom Sprong</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Leo A.B. Joosten</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jos W.M. van der Meer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bart-Jan Kullberg</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bernhard Hube</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lone Schejbel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Peter Garred</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marcel van Deuren</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mihai G. Netea</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142057</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142057</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142057</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>In experimental studies, the role of complement in antifungal host defense has been attributed to its opsonizing capability. In this study, we report that in humans an activated complement system mainly augments <em>Candida albicans</em>-induced host pro-inflammatory cytokine production via C5a-C5a receptor signaling, while phagocytosis and intracellular killing of <em>Candida</em> are not influenced. By blocking the C5a-C5aR signaling pathway, either with anti-C5a antagonist antibodies or with the C5aR antagonist W-54001, <em>C. albicans</em>-induced IL-6 and IL-1β levels were significantly reduced. Recombinant C5a augmented cytokine production. In addition, using serum from patients with various complement deficiencies, we demonstrated a crucial role of C5, but not C6 or the membrane attack complex, in <em>C. albicans</em>-induced IL-6 and IL-1β production in monocytes. These findings reveal a central role of anaphylatoxin C5a in augmenting host pro-inflammatory cytokine production upon contact with <em>C. albicans</em>, and define the role of the complement system in anti-<em>Candida</em> host defense in humans.</p></div>]]></content:encoded><description>In experimental studies, the role of complement in antifungal host defense has been attributed to its opsonizing capability. In this study, we report that in humans an activated complement system mainly augments Candida albicans-induced host pro-inflammatory cytokine production via C5a-C5a receptor signaling, while phagocytosis and intracellular killing of Candida are not influenced. By blocking the C5a-C5aR signaling pathway, either with anti-C5a antagonist antibodies or with the C5aR antagonist W-54001, C. albicans-induced IL-6 and IL-1β levels were significantly reduced. Recombinant C5a augmented cytokine production. In addition, using serum from patients with various complement deficiencies, we demonstrated a crucial role of C5, but not C6 or the membrane attack complex, in C. albicans-induced IL-6 and IL-1β production in monocytes. These findings reveal a central role of anaphylatoxin C5a in augmenting host pro-inflammatory cytokine production upon contact with C. albicans, and define the role of the complement system in anti-Candida host defense in humans.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141442" xmlns="http://purl.org/rss/1.0/"><title>Modulation of protein kinase Cα promotes lineage reprogramming of committed B lymphocytes1</title><link>http://dx.doi.org/10.1002%2Feji.201141442</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Modulation of protein kinase Cα promotes lineage reprogramming of committed B lymphocytes1</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rinako Nakagawa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Milica Vukovic</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Emilio Cosimo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alison M. Michie</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141442</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141442</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141442</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>During hematopoietic lineage development, HSCs sequentially commit towards myeloid or lymphoid lineages in a tightly regulated manner, which under normal circumstances is irreversible. However, studies have established that targeted deletion of the B-lineage-specific transcription factor, paired box gene 5 (Pax5), enables B cells to differentiate towards other hematopoietic lineages, in addition to generating progenitor B-cell lymphomas. Our previous studies showed that subversion of PKCα in developing B cells transforms B-lineage cells. Here we demonstrate that PKCα modulation in committed CD19<sup>+</sup> B-lymphocytes also promoted lineage conversion towards myeloid, NK- and T-cell lineages upon Notch ligation. This occurred via a reduction in Pax5 expression resulting from a downregulation of E47, a product of the <em>E2A</em> gene. T-cell lineage commitment was indicated by the expression of T-cell associated genes <em>Ptcra</em>, <em>Cd3e</em> and gene rearrangement at the <em>Tcrb</em> gene locus. Importantly, the lineage converted T-cells carried <em>Igh</em> gene rearrangements reminiscent of their B-cell origin. Our findings suggest that modulation of PKCα induces hematopoietic lineage plasticity in committed B-lineage cells by perturbing expression of critical B-lineage transcription factors, and deregulation of PKCα activity/expression represents a potential mechanism for lineage trans-differentiation during malignancies.</p></div>]]></content:encoded><description>During hematopoietic lineage development, HSCs sequentially commit towards myeloid or lymphoid lineages in a tightly regulated manner, which under normal circumstances is irreversible. However, studies have established that targeted deletion of the B-lineage-specific transcription factor, paired box gene 5 (Pax5), enables B cells to differentiate towards other hematopoietic lineages, in addition to generating progenitor B-cell lymphomas. Our previous studies showed that subversion of PKCα in developing B cells transforms B-lineage cells. Here we demonstrate that PKCα modulation in committed CD19+ B-lymphocytes also promoted lineage conversion towards myeloid, NK- and T-cell lineages upon Notch ligation. This occurred via a reduction in Pax5 expression resulting from a downregulation of E47, a product of the E2A gene. T-cell lineage commitment was indicated by the expression of T-cell associated genes Ptcra, Cd3e and gene rearrangement at the Tcrb gene locus. Importantly, the lineage converted T-cells carried Igh gene rearrangements reminiscent of their B-cell origin. Our findings suggest that modulation of PKCα induces hematopoietic lineage plasticity in committed B-lineage cells by perturbing expression of critical B-lineage transcription factors, and deregulation of PKCα activity/expression represents a potential mechanism for lineage trans-differentiation during malignancies.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201041225" xmlns="http://purl.org/rss/1.0/"><title>Universal vaccine against influenza virus: linking TLR signalling to anti-viral protection</title><link>http://dx.doi.org/10.1002%2Feji.201041225</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Universal vaccine against influenza virus: linking TLR signalling to anti-viral protection</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nicole Schmitz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Roger R. Beerli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Monika Bauer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrea Jegerlehner</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Klaus Dietmeier</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Melanie Maudrich</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paul Pumpens</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Philippe Saudan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Martin F. Bachmann</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201041225</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201041225</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201041225</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Short Communication</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>A vaccine protecting against all influenza strains is a long-sought goal, particularly for emerging pandemics. As previously shown, vaccines based on the highly conserved extracellular domain of M2 (M2e) may protect against all influenza A strains. Here we demonstrate that M2e-specific monoclonal antibodies (mAbs) protect mice from a lethal influenza infection. To be protective, antibodies had to be able to bind to Fc receptors and fix complement. Furthermore, mAbs of IgG2c isotype were protective in mice, while antibodies of identical specificity, but of the IgG1 isotype, failed to prevent disease. These findings readily translated into vaccine design. A vaccine targeting M2 in the absence of a toll-like receptor (TLR) 7 ligand primarily induced IgG1, whilst the same vaccine linked to a TLR7 ligand yielded high levels of IgG2c antibodies. Although both vaccines protected mice from a lethal challenge, mice treated with the vaccine containing a TLR7 ligand showed significantly lower morbidity. In accordance with these findings, vaccinations of TLR7<sup>−/−</sup> mice with a vaccine containing a TLR7 ligand were not protected from a lethal challenge. Hence, the innate immune system is required to direct isotype switching towards the more protective IgG2a/c antibodies.</p></div>]]></content:encoded><description>A vaccine protecting against all influenza strains is a long-sought goal, particularly for emerging pandemics. As previously shown, vaccines based on the highly conserved extracellular domain of M2 (M2e) may protect against all influenza A strains. Here we demonstrate that M2e-specific monoclonal antibodies (mAbs) protect mice from a lethal influenza infection. To be protective, antibodies had to be able to bind to Fc receptors and fix complement. Furthermore, mAbs of IgG2c isotype were protective in mice, while antibodies of identical specificity, but of the IgG1 isotype, failed to prevent disease. These findings readily translated into vaccine design. A vaccine targeting M2 in the absence of a toll-like receptor (TLR) 7 ligand primarily induced IgG1, whilst the same vaccine linked to a TLR7 ligand yielded high levels of IgG2c antibodies. Although both vaccines protected mice from a lethal challenge, mice treated with the vaccine containing a TLR7 ligand showed significantly lower morbidity. In accordance with these findings, vaccinations of TLR7−/− mice with a vaccine containing a TLR7 ligand were not protected from a lethal challenge. Hence, the innate immune system is required to direct isotype switching towards the more protective IgG2a/c antibodies.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141856" xmlns="http://purl.org/rss/1.0/"><title>Chronic smoke exposure induces rheumatoid factor and anti-heat shock protein 70 autoantibodies in susceptible mice and humans with lung disease</title><link>http://dx.doi.org/10.1002%2Feji.201141856</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Chronic smoke exposure induces rheumatoid factor and anti-heat shock protein 70 autoantibodies in susceptible mice and humans with lung disease</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marianna M. Newkirk</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Simeon Mitchell</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Procino</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zhenhong Li</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Manuel Cosio</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Witold Mazur</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vuokko L. Kinnula</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marie Hudson</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Murray Baron</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marvin Fritzler</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hani S. El-Gabalawy</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141856</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141856</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141856</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>The impact of cigarette smoke (CS), a risk factor for rheumatoid arthritis (RA), on autoantibody production was studied in humans and mice with and without chronic lung disease (LD). Rheumatoid factor (RF), anti-cyclic citrullinated peptides (CCP) and anti-HSP70 autoantibodies were measured in several mouse strains and in cohorts of smokers and non-smokers with and without autoimmune disease. Chronic smoking induced RFs in AKR/J mice, which are most susceptible to LD. RFs were identified in human smokers, preferentially in those with LD. Anti-HSP70 autoantibodies were identified in CS-exposed AKR/J mice but not in ambient air exposed AKR/J controls. Whereas inflammation could induce anti-HSP70 IgM, smoke exposure promoted the switch to anti-HSP70 IgG autoantibodies. Elevated anti-CCP autoantibodies were not detected in CS-exposed mice or smokers. AKR/J splenocytes stimulated in vitro by immune complexes (ICs) of HSP70/anti-HSP70 antibodies produced RFs. The CD91 scavenger pathway was required as anti-CD91 blocked the HSP70-IC induced RF response. Blocking Toll-like receptors did not influence the HSP70-IC induced RFs. These studies identify both anti-HSP70 and RFs as serological markers of smoke-related LD in humans and mice. Identification of these autoantibodies could suggest a common environmental insult, namely CS, in a number of different disease settings.</p></div>]]></content:encoded><description>The impact of cigarette smoke (CS), a risk factor for rheumatoid arthritis (RA), on autoantibody production was studied in humans and mice with and without chronic lung disease (LD). Rheumatoid factor (RF), anti-cyclic citrullinated peptides (CCP) and anti-HSP70 autoantibodies were measured in several mouse strains and in cohorts of smokers and non-smokers with and without autoimmune disease. Chronic smoking induced RFs in AKR/J mice, which are most susceptible to LD. RFs were identified in human smokers, preferentially in those with LD. Anti-HSP70 autoantibodies were identified in CS-exposed AKR/J mice but not in ambient air exposed AKR/J controls. Whereas inflammation could induce anti-HSP70 IgM, smoke exposure promoted the switch to anti-HSP70 IgG autoantibodies. Elevated anti-CCP autoantibodies were not detected in CS-exposed mice or smokers. AKR/J splenocytes stimulated in vitro by immune complexes (ICs) of HSP70/anti-HSP70 antibodies produced RFs. The CD91 scavenger pathway was required as anti-CD91 blocked the HSP70-IC induced RF response. Blocking Toll-like receptors did not influence the HSP70-IC induced RFs. These studies identify both anti-HSP70 and RFs as serological markers of smoke-related LD in humans and mice. Identification of these autoantibodies could suggest a common environmental insult, namely CS, in a number of different disease settings.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142045" xmlns="http://purl.org/rss/1.0/"><title>PACSIN1 regulates the TLR7/9-mediated type I interferon response in plasmacytoid dendritic cells</title><link>http://dx.doi.org/10.1002%2Feji.201142045</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">PACSIN1 regulates the TLR7/9-mediated type I interferon response in plasmacytoid dendritic cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eiji Esashi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Musheng Bao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yi-Hong Wang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wei Cao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yong-Jun Liu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142045</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142045</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142045</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Short Communication</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Plasmacytoid DCs (pDCs) are the professional interferon (IFN)-producing cells of the immune system. pDCs specifically express TLR7 and TLR9 molecules and produce massive amounts of type I IFN by sensing microbial nucleic acids via TLR7 and TLR9. Here we report that PACSIN1, a member of the protein kinase C and casein kinase substrate in neurons (PACSINs) family, is specifically expressed in human and mouse pDCs. Knockdown of PACSIN1 by shRNA in a human pDC cell line significantly inhibited the type 1 IFN response of the pDCs to TLR9 ligand. PACSIN1-deficient mice exhibited normal levels of conventional DCs and pDCs, demonstrating that development of pDCs was intact although PACSIN1-deficient pDCs showed reduced levels of IFN-α production in response to both CpG-ODN and virus. In contrast, the production of pro-inflammatory cytokines in response to those ligands was not affected in PACSIN1-deficient pDCs, suggesting that PACSIN1 represents a pDC-specific adaptor molecule that plays a specific role in the type I IFN signaling cascade.</p></div>]]></content:encoded><description>Plasmacytoid DCs (pDCs) are the professional interferon (IFN)-producing cells of the immune system. pDCs specifically express TLR7 and TLR9 molecules and produce massive amounts of type I IFN by sensing microbial nucleic acids via TLR7 and TLR9. Here we report that PACSIN1, a member of the protein kinase C and casein kinase substrate in neurons (PACSINs) family, is specifically expressed in human and mouse pDCs. Knockdown of PACSIN1 by shRNA in a human pDC cell line significantly inhibited the type 1 IFN response of the pDCs to TLR9 ligand. PACSIN1-deficient mice exhibited normal levels of conventional DCs and pDCs, demonstrating that development of pDCs was intact although PACSIN1-deficient pDCs showed reduced levels of IFN-α production in response to both CpG-ODN and virus. In contrast, the production of pro-inflammatory cytokines in response to those ligands was not affected in PACSIN1-deficient pDCs, suggesting that PACSIN1 represents a pDC-specific adaptor molecule that plays a specific role in the type I IFN signaling cascade.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141786" xmlns="http://purl.org/rss/1.0/"><title>Human polymorphonuclear neutrophils express the receptor activator of NFκB (RANK) and are activated by its ligand RANKL</title><link>http://dx.doi.org/10.1002%2Feji.201141786</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Human polymorphonuclear neutrophils express the receptor activator of NFκB (RANK) and are activated by its ligand RANKL</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alexander Riegel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas Maurer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Birgit Prior</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sabine Stegmaier</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Volkmar Heppert</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christof Wagner</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">G. Maria Hänsch</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141786</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141786</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141786</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>The receptor activator of NFkB (RANK) is especially well-studied in the context of bone remodelling, and RANK and its ligand, RANKL, are key molecules in the induction of bone resorbing osteoclasts. We now report that polymorphonuclear neutrophils (PMNs) contain preformed RANK, stored in secretory vesicles and in the specific granules. Upon stimulation of PMNs in vitro, RANK was translocated to the cell membrane. In patients with persistent bacterial infections, RANK surface expression was enhanced compared with that of healthy individuals. The functional activity of RANK was assessed by determining migration of PMNs towards RANKL. A time-and dose dependent migration was seen, leading to the conclusion that RANK on PMNs is functional. We presume that a regulated RANK expression contributes to the fine tuning of PMN migration e.g. on and through inflamed endothelium which is known to express RANKL.</p></div>]]></content:encoded><description>The receptor activator of NFkB (RANK) is especially well-studied in the context of bone remodelling, and RANK and its ligand, RANKL, are key molecules in the induction of bone resorbing osteoclasts. We now report that polymorphonuclear neutrophils (PMNs) contain preformed RANK, stored in secretory vesicles and in the specific granules. Upon stimulation of PMNs in vitro, RANK was translocated to the cell membrane. In patients with persistent bacterial infections, RANK surface expression was enhanced compared with that of healthy individuals. The functional activity of RANK was assessed by determining migration of PMNs towards RANKL. A time-and dose dependent migration was seen, leading to the conclusion that RANK on PMNs is functional. We presume that a regulated RANK expression contributes to the fine tuning of PMN migration e.g. on and through inflamed endothelium which is known to express RANKL.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141511" xmlns="http://purl.org/rss/1.0/"><title>Melanoma cells present high levels of HLA-A2-tyrosinase in association with instability and aberrant intracellular processing of tyrosinase</title><link>http://dx.doi.org/10.1002%2Feji.201141511</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Melanoma cells present high levels of HLA-A2-tyrosinase in association with instability and aberrant intracellular processing of tyrosinase</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yael Michaeli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Keren Sinik</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maya Haus-Cohen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yoram Reiter</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141511</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141511</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141511</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Short-lived protein translation products are proposed to be a major source of substrates for MHC class I antigen processing and presentation; however, a direct link between protein stability and the presentation level of MHC class I–peptide complexes has not been made. We have recently discovered that the peptide Tyr<sub>(369-377)</sub>, derived from the tyrosinase protein, is highly presented by HLA-A2 on the surface of melanoma cells. To examine the molecular mechanisms responsible for this presentation, we compared characteristics of tyrosinase in melanoma cell lines that present high or low levels of HLA-A2-Tyr<sub>(369-377)</sub> complexes. We found no correlation between mRNA levels and the levels of HLA-A2-Tyr<sub>(369-377)</sub> presentation. Co-localization experiments revealed that in cell lines presenting low levels of HLA-A2-Tyr<sub>(369-377)</sub> complexes, tyrosinase is co-localizes with LAMP-1, a melanosome marker, whereas in cell lines presenting high HLA-A2-Tyr<sub>(369-377)</sub> levels, tyrosinase localizes to the ER. We also observed differences in tyrosinase molecular weight and glycosylation composition as well as major differences in protein stability (t<sub>1/2</sub>). By stabilizing the tyrosinase protein we observed a dramatic decrease in HLA-A2-tyrosinase presentation. Our findings suggest that aberrant processing and instability of tyrosinase are responsible for the high presentation of HLA-A2-Tyr<sub>(369-377)</sub> complexes and thus shed new light on the relationship between intracellular processing, stability of proteins and MHC-restricted peptide presentation.</p></div>]]></content:encoded><description>Short-lived protein translation products are proposed to be a major source of substrates for MHC class I antigen processing and presentation; however, a direct link between protein stability and the presentation level of MHC class I–peptide complexes has not been made. We have recently discovered that the peptide Tyr(369-377), derived from the tyrosinase protein, is highly presented by HLA-A2 on the surface of melanoma cells. To examine the molecular mechanisms responsible for this presentation, we compared characteristics of tyrosinase in melanoma cell lines that present high or low levels of HLA-A2-Tyr(369-377) complexes. We found no correlation between mRNA levels and the levels of HLA-A2-Tyr(369-377) presentation. Co-localization experiments revealed that in cell lines presenting low levels of HLA-A2-Tyr(369-377) complexes, tyrosinase is co-localizes with LAMP-1, a melanosome marker, whereas in cell lines presenting high HLA-A2-Tyr(369-377) levels, tyrosinase localizes to the ER. We also observed differences in tyrosinase molecular weight and glycosylation composition as well as major differences in protein stability (t1/2). By stabilizing the tyrosinase protein we observed a dramatic decrease in HLA-A2-tyrosinase presentation. Our findings suggest that aberrant processing and instability of tyrosinase are responsible for the high presentation of HLA-A2-Tyr(369-377) complexes and thus shed new light on the relationship between intracellular processing, stability of proteins and MHC-restricted peptide presentation.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141519" xmlns="http://purl.org/rss/1.0/"><title>A novel function of murine B1 cells: Active phagocytic and microbicidal abilities</title><link>http://dx.doi.org/10.1002%2Feji.201141519</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A novel function of murine B1 cells: Active phagocytic and microbicidal abilities</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jixin Gao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiaoying Ma</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Weijie Gu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Meng Fu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jingang An</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ying Xing</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tianwen Gao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wei Li</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yufeng Liu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141519</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141519</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141519</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>B1 cells are evolutionarily conserved innate-like cells that share many features with macrophages. It has also been established that B1 cells have a close developmental relationship with macrophages. However, whether B1 cells are able to act as professional phagocytic cells is not clear. In this study, we report that mouse peritoneal cavity (PerC) B cells demonstrate in vivo and in vitro phagocytic activities for <em>Staphylococcus aureus, Escherichia coli</em> and polystyrene fluorescent microspheres. Approximately 5% of PerC B cells, mainly B1b cells, showed phagocytic activity. Ingested microbes were killed efficiently in the phagolysosome. The antigen-specific B-cell antigen receptor (BCR) promoted B-cell phagocytosis, resulting in antigen presentation to T cells after uptake of bacteria. Our results reveal for the first time that mouse B1 cells have active phagocytic capabilities and thereby act as a bridge linking innate and adaptive immunity.</p></div>]]></content:encoded><description>B1 cells are evolutionarily conserved innate-like cells that share many features with macrophages. It has also been established that B1 cells have a close developmental relationship with macrophages. However, whether B1 cells are able to act as professional phagocytic cells is not clear. In this study, we report that mouse peritoneal cavity (PerC) B cells demonstrate in vivo and in vitro phagocytic activities for Staphylococcus aureus, Escherichia coli and polystyrene fluorescent microspheres. Approximately 5% of PerC B cells, mainly B1b cells, showed phagocytic activity. Ingested microbes were killed efficiently in the phagolysosome. The antigen-specific B-cell antigen receptor (BCR) promoted B-cell phagocytosis, resulting in antigen presentation to T cells after uptake of bacteria. Our results reveal for the first time that mouse B1 cells have active phagocytic capabilities and thereby act as a bridge linking innate and adaptive immunity.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201041286" xmlns="http://purl.org/rss/1.0/"><title>Cytip regulates dendritic cell function in contact hypersensitivity</title><link>http://dx.doi.org/10.1002%2Feji.201041286</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cytip regulates dendritic cell function in contact hypersensitivity</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Valeska Heib</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Florian Sparber</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christoph H. Tripp</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniela Ortner</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Patrizia Stoitzner</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christine Heufler</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201041286</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201041286</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201041286</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Cytohesin 1 Interacting protein (Cytip) is induced during DC maturation and in T cells upon activation. It has also been shown to be involved in the regulation of immune responses. Here, we evaluated the functional consequences of Cytip deficiency in DCs using Cytip KO mice. No difference in DC subpopulations in the skin draining lymph nodes was found between Cytip KO mice and their WT counterparts, excluding a role in DC development. To investigate the function of Cytip in DCs in vivo, we used TNCB-induced contact hypersensitivity (CHS) as a model system. In the sensitisation as well as in the elicitation phase, DCs derived from Cytip KO mice induced an increased inflammatory reaction indicated by more pronounced ear swelling. Furthermore, IL-12 production was increased in Cytip KO BMDCs after CpG stimulation. Additionally, Cytip deficient DCs loaded with ovalbumin induced stronger proliferation of antigen specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells in vitro. Finally, migration of skin DCs was not altered after TNCB application due to Cytip deficiency. Taken together, these data suggest a suppressive function for Cytip in mouse DCs in limiting immune responses.</p></div>]]></content:encoded><description>Cytohesin 1 Interacting protein (Cytip) is induced during DC maturation and in T cells upon activation. It has also been shown to be involved in the regulation of immune responses. Here, we evaluated the functional consequences of Cytip deficiency in DCs using Cytip KO mice. No difference in DC subpopulations in the skin draining lymph nodes was found between Cytip KO mice and their WT counterparts, excluding a role in DC development. To investigate the function of Cytip in DCs in vivo, we used TNCB-induced contact hypersensitivity (CHS) as a model system. In the sensitisation as well as in the elicitation phase, DCs derived from Cytip KO mice induced an increased inflammatory reaction indicated by more pronounced ear swelling. Furthermore, IL-12 production was increased in Cytip KO BMDCs after CpG stimulation. Additionally, Cytip deficient DCs loaded with ovalbumin induced stronger proliferation of antigen specific CD4+ and CD8+ T cells in vitro. Finally, migration of skin DCs was not altered after TNCB application due to Cytip deficiency. Taken together, these data suggest a suppressive function for Cytip in mouse DCs in limiting immune responses.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141965" xmlns="http://purl.org/rss/1.0/"><title>Prostaglandin E2 modulates interleukin-8 expression through formation of a multiprotein enhanceosome in human colonic epithelial cells</title><link>http://dx.doi.org/10.1002%2Feji.201141965</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Prostaglandin E2 modulates interleukin-8 expression through formation of a multiprotein enhanceosome in human colonic epithelial cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vikas Srivastava</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Indranil Dey</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pearl Leung</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kris Chadee</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141965</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141965</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141965</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Gastrointestinal inflammation is mediated by the pro-inflammatory mediators interleukin-8 (IL-8) and prostaglandin E<sub>2</sub> (PGE<sub>2</sub>). PGE<sub>2</sub> binding and coupling through EP2/4 receptor subtypes on colonic epithelial cells stimulates cyclic AMP and IL-8 production. Here we determined the mechanisms whereby PGE<sub>2</sub> regulates IL-8 in Caco2 colonic epithelial cells and in cells over expressing EP2/4 receptors. PGE<sub>2</sub> coupling through EP2 activated the transcription factor inducible cAMP early repressor (ICER) whereas coupling through EP4 receptors activated the cyclic AMP-responsive element-binding protein (CREB). Activation of CREB in Caco2/EP2S was PKA dependent, whereas in EP4S cells, activation of CREB occurred through the PKA and PI3K pathways. Since ICER lacks the trans-activation domain, it functions as a transcription repressor as opposed to CREB. PGE<sub>2</sub> coupling through EP2/4 receptors therefore act in an opposing manner to either decrease or promote IL-8 expression by recruiting CREB binding protein (CBP), which formed a multiprotein IL-8 enhanceosome. A novel half CRE (167CRE) and a composite NFAT1-AP1-like site in the IL-8 promoter participated in binding and complex formation as confirmed by mutagenesis and expression studies. These data unravel the mechanisms by which expression of IL-8 is controlled by different signalling pathways that are activated by PGE<sub>2</sub> but acting through different EP receptors.</p></div>]]></content:encoded><description>Gastrointestinal inflammation is mediated by the pro-inflammatory mediators interleukin-8 (IL-8) and prostaglandin E2 (PGE2). PGE2 binding and coupling through EP2/4 receptor subtypes on colonic epithelial cells stimulates cyclic AMP and IL-8 production. Here we determined the mechanisms whereby PGE2 regulates IL-8 in Caco2 colonic epithelial cells and in cells over expressing EP2/4 receptors. PGE2 coupling through EP2 activated the transcription factor inducible cAMP early repressor (ICER) whereas coupling through EP4 receptors activated the cyclic AMP-responsive element-binding protein (CREB). Activation of CREB in Caco2/EP2S was PKA dependent, whereas in EP4S cells, activation of CREB occurred through the PKA and PI3K pathways. Since ICER lacks the trans-activation domain, it functions as a transcription repressor as opposed to CREB. PGE2 coupling through EP2/4 receptors therefore act in an opposing manner to either decrease or promote IL-8 expression by recruiting CREB binding protein (CBP), which formed a multiprotein IL-8 enhanceosome. A novel half CRE (167CRE) and a composite NFAT1-AP1-like site in the IL-8 promoter participated in binding and complex formation as confirmed by mutagenesis and expression studies. These data unravel the mechanisms by which expression of IL-8 is controlled by different signalling pathways that are activated by PGE2 but acting through different EP receptors.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141907" xmlns="http://purl.org/rss/1.0/"><title>Transcript profiling of CD16+ monocytes reveals a unique molecular fingerprint</title><link>http://dx.doi.org/10.1002%2Feji.201141907</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Transcript profiling of CD16+ monocytes reveals a unique molecular fingerprint</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marion Frankenberger</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas P.J. Hofer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ayman Marei</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Farshid Dayyani</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stefan Schewe</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christine Strasser</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Asaad Aldraihim</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Franz Stanzel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Roland Lang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Reinhard Hoffmann</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Olivia Prazeres da Costa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thorsten Buch</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Loems Ziegler-Heitbrock</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141907</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141907</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141907</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>CD16<sup>+</sup> monocytes have unique features with respect to phenotype and function. We have used transcriptional profiling for comparison of CD16<sup>+</sup> monocytes and classical monocytes. We show herein that 187 genes are greater than five-fold differentially expressed, including 90 genes relevant to immune response and inflammation. Hierarchical clustering of data for monocyte subsets and CD1c<sup>+</sup> myeloid blood dendritic cells (DCs) demonstrate that CD16<sup>+</sup> cells are more closely related to classical monocytes than to DCs.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>RT-PCR for ten genes with the strongest differential expression confirmed the pattern including a lower mRNA level for CD14, CD163 and versican in CD16<sup>+</sup> monocytes. The pattern was similar for CD16<sup>+</sup> monocytes at rest and after exercise mobilization from the marginal pool. By contrast, alveolar macrophages, small sputum macrophages, breast milk macrophages and synovial macrophages all showed a different pattern.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>When monocyte-derived macrophages (MDMs) were generated from CD16<sup>+</sup> monocytes by culture with M-CSF in vitro, then the MDMs maintained properties of their progeny with lower expression of CD14, CD163 and versican compared with CD14<sup>++</sup>CD16<sup>−</sup> MDMs. Furthermore, CD14<sup>+</sup>CD16<sup>++</sup> MDMs showed a higher phagocytosis for opsonized <em>E. coli</em>.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The data demonstrate that the CD16<sup>+</sup> monocytes form a distinct type of cell, which gives rise to a distinct macrophage phenotype.</p></div>]]></content:encoded><description>CD16+ monocytes have unique features with respect to phenotype and function. We have used transcriptional profiling for comparison of CD16+ monocytes and classical monocytes. We show herein that 187 genes are greater than five-fold differentially expressed, including 90 genes relevant to immune response and inflammation. Hierarchical clustering of data for monocyte subsets and CD1c+ myeloid blood dendritic cells (DCs) demonstrate that CD16+ cells are more closely related to classical monocytes than to DCs.RT-PCR for ten genes with the strongest differential expression confirmed the pattern including a lower mRNA level for CD14, CD163 and versican in CD16+ monocytes. The pattern was similar for CD16+ monocytes at rest and after exercise mobilization from the marginal pool. By contrast, alveolar macrophages, small sputum macrophages, breast milk macrophages and synovial macrophages all showed a different pattern.When monocyte-derived macrophages (MDMs) were generated from CD16+ monocytes by culture with M-CSF in vitro, then the MDMs maintained properties of their progeny with lower expression of CD14, CD163 and versican compared with CD14++CD16− MDMs. Furthermore, CD14+CD16++ MDMs showed a higher phagocytosis for opsonized E. coli.The data demonstrate that the CD16+ monocytes form a distinct type of cell, which gives rise to a distinct macrophage phenotype.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141958" xmlns="http://purl.org/rss/1.0/"><title>Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation towards Th17 cells</title><link>http://dx.doi.org/10.1002%2Feji.201141958</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation towards Th17 cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wanhong Ding</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michela Manni</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lori L. Stohl</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xi K. Zhou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John A. Wagner</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Richard D. Granstein</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141958</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141958</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141958</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Epidermal Langerhans cells (LCs) are dendritic APCs that play an important role in cutaneous immune responses. LCs are associated with epidermal nerves and the neuropeptides vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) inhibit LC Ag presentation for Th1-type immune responses. Here we examined whether PACAP or VIP modulates LC Ag presentation for induction of IL-17A-producing CD4<sup>+</sup> T cells. Treatment with VIP or PACAP prior to in vitro LC Ag presentation to CD4<sup>+</sup> T cells enhanced IL-17A, IL-6 and IL-4 production, decreased IFN-γ and IL-22 release and increased RORγt and Gata3 mRNA expression while decreasing T-bet expression. The CD4<sup>+</sup> T-cell population was increased in IL-17A- and IL-4-expressing cells and decreased in IFN-γ-expressing cells. Addition of anti-IL-6 mAb blocked the enhanced IL-17A production seen with LC pre-exposure to VIP or PACAP. Intradermal administration of VIP or PACAP prior to application of a contact sensitizer at the injection site, followed by harvesting of draining lymph node CD4<sup>+</sup> T cells and stimulation with anti-CD3/anti-CD28 mAbs, enhanced IL-17A and IL-4 production but reduced production of IL-22 and IFN-γ. PACAP and VIP are endogenous mediators that likely regulate immunity and immune-mediated diseases within the skin.</p></div>]]></content:encoded><description>Epidermal Langerhans cells (LCs) are dendritic APCs that play an important role in cutaneous immune responses. LCs are associated with epidermal nerves and the neuropeptides vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) inhibit LC Ag presentation for Th1-type immune responses. Here we examined whether PACAP or VIP modulates LC Ag presentation for induction of IL-17A-producing CD4+ T cells. Treatment with VIP or PACAP prior to in vitro LC Ag presentation to CD4+ T cells enhanced IL-17A, IL-6 and IL-4 production, decreased IFN-γ and IL-22 release and increased RORγt and Gata3 mRNA expression while decreasing T-bet expression. The CD4+ T-cell population was increased in IL-17A- and IL-4-expressing cells and decreased in IFN-γ-expressing cells. Addition of anti-IL-6 mAb blocked the enhanced IL-17A production seen with LC pre-exposure to VIP or PACAP. Intradermal administration of VIP or PACAP prior to application of a contact sensitizer at the injection site, followed by harvesting of draining lymph node CD4+ T cells and stimulation with anti-CD3/anti-CD28 mAbs, enhanced IL-17A and IL-4 production but reduced production of IL-22 and IFN-γ. PACAP and VIP are endogenous mediators that likely regulate immunity and immune-mediated diseases within the skin.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141613" xmlns="http://purl.org/rss/1.0/"><title>Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo</title><link>http://dx.doi.org/10.1002%2Feji.201141613</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nadine van Montfoort</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sara M. Mangsbo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marcel G. M. Camps</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wendy W. C. van Maren</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ingrid E. C. Verhaart</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ari Waisman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jan Wouter Drijfhout</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cornelis J. M. Melief</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">J. Sjef Verbeek</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ferry Ossendorp</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141613</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141613</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141613</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Increasing evidence suggests that antibodies can have stimulatory effects on T-cell immunity. However, the contribution of circulating antigen-specific antibodies on MHC class I cross-priming in vivo has not been conclusively established. Here, we defined the role of circulating antibodies in cross-presentation of antigen to CD8<sup>+</sup> T cells. Mice with hapten-specific circulating antibodies, but naïve for the T-cell antigen, were infused with haptenated antigen and CD8<sup>+</sup> T-cell induction was measured. Mice with circulating hapten-specific antibodies showed significantly enhanced cross-presentation of the injected antigen compared with mice that lacked these antibodies. The enhanced cross-presentation in mice with circulating antigen-specific antibodies was associated with improved antigen capture by APCs. Importantly, CD11c<sup>+</sup> APCs were responsible for the enhanced and sustained cross-presentation, although CD11c<sup>−</sup> APCs had initially captured a significant amount of the injected antigen.</p></div><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Thus, in vivo formation of antigen-antibody immune complexes improves MHC class I cross-presentation and CD8<sup>+</sup> T-cell activation, demonstrating that humoral immunity can aid the initiation of systemic cellular immunity. These findings have important implications for the understanding of the action of therapeutic antibodies against tumor-associated antigens intensively used in the clinic nowadays.</p></div>]]></content:encoded><description>Increasing evidence suggests that antibodies can have stimulatory effects on T-cell immunity. However, the contribution of circulating antigen-specific antibodies on MHC class I cross-priming in vivo has not been conclusively established. Here, we defined the role of circulating antibodies in cross-presentation of antigen to CD8+ T cells. Mice with hapten-specific circulating antibodies, but naïve for the T-cell antigen, were infused with haptenated antigen and CD8+ T-cell induction was measured. Mice with circulating hapten-specific antibodies showed significantly enhanced cross-presentation of the injected antigen compared with mice that lacked these antibodies. The enhanced cross-presentation in mice with circulating antigen-specific antibodies was associated with improved antigen capture by APCs. Importantly, CD11c+ APCs were responsible for the enhanced and sustained cross-presentation, although CD11c− APCs had initially captured a significant amount of the injected antigen.Thus, in vivo formation of antigen-antibody immune complexes improves MHC class I cross-presentation and CD8+ T-cell activation, demonstrating that humoral immunity can aid the initiation of systemic cellular immunity. These findings have important implications for the understanding of the action of therapeutic antibodies against tumor-associated antigens intensively used in the clinic nowadays.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141657" xmlns="http://purl.org/rss/1.0/"><title>α-defensin-induced MxA expression in healthy human periodontal tissue</title><link>http://dx.doi.org/10.1002%2Feji.201141657</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">α-defensin-induced MxA expression in healthy human periodontal tissue</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rangsini Mahanonda</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Noppadol Sa-Ard-Iam</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pimprapa Rerkyen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Arunee Thitithanyanont</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Keskanya Subbalekha</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sathit Pichyangkul</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141657</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141657</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141657</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regular Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Although periodontal tissue is continually challenged by microbial plaque, it is generally maintained in a healthy state. To understand the basis for this, we investigated innate antiviral immunity in human periodontal tissue. The expression of mRNA encoding different antiviral proteins, myxovirus resistance A (MxA), protein kinase R (PKR), oligoadenylate synthetase (OAS), and secretory leukocyte protease inhibitor (SLPI) were detected in both healthy tissue and that with periodontitis. Immunostaining data consistently showed higher MxA protein expression in the epithelial layer of healthy gingiva as compared with tissue with periodontitis. Human MxA is thought to be induced by type I and III IFNs but neither cytokine type was detected in healthy periodontal tissues. Treatment <em>in vitro</em> of primary human gingival epithelial cells (HGECs) with α-defensins, but not with the antimicrobial peptides β-defensins or LL37, led to MxA protein expression. α-defensin was also detected in healthy periodontal tissue. In addition, MxA in α-defensin-treated HGECs was associated with protection against avian influenza H5N1infection and silencing of the MxA gene using MxA-targeted-siRNA abolished this antiviral activity. To our knowledge, this is the first study to uncover a novel pathway of human MxA induction, which is initiated by an endogenous antimicrobial peptide, namely α-defensin. This pathway may play an important role in the first line of antiviral defense in periodontal tissue.</p></div>]]></content:encoded><description>Although periodontal tissue is continually challenged by microbial plaque, it is generally maintained in a healthy state. To understand the basis for this, we investigated innate antiviral immunity in human periodontal tissue. The expression of mRNA encoding different antiviral proteins, myxovirus resistance A (MxA), protein kinase R (PKR), oligoadenylate synthetase (OAS), and secretory leukocyte protease inhibitor (SLPI) were detected in both healthy tissue and that with periodontitis. Immunostaining data consistently showed higher MxA protein expression in the epithelial layer of healthy gingiva as compared with tissue with periodontitis. Human MxA is thought to be induced by type I and III IFNs but neither cytokine type was detected in healthy periodontal tissues. Treatment in vitro of primary human gingival epithelial cells (HGECs) with α-defensins, but not with the antimicrobial peptides β-defensins or LL37, led to MxA protein expression. α-defensin was also detected in healthy periodontal tissue. In addition, MxA in α-defensin-treated HGECs was associated with protection against avian influenza H5N1infection and silencing of the MxA gene using MxA-targeted-siRNA abolished this antiviral activity. To our knowledge, this is the first study to uncover a novel pathway of human MxA induction, which is initiated by an endogenous antimicrobial peptide, namely α-defensin. This pathway may play an important role in the first line of antiviral defense in periodontal tissue.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142193" xmlns="http://purl.org/rss/1.0/"><title>Utilization of the Snai3 transcription factor to influence hematopoietic cell differentiation: Suppression of lymphocyte and enhancement of myeloid lineages</title><link>http://dx.doi.org/10.1002%2Feji.201142193</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Utilization of the Snai3 transcription factor to influence hematopoietic cell differentiation: Suppression of lymphocyte and enhancement of myeloid lineages</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Timothy Dahlem</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Scott Cho</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gerald J. Spangrude</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Janis J. Weis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John H. Weis</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-04T10:19:33.895618-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142193</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142193</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142193</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Short Communication</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>The altered expression of transcription factors in hematopoietic stem cells and their subsequent lineages can alter the development of lymphoid and myeloid lineages. The role of the transcriptional repressor Snai3 protein in the derivation of cells of the hematopoietic system was investigated. Snai3 is expressed in terminal T-cell and myeloid lineages therefore we chose to determine if expressing Snai3 in the early stages of hematopoietic development would influence cell lineage determination. Expression of <em>Snai3</em> by retroviral transduction of hematopoietic stem cells using bone marrow chimera studies demonstrated a block in lymphoid cell development and enhanced expansion of myeloid lineage cells. Analysis of <em>Snai3</em> expressing hematopoietic precursor cells showed normal numbers of immature cells, but a block in the development of cells committed to lymphoid lineages. These data indicate that the over-expression of Snai3 does alter bone marrow cell development and that the identification of genes whose expression is altered by the presence of Snai3 would aid in our understanding of these developmental pathways.</p></div>]]></content:encoded><description>The altered expression of transcription factors in hematopoietic stem cells and their subsequent lineages can alter the development of lymphoid and myeloid lineages. The role of the transcriptional repressor Snai3 protein in the derivation of cells of the hematopoietic system was investigated. Snai3 is expressed in terminal T-cell and myeloid lineages therefore we chose to determine if expressing Snai3 in the early stages of hematopoietic development would influence cell lineage determination. Expression of Snai3 by retroviral transduction of hematopoietic stem cells using bone marrow chimera studies demonstrated a block in lymphoid cell development and enhanced expansion of myeloid lineage cells. Analysis of Snai3 expressing hematopoietic precursor cells showed normal numbers of immature cells, but a block in the development of cells committed to lymphoid lineages. These data indicate that the over-expression of Snai3 does alter bone marrow cell development and that the identification of genes whose expression is altered by the presence of Snai3 would aid in our understanding of these developmental pathways.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142035" xmlns="http://purl.org/rss/1.0/"><title>Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9</title><link>http://dx.doi.org/10.1002%2Feji.201142035</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Expression of IL-1Rrp2 by human myelomonocytic cells is unique to DCs and facilitates DC maturation by IL-1F8 and IL-1F9</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shilla Mutamba</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Asher Allison</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yashwant Mahida</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paul Barrow</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Neil Foster</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-05T06:31:34.121951-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142035</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142035</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142035</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cellular immune response</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We report for the first time that expression of the novel IL-1 cytokine receptor IL-1Rrp2 (IL-1R6) is unique to dendritic cells (DCs) within the human myelomonocytic lineage. IL-1Rrp2 was expressed by monocyte derived dendritic cells (MDDCs) which was dose-dependently increased by IL-4 and correlated with increased numbers of differentiated MDDCs. Human plasmacytoid DCs also express IL-1Rrp2 but the receptor is not expressed by either myeloid DC type 1 (mDC1) or mDC2 cells. We also show that IL-1F8 or IL-1F9 cytokines, which signal through IL-1Rrp2, induce maturation of MDDCs, as measured by increased expression of HLA-DR and CD83 and decreased expression of CD1a. Furthermore, IL-1F8 stimulated increased CD40 and CD80 expression and IL-18 and IL-12 p70 production by MDDCs, which induced proliferation of IFN-ã-producing CD3<sup>+</sup> lymphocytes (indicative of inflammatory Th1 subsets). IL-1F8 and IL-1F2 were equipotent in their ability to stimulate IL-18 secretion from MDDC but IL-1F8 was not as potent as IL-1F2 in stimulating secretion of IL-12p70 from MDDCs or inducing lymphocyte proliferation Therefore, IL-1Rrp2 expression by some DC subsets may have an important function in the human immune response in vivo via its role in differentiation of inflammatory Th1 lymphocytes.</p></div>]]></content:encoded><description>We report for the first time that expression of the novel IL-1 cytokine receptor IL-1Rrp2 (IL-1R6) is unique to dendritic cells (DCs) within the human myelomonocytic lineage. IL-1Rrp2 was expressed by monocyte derived dendritic cells (MDDCs) which was dose-dependently increased by IL-4 and correlated with increased numbers of differentiated MDDCs. Human plasmacytoid DCs also express IL-1Rrp2 but the receptor is not expressed by either myeloid DC type 1 (mDC1) or mDC2 cells. We also show that IL-1F8 or IL-1F9 cytokines, which signal through IL-1Rrp2, induce maturation of MDDCs, as measured by increased expression of HLA-DR and CD83 and decreased expression of CD1a. Furthermore, IL-1F8 stimulated increased CD40 and CD80 expression and IL-18 and IL-12 p70 production by MDDCs, which induced proliferation of IFN-ã-producing CD3+ lymphocytes (indicative of inflammatory Th1 subsets). IL-1F8 and IL-1F2 were equipotent in their ability to stimulate IL-18 secretion from MDDC but IL-1F8 was not as potent as IL-1F2 in stimulating secretion of IL-12p70 from MDDCs or inducing lymphocyte proliferation Therefore, IL-1Rrp2 expression by some DC subsets may have an important function in the human immune response in vivo via its role in differentiation of inflammatory Th1 lymphocytes.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142011" xmlns="http://purl.org/rss/1.0/"><title>Enhanced structural stability of Concholepas hemocyanin increases its immunogenicity and maintains its non-specific immunostimulatory effects</title><link>http://dx.doi.org/10.1002%2Feji.201142011</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Enhanced structural stability of Concholepas hemocyanin increases its immunogenicity and maintains its non-specific immunostimulatory effects</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sergio Arancibia</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Miguel Del Campo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Esteban Nova</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fabián Salazar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">María Inés Becker</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-05T06:30:52.190532-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142011</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142011</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142011</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunomodulation</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Hemocyanins, which boost the immune system of mammals, have been used as carrier-adjuvants to promote antibody production against haptens and peptides, as immunostimulants during therapy for bladder carcinoma and as a component in therapeutic vaccines for cancer. These biomedical applications have led to growing interest in obtaining hemocyanins with high immunogenicity. Here, we study the immunological properties of a modified <em>Concholepas</em> hemocyanin (Ox-CCH) obtained by the oxidation of its carbohydrates using sodium periodate. We assessed the internalization of Ox-CCH into DCs and its immunogenicity and antitumor effects. Transmission electron microscopy showed no changes in Ox-CCH quaternary structure with respect to native CCH, although proteolytic treatment followed by SDS-PAGE analysis demonstrated that Schiff bases were formed. Interestingly, DCs internalized Ox-CCH faster than CCH, mainly through macropinocytosis. During this process, Ox-CCH remained inside endosome-like structures for a longer period. Mouse immunization experiments demonstrated that Ox-CCH is more immunogenic and a better carrier than CCH. Moreover, Ox-CCH showed a significant antitumor effect in the B16F10 melanoma model similar to that produced by CCH, inducing IFN-secretion Together these data demonstrate that the aldehydes formed by the periodate oxidation of sugar-moieties stabilizes the CCH structure, increasing its adjuvant/immunostimulatory carrier effects.</p></div>]]></content:encoded><description>Hemocyanins, which boost the immune system of mammals, have been used as carrier-adjuvants to promote antibody production against haptens and peptides, as immunostimulants during therapy for bladder carcinoma and as a component in therapeutic vaccines for cancer. These biomedical applications have led to growing interest in obtaining hemocyanins with high immunogenicity. Here, we study the immunological properties of a modified Concholepas hemocyanin (Ox-CCH) obtained by the oxidation of its carbohydrates using sodium periodate. We assessed the internalization of Ox-CCH into DCs and its immunogenicity and antitumor effects. Transmission electron microscopy showed no changes in Ox-CCH quaternary structure with respect to native CCH, although proteolytic treatment followed by SDS-PAGE analysis demonstrated that Schiff bases were formed. Interestingly, DCs internalized Ox-CCH faster than CCH, mainly through macropinocytosis. During this process, Ox-CCH remained inside endosome-like structures for a longer period. Mouse immunization experiments demonstrated that Ox-CCH is more immunogenic and a better carrier than CCH. Moreover, Ox-CCH showed a significant antitumor effect in the B16F10 melanoma model similar to that produced by CCH, inducing IFN-secretion Together these data demonstrate that the aldehydes formed by the periodate oxidation of sugar-moieties stabilizes the CCH structure, increasing its adjuvant/immunostimulatory carrier effects.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141581" xmlns="http://purl.org/rss/1.0/"><title>Tim-1 Regulates Th2 Responses in an Airway Hypersensitivity Model</title><link>http://dx.doi.org/10.1002%2Feji.201141581</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Tim-1 Regulates Th2 Responses in an Airway Hypersensitivity Model</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Miranda L. Curtiss</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jacob V. Gorman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas R. Businga</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Geri Traver</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Melody Singh</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David K. Meyerholz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Joel N. Kline</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John D. Colgan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paul B. Rothman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Suzanne L. Cassel</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-05T06:30:38.210092-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141581</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141581</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141581</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunomodulation</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>T-cell immunoglobulin mucin-1 (Tim-1) is a transmembrane protein postulated to be a key regulator of Th2-type immune responses. This hypothesis is based in part upon genetic studies associating Tim-1 polymorphisms in mice with a bias toward airway hyperresponsiveness (AHR) and the development of Th2-type CD4+ T cells. Tim-1 expressed by Th2 CD4+ T cells has been proposed to function as a co-stimulatory molecule. Tim-1 is also expressed by B cells, macrophages, and dendritic cells, but its role in responses by these cell types has not been firmly established. Here we generated Tim-1 deficient mice to determine the role of Tim-1 in a murine model of allergic airway disease that depends on the development and function of Th2 effector cells and results in the generation of AHR.We found antigen-driven recruitment of inflammatory cells into airways is increased in Tim-1 deficient mice relative to wild-type mice.addition, we observed increased antigen-specific cytokine production by splenocytes from antigen-sensitized Tim-1 deficient mice relative to those from controls.These data support the conclusion that Tim-1 functions in pathways that suppress recruitment of inflammatory cells into the airways and the generation or activity of CD4+ T cells.</p></div>]]></content:encoded><description>T-cell immunoglobulin mucin-1 (Tim-1) is a transmembrane protein postulated to be a key regulator of Th2-type immune responses. This hypothesis is based in part upon genetic studies associating Tim-1 polymorphisms in mice with a bias toward airway hyperresponsiveness (AHR) and the development of Th2-type CD4+ T cells. Tim-1 expressed by Th2 CD4+ T cells has been proposed to function as a co-stimulatory molecule. Tim-1 is also expressed by B cells, macrophages, and dendritic cells, but its role in responses by these cell types has not been firmly established. Here we generated Tim-1 deficient mice to determine the role of Tim-1 in a murine model of allergic airway disease that depends on the development and function of Th2 effector cells and results in the generation of AHR.We found antigen-driven recruitment of inflammatory cells into airways is increased in Tim-1 deficient mice relative to wild-type mice.addition, we observed increased antigen-specific cytokine production by splenocytes from antigen-sensitized Tim-1 deficient mice relative to those from controls.These data support the conclusion that Tim-1 functions in pathways that suppress recruitment of inflammatory cells into the airways and the generation or activity of CD4+ T cells.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141950" xmlns="http://purl.org/rss/1.0/"><title>Death receptor 3 is essential for generating optimal protective CD4+ T-cell immunity against Salmonella</title><link>http://dx.doi.org/10.1002%2Feji.201141950</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Death receptor 3 is essential for generating optimal protective CD4+ T-cell immunity against Salmonella</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sarah L. Buchan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vadim Y. Taraban</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tomasz J. Slebioda</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sonya James</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Adam F. Cunningham</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Aymen Al-Shamkhani</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-25T07:20:31.890735-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141950</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141950</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141950</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunity to infection</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The TNF receptor superfamily member death receptor 3 (DR3) exacerbates Th2 and Th17-mediated inflammatory and autoimmune conditions, yet no role in host defence has been reported. Here we examined the role of DR3 during infection with <em>Salmonella enterica</em> serovar Typhimurium. Infection resulted in protracted expression of the DR3 ligand TL1A but not the related TNF superfamily proteins OX40L or CD30L. TL1A expression was localized to splenic F4/80<sup>+</sup> macrophages where <em>S. enterica</em> Typhimurium replicates, and temporally coincided with the onset of CD4<sup>+</sup>-cell expansion. To address the relevance of the TL1A-DR3 interaction, we examined immune responses to <em>S. enterica</em> Typhimurium in mice lacking DR3. Infected DR3<sup>-/-</sup> mice harboured reduced numbers of antigen-experienced and proliferating CD4<sup>+</sup> T cells compared with wild-type mice. Furthermore, the frequency of IFN-ã<sup>+</sup> CD4<sup>+</sup> T cells in DR3<sup>-/-</sup> mice was lower throughout the time of bacterial clearance. Importantly, bacterial clearance, which is dependent on Th1 cells, was also impaired in DR3<sup>-/-</sup> mice. This defect was intrinsic to CD4<sup>+</sup> T cells as evidenced by an increase in bacterial burden in RAG2-deficient mice receiving DR3<sup>-/-</sup>CD4<sup>+</sup> T cells compared with wild-type CD4<sup>+</sup>-cell recipients. These data establish for the first time a role for DR3 in a host defence response.</p></div>]]></content:encoded><description>The TNF receptor superfamily member death receptor 3 (DR3) exacerbates Th2 and Th17-mediated inflammatory and autoimmune conditions, yet no role in host defence has been reported. Here we examined the role of DR3 during infection with Salmonella enterica serovar Typhimurium. Infection resulted in protracted expression of the DR3 ligand TL1A but not the related TNF superfamily proteins OX40L or CD30L. TL1A expression was localized to splenic F4/80+ macrophages where S. enterica Typhimurium replicates, and temporally coincided with the onset of CD4+-cell expansion. To address the relevance of the TL1A-DR3 interaction, we examined immune responses to S. enterica Typhimurium in mice lacking DR3. Infected DR3-/- mice harboured reduced numbers of antigen-experienced and proliferating CD4+ T cells compared with wild-type mice. Furthermore, the frequency of IFN-ã+ CD4+ T cells in DR3-/- mice was lower throughout the time of bacterial clearance. Importantly, bacterial clearance, which is dependent on Th1 cells, was also impaired in DR3-/- mice. This defect was intrinsic to CD4+ T cells as evidenced by an increase in bacterial burden in RAG2-deficient mice receiving DR3-/-CD4+ T cells compared with wild-type CD4+-cell recipients. These data establish for the first time a role for DR3 in a host defence response.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201040865" xmlns="http://purl.org/rss/1.0/"><title>Glycotranscriptome study reveals an enzymatic switch modulating glycosaminoglycan synthesis during B cell development and activation</title><link>http://dx.doi.org/10.1002%2Feji.201040865</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Glycotranscriptome study reveals an enzymatic switch modulating glycosaminoglycan synthesis during B cell development and activation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sophie Duchez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Virginie Pascal</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nadine Cogné</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chantal Jayat-Vignoles</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Raymond Julien</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michel Cogné</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-10-04T05:21:23.447752-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201040865</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201040865</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201040865</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Molecular immunology</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>B-cell fate and responses are modulated by soluble mediators and direct cellular interactions. Migration properties also vary during differentiation, commitment and activation. In many cells, modulation of responses to stimuli involves cell surface glycans, whose architecture depends on the simultaneous expression of multiple enzymes. By looking at the glycosylation-related gene expression patterns among B cell populations, we determined in this study that the strongest variations were observed for CSGalNAcT-1 and EXTL1. These are enzymes involved in the biosynthesis of alternative forms of glycosaminoglycans, namely chondroitin sulphate and heparan sulphate respectively. These two enzymes showed inverse fluctuations in progenitors, resting B cells and activated B cells, suggesting a developmentally regulated switch between chondroitin and heparan sulphate synthesis. To explore whether these variations contributed to optimal B cell differentiation, we over-expressed EXTL1 in the B-cell lineage of transgenic mice, yielding a partial differentiation blockade at the pro-B to pre-B transition. In the periphery, this defect was almost fully compensated for <em>in vivo</em>, with normal-size B-cell compartments and normal serum immunoglobulin levels in the transgenic EXTL1 mice. The peripheral B cells from EXTL1 transgenics were only affected with regard to their <em>in vitro</em> responses to polyclonal activation, showing reduced proliferation. Together the data suggest that, despite their low amounts in lymphocytes, the heparan sulphate chains decorating the endogenous glycosaminoglycans appear to be regulators of B-cell physiology.</p></div>]]></content:encoded><description>B-cell fate and responses are modulated by soluble mediators and direct cellular interactions. Migration properties also vary during differentiation, commitment and activation. In many cells, modulation of responses to stimuli involves cell surface glycans, whose architecture depends on the simultaneous expression of multiple enzymes. By looking at the glycosylation-related gene expression patterns among B cell populations, we determined in this study that the strongest variations were observed for CSGalNAcT-1 and EXTL1. These are enzymes involved in the biosynthesis of alternative forms of glycosaminoglycans, namely chondroitin sulphate and heparan sulphate respectively. These two enzymes showed inverse fluctuations in progenitors, resting B cells and activated B cells, suggesting a developmentally regulated switch between chondroitin and heparan sulphate synthesis. To explore whether these variations contributed to optimal B cell differentiation, we over-expressed EXTL1 in the B-cell lineage of transgenic mice, yielding a partial differentiation blockade at the pro-B to pre-B transition. In the periphery, this defect was almost fully compensated for in vivo, with normal-size B-cell compartments and normal serum immunoglobulin levels in the transgenic EXTL1 mice. The peripheral B cells from EXTL1 transgenics were only affected with regard to their in vitro responses to polyclonal activation, showing reduced proliferation. Together the data suggest that, despite their low amounts in lymphocytes, the heparan sulphate chains decorating the endogenous glycosaminoglycans appear to be regulators of B-cell physiology.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201041383" xmlns="http://purl.org/rss/1.0/"><title>Enhancement of Anti-Tumor Immunity Through Local Modulation of CTLA-4 and GITR by Dendritic Cells</title><link>http://dx.doi.org/10.1002%2Feji.201041383</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Enhancement of Anti-Tumor Immunity Through Local Modulation of CTLA-4 and GITR by Dendritic Cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Scott K. Pruitt</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David Boczkowski</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nicole de Rosa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">N. Rebecca Haley</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael A. Morse</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Douglas S. Tyler</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jens Dannull</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Smita Nair</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-09-09T04:31:16.669062-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201041383</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201041383</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201041383</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunomodulation</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Cancer vaccines have now demonstrated clinical efficacy, but immune modulatory mechanisms that prevent autoimmunity limit their effectiveness. Systemic administration of mAbs targeting immune modulatory receptors CTLA-4 and glucocorticoid-induced TNFR-related protein (GITR) on Treg cells and effector T cells augments anti-tumor immunity both experimentally and clinically, but can induce life-threatening autoimmunity. We hypothesized that local delivery of anti-CTLA-4 and anti-GITR mAbs to the sites where T cells and tumor antigen-loaded DC vaccines interact would enhance the induction of anti-tumor immunity while avoiding autoimmunity. To achieve this goal, DCs transfected with mRNA encoding the H and L chains of anti-mouse CTLA-4 and GITR mAbs were co-administered with tumor antigen mRNA-transfected DCs. We observed enhanced induction of anti-tumor immunity and significantly improved survival in melanoma-bearing mice, without signs of autoimmunity. In human in vitro assays, we demonstrated that DCs transfected with mRNA encoding humanized anti-CTLA-4 mAb and mRNA encoding a soluble human GITR-L fusion protein enhance the induction of anti-tumor CTLs in response to DCs transfected with mRNAs encoding either melanoma or breast cancer antigens. Based on these results, this approach of using local delivery of immune modulators to enhance vaccine-induced immunity is currently being evaluated in a Phase I clinical cancer immunotherapy trial.</p></div>]]></content:encoded><description>Cancer vaccines have now demonstrated clinical efficacy, but immune modulatory mechanisms that prevent autoimmunity limit their effectiveness. Systemic administration of mAbs targeting immune modulatory receptors CTLA-4 and glucocorticoid-induced TNFR-related protein (GITR) on Treg cells and effector T cells augments anti-tumor immunity both experimentally and clinically, but can induce life-threatening autoimmunity. We hypothesized that local delivery of anti-CTLA-4 and anti-GITR mAbs to the sites where T cells and tumor antigen-loaded DC vaccines interact would enhance the induction of anti-tumor immunity while avoiding autoimmunity. To achieve this goal, DCs transfected with mRNA encoding the H and L chains of anti-mouse CTLA-4 and GITR mAbs were co-administered with tumor antigen mRNA-transfected DCs. We observed enhanced induction of anti-tumor immunity and significantly improved survival in melanoma-bearing mice, without signs of autoimmunity. In human in vitro assays, we demonstrated that DCs transfected with mRNA encoding humanized anti-CTLA-4 mAb and mRNA encoding a soluble human GITR-L fusion protein enhance the induction of anti-tumor CTLs in response to DCs transfected with mRNAs encoding either melanoma or breast cancer antigens. Based on these results, this approach of using local delivery of immune modulators to enhance vaccine-induced immunity is currently being evaluated in a Phase I clinical cancer immunotherapy trial.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201041291" xmlns="http://purl.org/rss/1.0/"><title>Regulation of the development of acute hepatitis by IL-23 through IL-22 and IL-17 production</title><link>http://dx.doi.org/10.1002%2Feji.201041291</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Regulation of the development of acute hepatitis by IL-23 through IL-22 and IL-17 production</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mingli Xu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Noriko Morishima</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Izuru Mizoguchi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yukino Chiba</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Koji Fujita</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Masahiko Kuroda</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yoichiro Iwakura</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniel J. Cua</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Koji Yasutomo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Junichiro Mizuguchi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Takayuki Yoshimoto</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-07-18T06:10:21.951345-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201041291</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201041291</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201041291</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cellular immune response</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>IL-23 plays a critical role in the expansion of highly proinflammatory Th17 cells secreting IL-17 and IL-22. Recently, we demonstrated that Notch signaling drives IL-22 secretion through the aryl hydrocarbon receptor (AHR) and plays a protective role in Con A-induced hepatitis. In this study, we investigated the role of IL-23 in hepatitis using <em>IL-23p19</em>- and <em>IL-17</em>-deficient mice. In WT mice, the injection of Con A induced the upregulation of various cytokines which included IL-23, IL-22, IL-17, IFN-γ and TNF-α. In <em>IL-23p19</em>-deficient mice, exacerbated hepatitis was observed and serum IL-22 and IL-17 levels were greatly reduced, whereas in IL-17-deficient mice, ameliorated hepatitis was observed. The injection of exogenous IL-22 protected <em>p19</em>-deficient mice from hepatitis, whereas the injection of exogenous IL-23 significantly increased the serum levels of not only IL-22 but also IL-17, and less effectively protected against hepatitis in IL-17-dependent and -independent manners. Finally, it was revealed that STAT3, STAT4 and Notch contributed to the production of both cytokines, and that the AHR was important only for IL-22 production in response to Con A and IL-23 in liver mononuclear cells. These results suggest that IL-23 plays a protective role in hepatitis through IL-22 production and also a pathological role via IL-17-dependent and -independent mechanisms.</p></div>]]></content:encoded><description>IL-23 plays a critical role in the expansion of highly proinflammatory Th17 cells secreting IL-17 and IL-22. Recently, we demonstrated that Notch signaling drives IL-22 secretion through the aryl hydrocarbon receptor (AHR) and plays a protective role in Con A-induced hepatitis. In this study, we investigated the role of IL-23 in hepatitis using IL-23p19- and IL-17-deficient mice. In WT mice, the injection of Con A induced the upregulation of various cytokines which included IL-23, IL-22, IL-17, IFN-γ and TNF-α. In IL-23p19-deficient mice, exacerbated hepatitis was observed and serum IL-22 and IL-17 levels were greatly reduced, whereas in IL-17-deficient mice, ameliorated hepatitis was observed. The injection of exogenous IL-22 protected p19-deficient mice from hepatitis, whereas the injection of exogenous IL-23 significantly increased the serum levels of not only IL-22 but also IL-17, and less effectively protected against hepatitis in IL-17-dependent and -independent manners. Finally, it was revealed that STAT3, STAT4 and Notch contributed to the production of both cytokines, and that the AHR was important only for IL-22 production in response to Con A and IL-23 in liver mononuclear cells. These results suggest that IL-23 plays a protective role in hepatitis through IL-22 production and also a pathological role via IL-17-dependent and -independent mechanisms.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201041408" xmlns="http://purl.org/rss/1.0/"><title>Group 1 CD1-restricted T cells take center stage</title><link>http://dx.doi.org/10.1002%2Feji.201041408</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Group 1 CD1-restricted T cells take center stage</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mary H. Young</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laurent Gapin</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-02-09T04:41:11.974575-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201041408</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201041408</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201041408</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Highlights</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The recognition of lipid antigens by T cells is a complex and fascinating phenomenon. The MHC-like molecules of the CD1 family have evolved to present a wide variety of both self and foreign lipids for recognition by T-cell receptors. While much progress has been made in our understanding of the Natural Killer T (NKT) cells that recognize lipids presented by CD1d molecules, our knowledge of the T-cell populations directed at the related group 1 CD1 molecules, <em>i.e</em>. CD1a, CD1b and CD1c, has lagged behind. In this issue of the <em>European Journal of Immunology</em>, a study identifies a surprisingly large portion of human peripheral blood T cells as being autoreactive to the group 1 CD1 proteins. This work and other recent developments highlight the presence of a substantial number of unconventional T cells as part of our normal T-cell repertoire. This interesting finding is discussed in details in this Commentary.</p></div>]]></content:encoded><description>The recognition of lipid antigens by T cells is a complex and fascinating phenomenon. The MHC-like molecules of the CD1 family have evolved to present a wide variety of both self and foreign lipids for recognition by T-cell receptors. While much progress has been made in our understanding of the Natural Killer T (NKT) cells that recognize lipids presented by CD1d molecules, our knowledge of the T-cell populations directed at the related group 1 CD1 molecules, i.e. CD1a, CD1b and CD1c, has lagged behind. In this issue of the European Journal of Immunology, a study identifies a surprisingly large portion of human peripheral blood T cells as being autoreactive to the group 1 CD1 proteins. This work and other recent developments highlight the presence of a substantial number of unconventional T cells as part of our normal T-cell repertoire. This interesting finding is discussed in details in this Commentary.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141931" xmlns="http://purl.org/rss/1.0/"><title>Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8+ T cells</title><link>http://dx.doi.org/10.1002%2Feji.201141931</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8+ T cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrew D. Kaiser</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kerstin Schuster</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jules Gadiot</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lisa Borkner</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Henry Daebritz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Clemens Schmitt</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Reinhard Andreesen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christian Blank</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-05T06:30:58.027822-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141931</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141931</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141931</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunomodulation</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Clinical progression of cancer patients is often observed despite the presence of tumor-reactive T cells. Co-inhibitory ligands of the B7 superfamily have been postulated to play a part in this tumor-immune escape. One of these molecules, PD-L1 (B7-H1, CD274), is widely expressed on tumor cells and has been shown to mediate T-cell inhibition. However, attempts to correlate PD-L1 tumor expression with negative prognosis have been conflicting. To better understand when PD-1/PD-L1-mediated inhibition contributes to the functional impairment of tumor-specific CD8<sup>+</sup> T cells, we varied the levels of antigen density and/or PD-L1 expression at the surface of tumor cells and exposed them to CD8<sup>+</sup> T cells at different levels of functional exhaustion. We found that the gradual reduction of cognate antigen expression by PD-L1-expressing tumor cells increased the susceptibility of partially exhausted T cells to PD-1/PD-L1-mediated inhibition in vitro as well as in vivo. In conclusion, chronically stimulated CD8<sup>+</sup> T cells become sensitive to PD-1/PD-L1-mediated functional inhibition upon low antigen detection; a setting which is likely involved during tumor-immune escape.</p></div>]]></content:encoded><description>Clinical progression of cancer patients is often observed despite the presence of tumor-reactive T cells. Co-inhibitory ligands of the B7 superfamily have been postulated to play a part in this tumor-immune escape. One of these molecules, PD-L1 (B7-H1, CD274), is widely expressed on tumor cells and has been shown to mediate T-cell inhibition. However, attempts to correlate PD-L1 tumor expression with negative prognosis have been conflicting. To better understand when PD-1/PD-L1-mediated inhibition contributes to the functional impairment of tumor-specific CD8+ T cells, we varied the levels of antigen density and/or PD-L1 expression at the surface of tumor cells and exposed them to CD8+ T cells at different levels of functional exhaustion. We found that the gradual reduction of cognate antigen expression by PD-L1-expressing tumor cells increased the susceptibility of partially exhausted T cells to PD-1/PD-L1-mediated inhibition in vitro as well as in vivo. In conclusion, chronically stimulated CD8+ T cells become sensitive to PD-1/PD-L1-mediated functional inhibition upon low antigen detection; a setting which is likely involved during tumor-immune escape.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141737" xmlns="http://purl.org/rss/1.0/"><title>Macrophages participate in IL-17-mediated inflammation</title><link>http://dx.doi.org/10.1002%2Feji.201141737</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Macrophages participate in IL-17-mediated inflammation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jobert G. Barin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">G. Christian Baldeviano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Monica V. Talor</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lei Wu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">SuFey Ong</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Farhan Quader</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ping Chen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dongfeng Zheng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Patrizio Caturegli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Noel R. Rose</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniela Čiháková</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-12T05:11:08.398903-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141737</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141737</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141737</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Innate immunity</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The involvement of macrophages (MΦs) in Th17-cell responses is still poorly understood. While neutrophils are thought to be the predominant effector of Th17-cell responses, IL-17 is also known to induce myelotropic chemokines and growth factors. Other T-cell-derived cytokines induce non-classical functions, suggesting that IL-17 signaling may similarly elicit unique MΦ functions. Here, we characterized the expression of subunits of the IL-17 receptor on primary murine MΦs from different anatomical compartments. The greatest expression of IL-17 receptors was observed on mucosal Ly6C<sup>hi</sup> “inflammatory” MΦs. We further observed upregulation of IL-17 receptors in vitro on bone marrow-derived macrophages (BMMΦs) in response to peptidoglycan or CpG oligonucleotide stimuli, and in vivo, upon CFA administration. Macrophages expressing IL-17 receptors were observed infiltrating the hearts of mice with myocarditis, and genetic ablation of IL-17RA altered MΦ recruitment. Treating primary MΦs from a wide variety of different anatomic sources (as well as cell lines) with IL-17A induced the production of unique profiles of cytokines and chemokines, including GM-CSF, IL-3, IL-9, CCL4/MIP-1β and CCL5/RANTES. IL-17A also induced production of IL-12p70; IL-17-signaling-deficient MΦs elicited diminished IFN-γ production by responding DO11.10 CD4<sup>+</sup> T cells when used as APCs. These data indicate that MΦs from different anatomic locations direct IL-17-mediated responses.</p></div>]]></content:encoded><description>The involvement of macrophages (MΦs) in Th17-cell responses is still poorly understood. While neutrophils are thought to be the predominant effector of Th17-cell responses, IL-17 is also known to induce myelotropic chemokines and growth factors. Other T-cell-derived cytokines induce non-classical functions, suggesting that IL-17 signaling may similarly elicit unique MΦ functions. Here, we characterized the expression of subunits of the IL-17 receptor on primary murine MΦs from different anatomical compartments. The greatest expression of IL-17 receptors was observed on mucosal Ly6Chi “inflammatory” MΦs. We further observed upregulation of IL-17 receptors in vitro on bone marrow-derived macrophages (BMMΦs) in response to peptidoglycan or CpG oligonucleotide stimuli, and in vivo, upon CFA administration. Macrophages expressing IL-17 receptors were observed infiltrating the hearts of mice with myocarditis, and genetic ablation of IL-17RA altered MΦ recruitment. Treating primary MΦs from a wide variety of different anatomic sources (as well as cell lines) with IL-17A induced the production of unique profiles of cytokines and chemokines, including GM-CSF, IL-3, IL-9, CCL4/MIP-1β and CCL5/RANTES. IL-17A also induced production of IL-12p70; IL-17-signaling-deficient MΦs elicited diminished IFN-γ production by responding DO11.10 CD4+ T cells when used as APCs. These data indicate that MΦs from different anatomic locations direct IL-17-mediated responses.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141983" xmlns="http://purl.org/rss/1.0/"><title>Letter to the Editor</title><link>http://dx.doi.org/10.1002%2Feji.201141983</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Letter to the Editor</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Priscilla Biswas</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marina Ferrarini</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-23T09:30:39.153024-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141983</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141983</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141983</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Letter to the Editor</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142024" xmlns="http://purl.org/rss/1.0/"><title>CD24 on thymic APCs regulates negative selection of myelin antigen-specific T lymphocytes</title><link>http://dx.doi.org/10.1002%2Feji.201142024</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">CD24 on thymic APCs regulates negative selection of myelin antigen-specific T lymphocytes</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xuejun Zhang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jin-Qing Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yun Shi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hugh H. Reid</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Richard L. Boyd</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mazin Khattabi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hani Y. El-Omrani</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pan Zheng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yang Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xue-Feng Bai</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-23T09:30:46.241734-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142024</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142024</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142024</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunomodulation</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Negative selection plays a key role in the clonal deletion of autoreactive T cells in the thymus. However, negative selection is incomplete; as high numbers of autoreactive T cells can be detected in normal individuals, mechanisms that regulate negative selection must exist. In this regard, we previously reported that CD24, a GPI-anchored glycoprotein, is required for thymic generation of autoreactive T lymphocytes. The CD24-deficient 2D2 TCR transgenic mice (2D2<sup>+</sup>CD24<sup>−/−</sup>), whose TCR recognizes myelin oligodendrocyte glycoprotein (MOG), fail to generate functional 2D2 T cells. However, it was unclear if CD24 regulated negative selection, and if so, what cellular mechanisms were involved. Here, we show that elimination of MOG or Aire gene expression in 2D2<sup>+</sup>CD24<sup>−/−</sup> mice — through the creation of 2D2<sup>+</sup>CD24<sup>−/−</sup>MOG<sup>−/−</sup> or 2D2<sup>+</sup>CD24<sup>−/−</sup>Aire<sup>−/−</sup>mice — completely restores thymic cellularity and function of 2D2 T cells. Restoration of CD24 expression on DCs, but not on thymocytes also partially restores 2D2 T-cell generation in 2D2<sup>+</sup>CD24<sup>−/−</sup> mice. Taken together, we propose that CD24 expression on thymic antigen-presenting cells (mTECs, DCs) down-regulates autoantigen-mediated clonal deletion of autoreactive thymocytes.</p></div>]]></content:encoded><description>Negative selection plays a key role in the clonal deletion of autoreactive T cells in the thymus. However, negative selection is incomplete; as high numbers of autoreactive T cells can be detected in normal individuals, mechanisms that regulate negative selection must exist. In this regard, we previously reported that CD24, a GPI-anchored glycoprotein, is required for thymic generation of autoreactive T lymphocytes. The CD24-deficient 2D2 TCR transgenic mice (2D2+CD24−/−), whose TCR recognizes myelin oligodendrocyte glycoprotein (MOG), fail to generate functional 2D2 T cells. However, it was unclear if CD24 regulated negative selection, and if so, what cellular mechanisms were involved. Here, we show that elimination of MOG or Aire gene expression in 2D2+CD24−/− mice — through the creation of 2D2+CD24−/−MOG−/− or 2D2+CD24−/−Aire−/−mice — completely restores thymic cellularity and function of 2D2 T cells. Restoration of CD24 expression on DCs, but not on thymocytes also partially restores 2D2 T-cell generation in 2D2+CD24−/− mice. Taken together, we propose that CD24 expression on thymic antigen-presenting cells (mTECs, DCs) down-regulates autoantigen-mediated clonal deletion of autoreactive thymocytes.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141991" xmlns="http://purl.org/rss/1.0/"><title>Interferon regulatory factor modulation underlies the bystander suppression of malaria antigen-driven IL-12 and IFN-γ in filaria–malaria co-infection</title><link>http://dx.doi.org/10.1002%2Feji.201141991</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Interferon regulatory factor modulation underlies the bystander suppression of malaria antigen-driven IL-12 and IFN-γ in filaria–malaria co-infection</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Simon Metenou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Kovacs</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Benoit Dembele</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yaya I. Coulibaly</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Amy D. Klion</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas B. Nutman</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-23T09:30:58.611664-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141991</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141991</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141991</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunomodulation</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>In areas where polyparasitism is highly prevalent, the impact of multiple parasites on the host response is underestimated. In particular, the presence of helminth infection coincident with malaria profoundly alters the production of malaria-specific IFN-γ, IL-12p70, CXCL9, CXCL10 and CXCL11, cytokines/chemokines known to be critical in mediating malaria-specific immunity. In order to elucidate the mechanisms underlying the suppression of malaria-specific cytokines/chemokines, we assessed the expression of malaria-specific IL-12Rβ1, IL-12Rβ2 and interferon regulatory factor (IRF)-1 in blood obtained from 18 filaria-infected (Fil<sup>+</sup>) and 17 filaria-uninfected (Fil<sup>−</sup>) individuals in a filaria–malaria co-endemic region of Mali. We found that Fil<sup>+</sup> individuals had significantly lower RNA expression of IRF-1 but not IL-12Rβ1 or IL-12Rβ2 in response to malaria antigen stimulation. We also measured the frequency of IL-12-producing DCs from these subjects and found that Fil<sup>+</sup> subjects had lower frequencies of IL-12<sup>+</sup> mDCs after malaria antigen stimulation than did the Fil<sup>−</sup> subjects. Modeling these data in vitro, we found that mDCs pre-exposed to live microfilariae not only produced significantly lower levels of CXCL-9, CXCL-10, IL-12p35, IL-12p40, IL-12p19 and CXCL-11 following stimulation with malaria antigen but also markedly downregulated the expression of IRF-1, IRF-2 and IRF-3 compared with microfilaria-unexposed mDCs. siRNA-inhibition of <em>irf-1</em> in mDCs downregulated the production of IL-12p70 through repression of IL-12p35. Our data demonstrate that the modulation of IRFs seen in filarial (and presumably other tissue-invasive helminths) infection underlies the suppression of malaria-specific cytokines/chemokines that play a crucial role in immunity to malaria.</p></div>]]></content:encoded><description>In areas where polyparasitism is highly prevalent, the impact of multiple parasites on the host response is underestimated. In particular, the presence of helminth infection coincident with malaria profoundly alters the production of malaria-specific IFN-γ, IL-12p70, CXCL9, CXCL10 and CXCL11, cytokines/chemokines known to be critical in mediating malaria-specific immunity. In order to elucidate the mechanisms underlying the suppression of malaria-specific cytokines/chemokines, we assessed the expression of malaria-specific IL-12Rβ1, IL-12Rβ2 and interferon regulatory factor (IRF)-1 in blood obtained from 18 filaria-infected (Fil+) and 17 filaria-uninfected (Fil−) individuals in a filaria–malaria co-endemic region of Mali. We found that Fil+ individuals had significantly lower RNA expression of IRF-1 but not IL-12Rβ1 or IL-12Rβ2 in response to malaria antigen stimulation. We also measured the frequency of IL-12-producing DCs from these subjects and found that Fil+ subjects had lower frequencies of IL-12+ mDCs after malaria antigen stimulation than did the Fil− subjects. Modeling these data in vitro, we found that mDCs pre-exposed to live microfilariae not only produced significantly lower levels of CXCL-9, CXCL-10, IL-12p35, IL-12p40, IL-12p19 and CXCL-11 following stimulation with malaria antigen but also markedly downregulated the expression of IRF-1, IRF-2 and IRF-3 compared with microfilaria-unexposed mDCs. siRNA-inhibition of irf-1 in mDCs downregulated the production of IL-12p70 through repression of IL-12p35. Our data demonstrate that the modulation of IRFs seen in filarial (and presumably other tissue-invasive helminths) infection underlies the suppression of malaria-specific cytokines/chemokines that play a crucial role in immunity to malaria.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201041950" xmlns="http://purl.org/rss/1.0/"><title>Death receptor 3 is essential for generating optimal protective CD4+ T-cell immunity against Salmonella</title><link>http://dx.doi.org/10.1002%2Feji.201041950</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Death receptor 3 is essential for generating optimal protective CD4+ T-cell immunity against Salmonella</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sarah L. Buchan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vadim Y. Taraban</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tomasz J. Slebioda</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sonya James</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Adam F. Cunningham</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Aymen Al-Shamkhani</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-19T05:20:17.166086-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201041950</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201041950</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201041950</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Highlights</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The TNF receptor superfamily member death receptor 3 (DR3) exacerbates Th2- and Th17-cell-mediated inflammatory and autoimmune conditions, yet no role in host defence has been reported. Here, we examined the role of DR3 during infection with <em>Salmonella enterica</em> serovar Typhimurium. Infection resulted in protracted expression of the DR3 ligand TL1A but not the related TNF superfamily proteins OX40L or CD30L. TL1A expression was localized to splenic F4/80<sup>+</sup> macrophages where <em>S. enterica</em> Typhimurium replicates, and temporally coincided with the onset of CD4<sup>+</sup>-cell expansion. To address the relevance of the TL1A-DR3 interaction, we examined immune responses to <em>S. enterica</em> Typhimurium in mice lacking DR3. Infected DR3<sup>−/−</sup> mice harboured reduced numbers of antigen-experienced and proliferating CD4<sup>+</sup> T cells compared with WT mice. Furthermore, the frequency of IFN-γ<sup>+</sup> CD4<sup>+</sup> T cells in DR3<sup>−/−</sup> mice was lower throughout the time of bacterial clearance. Importantly, bacterial clearance, which is dependent on Th1 cells, was also impaired in DR3<sup>−/−</sup> mice. This defect was intrinsic to CD4<sup>+</sup> T cells as evidenced by an increase in bacterial burden in RAG2-deficient mice receiving DR3<sup>−/−</sup>CD4<sup>+</sup> T cells compared with WT CD4<sup>+</sup>-cell recipients. These data establish for the first time a role for DR3 in a host defence response.</p></div>]]></content:encoded><description>The TNF receptor superfamily member death receptor 3 (DR3) exacerbates Th2- and Th17-cell-mediated inflammatory and autoimmune conditions, yet no role in host defence has been reported. Here, we examined the role of DR3 during infection with Salmonella enterica serovar Typhimurium. Infection resulted in protracted expression of the DR3 ligand TL1A but not the related TNF superfamily proteins OX40L or CD30L. TL1A expression was localized to splenic F4/80+ macrophages where S. enterica Typhimurium replicates, and temporally coincided with the onset of CD4+-cell expansion. To address the relevance of the TL1A-DR3 interaction, we examined immune responses to S. enterica Typhimurium in mice lacking DR3. Infected DR3−/− mice harboured reduced numbers of antigen-experienced and proliferating CD4+ T cells compared with WT mice. Furthermore, the frequency of IFN-γ+ CD4+ T cells in DR3−/− mice was lower throughout the time of bacterial clearance. Importantly, bacterial clearance, which is dependent on Th1 cells, was also impaired in DR3−/− mice. This defect was intrinsic to CD4+ T cells as evidenced by an increase in bacterial burden in RAG2-deficient mice receiving DR3−/−CD4+ T cells compared with WT CD4+-cell recipients. These data establish for the first time a role for DR3 in a host defence response.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141930" xmlns="http://purl.org/rss/1.0/"><title>HLA-G inhibition of NK-cell cytolytic function is uncoupled from tumor cell lipid raft reorganization</title><link>http://dx.doi.org/10.1002%2Feji.201141930</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">HLA-G inhibition of NK-cell cytolytic function is uncoupled from tumor cell lipid raft reorganization</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeremy Baudhuin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Emilie Lesport</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sylvie Sousa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Julie Migraine</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James Vigneron</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Joel Lemaoult</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Edgardo D. Carosella</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nuala Mooney</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Benoit Favier</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-05T06:30:45.22365-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141930</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141930</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141930</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunomodulation</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>HLA-G is a non-classical HLA class I molecule with tolerogenic properties and restricted tissue distribution. The expression of HLA-G can be induced by tumors thus providing an efficient way to escape the anti-tumoral immune response. Although lipid rafts regulate diverse immunological mechanisms their relationship with HLA-G remains controversial. Our results show that HLA-G-mediated inhibition of both the interaction between NK and tumor cells, and of intracellular calcium flux in NK cells conjugated to their target cells were independent of lipid raft integrity. In addition, cytotoxicity assays indicated that HLA-G continued to efficiently inhibit NK-cell cytolytic function in several different tumor cells independently of lipid raft integrity. Confocal microscopy with 3D reconstruction combined with biochemical analysis showed that HLA-G was mainly localized outside the lipid rafts of tumor cells after cross-linking with specific antibody and remained excluded from lipid rafts during interaction with the ILT2 inhibitory receptor of NK cells. This study indicates that the inhibitory function of HLA-G is uncoupled from lipid raft organization, further distinguishing HLA-G from classical HLA molecules and providing novel information in the understanding of tumor immune escape mechanism mediated through HLA-G.</p></div>]]></content:encoded><description>HLA-G is a non-classical HLA class I molecule with tolerogenic properties and restricted tissue distribution. The expression of HLA-G can be induced by tumors thus providing an efficient way to escape the anti-tumoral immune response. Although lipid rafts regulate diverse immunological mechanisms their relationship with HLA-G remains controversial. Our results show that HLA-G-mediated inhibition of both the interaction between NK and tumor cells, and of intracellular calcium flux in NK cells conjugated to their target cells were independent of lipid raft integrity. In addition, cytotoxicity assays indicated that HLA-G continued to efficiently inhibit NK-cell cytolytic function in several different tumor cells independently of lipid raft integrity. Confocal microscopy with 3D reconstruction combined with biochemical analysis showed that HLA-G was mainly localized outside the lipid rafts of tumor cells after cross-linking with specific antibody and remained excluded from lipid rafts during interaction with the ILT2 inhibitory receptor of NK cells. This study indicates that the inhibitory function of HLA-G is uncoupled from lipid raft organization, further distinguishing HLA-G from classical HLA molecules and providing novel information in the understanding of tumor immune escape mechanism mediated through HLA-G.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141955" xmlns="http://purl.org/rss/1.0/"><title>Nematode-induced interference with the anti-Plasmodium CD8+ T-cell response can be overcome by optimizing antigen administration</title><link>http://dx.doi.org/10.1002%2Feji.201141955</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Nematode-induced interference with the anti-Plasmodium CD8+ T-cell response can be overcome by optimizing antigen administration</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Julia Kolbaum</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Susanne Tartz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wiebke Hartmann</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Susanne Helm</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andreas Nagel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Volker Heussler</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Peter Sebo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bernhard Fleischer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas Jacobs</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Minka Breloer</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-12T05:10:55.484355-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141955</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141955</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141955</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunity to infection</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Malaria is still responsible for up to 1 million deaths per year worldwide, highlighting the need for protective malaria vaccines. Helminth infections that are prevalent in malaria endemic areas can modulate immune responses of the host. Here we show that <em>Strongyloides ratti</em>, a gut-dwelling nematode that causes transient infections, did not change the efficacy of vaccination against <em>Plasmodium berghei</em>. An ongoing infection with <em>Litomosoides sigmodontis</em>, a tissue-dwelling filaria that induces chronic infections in BALB/c mice, significantly interfered with vaccination efficacy. The induction of <em>P. berghei</em> circumsporozoite protein (CSP)-specific CD8<sup>+</sup> T cells, achieved by a single immunization with a CSP fusion protein, was diminished in <em>L. sigmodontis-</em>infected mice. This modulation was reflected by reduced frequencies of CSP-specific CD8<sup>+</sup> T cells, reduced CSP-specific IFN-γ and TNF-α production, reduced CSP-specific cytotoxicity, and reduced protection against <em>P. berghei</em> challenge infection. Implementation of a more potent vaccine regime, by first priming with CSP-expressing recombinant live <em>Salmonella</em> prior to CSP fusion protein immunization, restored induction of CSP-specific CD8<sup>+</sup> T cells and conferred almost sterile immunity to <em>P. berghei</em> challenge infection also in <em>L. sigmodontis</em>-infected mice. In summary, we show that appropriate vaccination regimes can overcome helminth-induced interference with vaccination efficacy.</p></div>]]></content:encoded><description>Malaria is still responsible for up to 1 million deaths per year worldwide, highlighting the need for protective malaria vaccines. Helminth infections that are prevalent in malaria endemic areas can modulate immune responses of the host. Here we show that Strongyloides ratti, a gut-dwelling nematode that causes transient infections, did not change the efficacy of vaccination against Plasmodium berghei. An ongoing infection with Litomosoides sigmodontis, a tissue-dwelling filaria that induces chronic infections in BALB/c mice, significantly interfered with vaccination efficacy. The induction of P. berghei circumsporozoite protein (CSP)-specific CD8+ T cells, achieved by a single immunization with a CSP fusion protein, was diminished in L. sigmodontis-infected mice. This modulation was reflected by reduced frequencies of CSP-specific CD8+ T cells, reduced CSP-specific IFN-γ and TNF-α production, reduced CSP-specific cytotoxicity, and reduced protection against P. berghei challenge infection. Implementation of a more potent vaccine regime, by first priming with CSP-expressing recombinant live Salmonella prior to CSP fusion protein immunization, restored induction of CSP-specific CD8+ T cells and conferred almost sterile immunity to P. berghei challenge infection also in L. sigmodontis-infected mice. In summary, we show that appropriate vaccination regimes can overcome helminth-induced interference with vaccination efficacy.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141921" xmlns="http://purl.org/rss/1.0/"><title>The NLRP3/ASC/Caspase-1 axis regulates IL-1β processing in neutrophils</title><link>http://dx.doi.org/10.1002%2Feji.201141921</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The NLRP3/ASC/Caspase-1 axis regulates IL-1β processing in neutrophils</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Arun K. Mankan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Therese Dau</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dieter Jenne</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Veit Hornung</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-23T09:30:52.241029-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141921</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141921</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141921</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Innate immunity</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Neutrophils play a pivotal role in the defense against bacterial, viral and fungal infections and are important mediators in the acute inflammatory response. At the same time, neutrophils are also involved in sterile inflammatory responses that are triggered by endogenous ligands. A series of immediate effector functions and the expression of proinflammatory genes enable neutrophils to initiate the immune response against the injurious agent. Among these, interleukin-1β (IL-1β) plays a key role in the orchestration of the inflammatory response. Induction of IL-1β expression leads to production of cytosolic pro-IL-1β, which requires further processing by a proteolytic cleavage event. Caspase-1 was initially identified as the main IL-1β-converting enzyme, and the upstream events leading to caspase-1 activation were identified as so-called inflammasome complexes. Up to now, the inflammasome system has mainly been studied in macrophages, whereas the inflammasome was thought to play a redundant or no role in the cell intrinsic processing of pro-IL-1β in neutrophils. Here, we identify the expression of the components of the NLRP3 inflammasome complex in neutrophils and show that the NLRP3 inflammasome pathway is indeed operational in neutrophils. Our findings establish the NLRP3 inflammasome as a key step in the secretion of matured IL-1β by neutrophils.</p></div>]]></content:encoded><description>Neutrophils play a pivotal role in the defense against bacterial, viral and fungal infections and are important mediators in the acute inflammatory response. At the same time, neutrophils are also involved in sterile inflammatory responses that are triggered by endogenous ligands. A series of immediate effector functions and the expression of proinflammatory genes enable neutrophils to initiate the immune response against the injurious agent. Among these, interleukin-1β (IL-1β) plays a key role in the orchestration of the inflammatory response. Induction of IL-1β expression leads to production of cytosolic pro-IL-1β, which requires further processing by a proteolytic cleavage event. Caspase-1 was initially identified as the main IL-1β-converting enzyme, and the upstream events leading to caspase-1 activation were identified as so-called inflammasome complexes. Up to now, the inflammasome system has mainly been studied in macrophages, whereas the inflammasome was thought to play a redundant or no role in the cell intrinsic processing of pro-IL-1β in neutrophils. Here, we identify the expression of the components of the NLRP3 inflammasome complex in neutrophils and show that the NLRP3 inflammasome pathway is indeed operational in neutrophils. Our findings establish the NLRP3 inflammasome as a key step in the secretion of matured IL-1β by neutrophils.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141902" xmlns="http://purl.org/rss/1.0/"><title>Perforin plays an unexpected role in regulating T-cell contraction during prolonged Listeria monocytogenes infection</title><link>http://dx.doi.org/10.1002%2Feji.201141902</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Perforin plays an unexpected role in regulating T-cell contraction during prolonged Listeria monocytogenes infection</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nathan W. Schmidt</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Aaruni Khanolkar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lisa Hancox</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jonathan W. Heusel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John T. Harty</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-12T05:11:02.535316-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141902</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141902</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141902</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunity to infection</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>After infection or vaccination, antigen-specific T cells proliferate then contract in numbers to a memory set point. T-cell contraction is observed after both acute and prolonged infections although it is unknown if contraction is regulated similarly in both scenarios. Here, we show that contraction of antigen-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cells is markedly reduced in TNF/perforin-double deficient (DKO) mice responding to attenuated <em>Listeria monocytogenes</em> infection. Reduced contraction in DKO mice was associated with delayed clearance of infection and sustained T-cell proliferation during the normal contraction interval. Mechanistically, sustained T-cell proliferation mapped to prolonged infection in the absence of TNF; however, reduced contraction required the additional absence of perforin since T cells in mice lacking either TNF or perforin (singly deficient) underwent normal contraction. Thus, while T-cell contraction after acute infection is independent of peforin, a perforin-dependent pathway plays a previously unappreciated role to mediate contraction of antigen-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cells during prolonged <em>L. monocytogenes</em> infection.</p></div>]]></content:encoded><description>After infection or vaccination, antigen-specific T cells proliferate then contract in numbers to a memory set point. T-cell contraction is observed after both acute and prolonged infections although it is unknown if contraction is regulated similarly in both scenarios. Here, we show that contraction of antigen-specific CD8+ and CD4+ T cells is markedly reduced in TNF/perforin-double deficient (DKO) mice responding to attenuated Listeria monocytogenes infection. Reduced contraction in DKO mice was associated with delayed clearance of infection and sustained T-cell proliferation during the normal contraction interval. Mechanistically, sustained T-cell proliferation mapped to prolonged infection in the absence of TNF; however, reduced contraction required the additional absence of perforin since T cells in mice lacking either TNF or perforin (singly deficient) underwent normal contraction. Thus, while T-cell contraction after acute infection is independent of peforin, a perforin-dependent pathway plays a previously unappreciated role to mediate contraction of antigen-specific CD8+ and CD4+ T cells during prolonged L. monocytogenes infection.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141910" xmlns="http://purl.org/rss/1.0/"><title>IKKβ-induced inflammation impacts the kinetics but not the magnitude of the immune response to a viral vector</title><link>http://dx.doi.org/10.1002%2Feji.201141910</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">IKKβ-induced inflammation impacts the kinetics but not the magnitude of the immune response to a viral vector</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Emily L. Hopewell</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Crystina C. Bronk</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Massengill</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robert W. Engelman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Amer A. Beg</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-12T05:11:14.75012-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141910</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141910</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141910</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunomodulation</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Microbial adjuvants in vaccines activate key transcription factors, including NF-κB and interferon response factors (IRFs). However, the individual role of these transcription factor pathways in promoting adaptive immunity by adjuvants is not clear. It is widely believed that induction of a strong inflammatory response potentiates an adaptive immune response. In this study, we sought to determine whether activation of the pro-inflammatory inhibitor of κB kinase β (IKKβ) canonical NF-κB pathway promoted vaccine-induced immune responses. An adenovirus expressing constitutively activated IKKβ (AdIKK) induced robust DC maturation and high expression of key cytokines compared with a control virus. In vivo, AdIKK triggered rapid inflammation after pulmonary infection, increased leukocyte entry into draining LNs, and enhanced early antibody and T-cell responses. Notably, AdIKK did not influence the overall magnitude of the adaptive immune response. These results indicate that induction of inflammation by IKKβ/NF-κB in this setting impacts the kinetics but not the magnitude of adaptive immune responses. These findings therefore help define the individual role of a key pathway induced by vaccine adjuvants in promoting adaptive immunity.</p></div>]]></content:encoded><description>Microbial adjuvants in vaccines activate key transcription factors, including NF-κB and interferon response factors (IRFs). However, the individual role of these transcription factor pathways in promoting adaptive immunity by adjuvants is not clear. It is widely believed that induction of a strong inflammatory response potentiates an adaptive immune response. In this study, we sought to determine whether activation of the pro-inflammatory inhibitor of κB kinase β (IKKβ) canonical NF-κB pathway promoted vaccine-induced immune responses. An adenovirus expressing constitutively activated IKKβ (AdIKK) induced robust DC maturation and high expression of key cytokines compared with a control virus. In vivo, AdIKK triggered rapid inflammation after pulmonary infection, increased leukocyte entry into draining LNs, and enhanced early antibody and T-cell responses. Notably, AdIKK did not influence the overall magnitude of the adaptive immune response. These results indicate that induction of inflammation by IKKβ/NF-κB in this setting impacts the kinetics but not the magnitude of adaptive immune responses. These findings therefore help define the individual role of a key pathway induced by vaccine adjuvants in promoting adaptive immunity.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141800" xmlns="http://purl.org/rss/1.0/"><title>Downregulation of MUC1 expression and its recognition by CD8+ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi</title><link>http://dx.doi.org/10.1002%2Feji.201141800</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Downregulation of MUC1 expression and its recognition by CD8+ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David Roulois</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christophe Blanquart</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Clarisse Panterne</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fabien Gueugnon</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marc Grégoire</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jean-François Fonteneau</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-05T06:31:26.232345-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141800</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141800</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141800</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical immunology</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Research into new treatments against malignant pleural mesothelioma (MPM) is of great interest, as this aggressive cancer is often resistant to conventional therapies. One potential strategy is the use of epigenetic drugs, such as 5-aza-2′-deoxycytidine (5-azaCdR), a DNA-hypomethylating drug, and valproate (VPA), a histone deacetylase inhibitor (HDACi). Indeed, these drugs not only trigger MPM cell death, but also induce the expression of cancer testis antigens recognized by CD8<sup>+</sup> T cells, such as New York-esophageal cancer-1 (NY-ESO-1). The objective of this study was to assess effects of these drugs on the expression and recognition by CD8<sup>+</sup> T cells of Mucin1 (MUC1), a tumor-associated antigen that is overexpressed by MPM. MPM tumor cell lines were treated with epigenetic drugs, alone or in combination. MUC1 expression by MPM cells, and its recognition by a MUC1-specific CD8<sup>+</sup> T-cell clone, was downregulated by HDACi when used alone or in combination with 5-azaCdR. This effect was not due to a blocking of the HLA class I presentation pathway in treated MPM cells, as NY-ESO-1 induced by 5-azaCdR alone, or with VPA, was recognized by a NY-ESO-1-specific T-cell clone. This study suggests that the choice of tumor antigens could be critical for strategies combining epigenetic drugs with immunotherapy.</p></div>]]></content:encoded><description>Research into new treatments against malignant pleural mesothelioma (MPM) is of great interest, as this aggressive cancer is often resistant to conventional therapies. One potential strategy is the use of epigenetic drugs, such as 5-aza-2′-deoxycytidine (5-azaCdR), a DNA-hypomethylating drug, and valproate (VPA), a histone deacetylase inhibitor (HDACi). Indeed, these drugs not only trigger MPM cell death, but also induce the expression of cancer testis antigens recognized by CD8+ T cells, such as New York-esophageal cancer-1 (NY-ESO-1). The objective of this study was to assess effects of these drugs on the expression and recognition by CD8+ T cells of Mucin1 (MUC1), a tumor-associated antigen that is overexpressed by MPM. MPM tumor cell lines were treated with epigenetic drugs, alone or in combination. MUC1 expression by MPM cells, and its recognition by a MUC1-specific CD8+ T-cell clone, was downregulated by HDACi when used alone or in combination with 5-azaCdR. This effect was not due to a blocking of the HLA class I presentation pathway in treated MPM cells, as NY-ESO-1 induced by 5-azaCdR alone, or with VPA, was recognized by a NY-ESO-1-specific T-cell clone. This study suggests that the choice of tumor antigens could be critical for strategies combining epigenetic drugs with immunotherapy.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142108" xmlns="http://purl.org/rss/1.0/"><title>Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis</title><link>http://dx.doi.org/10.1002%2Feji.201142108</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Raquel Planas</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ilijas Jelčić</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sven Schippling</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Roland Martin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mireia Sospedra</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-05T06:31:20.658713-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142108</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142108</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142108</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical immunology</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Natalizumab, an antibody against the α4 subunit of α4 integrins, has been approved for multiple sclerosis (MS) therapy based on its high efficacy and safety profile. However, natalizumab has been associated with the development of progressive multifocal leukoencephalopathy (PML), a disorder caused by JC virus (JCV) infection. In order to improve our understanding of the mechanism of action of natalizumab and to identify possible risk factors for PML development, we have characterized in detail the cell blood composition in MS patients treated with natalizumab for more than 30 months. Natalizumab induced the release of lymphoid- but not myeloid precursor cells, which resulted in a chronic increase ofT-, NK- and particularly B cells. While the percentage of recent thymic emigrants (RTEs), naïve, effector or memory T cells remained unchanged during treatment, a higher percentage of memory- and marginal zone (MZ)-like, but not of naïve B cells, was observed, which most likely is due to a decreased retention of these cells within the splenic MZ. The ability of natalizumab to influence B-cell migration and homeostasis through the splenic MZ, where JCV has been detected, adds to the list of natalizumab effects and may contribute to PML development by disseminating JCV.</p></div>]]></content:encoded><description>Natalizumab, an antibody against the α4 subunit of α4 integrins, has been approved for multiple sclerosis (MS) therapy based on its high efficacy and safety profile. However, natalizumab has been associated with the development of progressive multifocal leukoencephalopathy (PML), a disorder caused by JC virus (JCV) infection. In order to improve our understanding of the mechanism of action of natalizumab and to identify possible risk factors for PML development, we have characterized in detail the cell blood composition in MS patients treated with natalizumab for more than 30 months. Natalizumab induced the release of lymphoid- but not myeloid precursor cells, which resulted in a chronic increase ofT-, NK- and particularly B cells. While the percentage of recent thymic emigrants (RTEs), naïve, effector or memory T cells remained unchanged during treatment, a higher percentage of memory- and marginal zone (MZ)-like, but not of naïve B cells, was observed, which most likely is due to a decreased retention of these cells within the splenic MZ. The ability of natalizumab to influence B-cell migration and homeostasis through the splenic MZ, where JCV has been detected, adds to the list of natalizumab effects and may contribute to PML development by disseminating JCV.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142079" xmlns="http://purl.org/rss/1.0/"><title>Sphingosine regulates the NLRP3-inflammasome and IL-1β release from macrophages</title><link>http://dx.doi.org/10.1002%2Feji.201142079</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Sphingosine regulates the NLRP3-inflammasome and IL-1β release from macrophages</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nadia M. Luheshi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James A. Giles</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gloria Lopez-Castejon</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David Brough</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-22T06:31:13.800991-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142079</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142079</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142079</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Innate immunity</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Interleukin-1β (IL-1β) is a pro-inflammatory cytokine that regulates inflammatory responses to injury and infection. IL-1β secretion requires the protease caspase-1, which is activated following recruitment to inflammasomes. Endogenous danger-associated molecular patterns (DAMPs) released from necrotic cells activate caspase-1 through an NLRP3-inflammasome. Here, we show that the endogenous lipid metabolite sphingosine (Sph) acts as a DAMP by inducing the NLRP3-inflammasome-dependent secretion of IL-1β from macrophages. This process was dependent upon serine/threonine protein phosphatases since the PP1/PP2A inhibitors okadaic acid and calyculin A inhibited Sph-induced IL-1β release. IL-1β release induced by other well-characterized NLRP3-inflammasome activators, such as ATP and uric acid crystals, in addition to NLRC4 and AIM2 inflammasome activators was also blocked by these inhibitors. Thus, we propose Sph as a new DAMP, and that a serine/threonine phosphatase (PP1/PP2A)-dependent signal is central to the endogenous host mechanism through which diverse stimuli regulate inflammasome activation.</p></div>]]></content:encoded><description>Interleukin-1β (IL-1β) is a pro-inflammatory cytokine that regulates inflammatory responses to injury and infection. IL-1β secretion requires the protease caspase-1, which is activated following recruitment to inflammasomes. Endogenous danger-associated molecular patterns (DAMPs) released from necrotic cells activate caspase-1 through an NLRP3-inflammasome. Here, we show that the endogenous lipid metabolite sphingosine (Sph) acts as a DAMP by inducing the NLRP3-inflammasome-dependent secretion of IL-1β from macrophages. This process was dependent upon serine/threonine protein phosphatases since the PP1/PP2A inhibitors okadaic acid and calyculin A inhibited Sph-induced IL-1β release. IL-1β release induced by other well-characterized NLRP3-inflammasome activators, such as ATP and uric acid crystals, in addition to NLRC4 and AIM2 inflammasome activators was also blocked by these inhibitors. Thus, we propose Sph as a new DAMP, and that a serine/threonine phosphatase (PP1/PP2A)-dependent signal is central to the endogenous host mechanism through which diverse stimuli regulate inflammasome activation.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141748" xmlns="http://purl.org/rss/1.0/"><title>Expansion of Tfh-like cells during chronic Salmonella exposure mediates the generation of autoimmune hypergammaglobulinemia in MyD88-deficient mice</title><link>http://dx.doi.org/10.1002%2Feji.201141748</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Expansion of Tfh-like cells during chronic Salmonella exposure mediates the generation of autoimmune hypergammaglobulinemia in MyD88-deficient mice</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hyun-Jeong Ko</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hyungjun Yang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jin-Young Yang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sang-Uk Seo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sun-Young Chang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Je Kyung Seong</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mi-Na Kweon</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-22T06:20:52.207581-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141748</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141748</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141748</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunity to infection</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The role of TLR signaling in linking the innate and adaptive immune systems has been a controversial issue that remains to be solved. Here, we determined whether MyD88-dependent TLR signals are required for the generation of B-cell responses during chronic <em>Salmonella</em> infection. Oral administration of recombinant attenuated <em>Salmonella enterica</em> serovar Typhimurium vaccine (RASV) strain in MyD88<sup>−/−</sup> mice resulted in chronic infection. Infection was accompanied by enlarged germinal centers and hypergammaglobulinemia with anti-double-stranded DNA (dsDNA)-specific Ab in sera, and the deposition of immune complexes in the kidneys, suggesting onset of autoimmunity. CD4<sup>+</sup> T cells expressing PD-1, CXCR5, ICOS, and IL-21 were dramatically increased in chronically infected mice, indicating the expansion of follicular helper T (Tfh)-like cells. Of note, the depletion of CD4<sup>+</sup> T cells completely blocked the generation of polyclonal IgG Ab in sera after oral RASV challenge. Inflammatory myeloid cells expressing CD11b and Gr-1 accumulated in high numbers in the spleen of MyD88<sup>−/−</sup> mice. Interestingly, the blockade of PD-1 or ICOS significantly reduced the hypergammaglobulinemia and dsDNA-specific autoantibody production. Overall, these results suggest that Tfh-like cells in chronic bacterial infection trigger autoimmune hypergammaglobulinemia in a PD-1- and ICOS-dependent manner.</p></div>]]></content:encoded><description>The role of TLR signaling in linking the innate and adaptive immune systems has been a controversial issue that remains to be solved. Here, we determined whether MyD88-dependent TLR signals are required for the generation of B-cell responses during chronic Salmonella infection. Oral administration of recombinant attenuated Salmonella enterica serovar Typhimurium vaccine (RASV) strain in MyD88−/− mice resulted in chronic infection. Infection was accompanied by enlarged germinal centers and hypergammaglobulinemia with anti-double-stranded DNA (dsDNA)-specific Ab in sera, and the deposition of immune complexes in the kidneys, suggesting onset of autoimmunity. CD4+ T cells expressing PD-1, CXCR5, ICOS, and IL-21 were dramatically increased in chronically infected mice, indicating the expansion of follicular helper T (Tfh)-like cells. Of note, the depletion of CD4+ T cells completely blocked the generation of polyclonal IgG Ab in sera after oral RASV challenge. Inflammatory myeloid cells expressing CD11b and Gr-1 accumulated in high numbers in the spleen of MyD88−/− mice. Interestingly, the blockade of PD-1 or ICOS significantly reduced the hypergammaglobulinemia and dsDNA-specific autoantibody production. Overall, these results suggest that Tfh-like cells in chronic bacterial infection trigger autoimmune hypergammaglobulinemia in a PD-1- and ICOS-dependent manner.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142094" xmlns="http://purl.org/rss/1.0/"><title>Modulation of human memory T-cell function by different antigen-presenting cells</title><link>http://dx.doi.org/10.1002%2Feji.201142094</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Modulation of human memory T-cell function by different antigen-presenting cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Matthieu Perreau</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hugh C. Welles</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alexandre Harari</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thierry Calandra</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thierry Roger</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giuseppe Pantaleo</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-05T06:31:41.237018-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142094</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142094</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142094</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Technical Comment</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141920" xmlns="http://purl.org/rss/1.0/"><title>4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia</title><link>http://dx.doi.org/10.1002%2Feji.201141920</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Corina Buechele</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tina Baessler</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Benjamin J. Schmiedel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carla E. Schumacher</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ludger Grosse-Hovest</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kilian Rittig</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Helmut R. Salih</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-05T06:31:13.20327-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141920</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141920</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141920</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Innate immunity</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>NK cells play an important role in tumor immunosurveillance and largely contribute to the therapeutic success of anti-tumor antibodies like Rituximab. Here, we studied the role of the TNF family member 4-1BB ligand (4-1BBL) during the interaction of NK cells with chronic lymphocytic leukemia (CLL) cells. 4-1BBL was highly expressed on patient B-CLL cells in all 56 investigated cases. Signaling via 4-1BBL following interaction with 4-1BB, which was detected on NK cells of CLL patients but not healthy individuals, led to the release of immunoregulatory cytokines including TNF by CLL cells. CLL patient sera contained elevated levels of TNF and induced 4-1BB upregulation on NK cells, which in turn impaired direct and Rituximab-induced NK-cell reactivity against 4-1BBL-expressing targets. NK-cell reactivity was not only enhanced by blocking the interaction of NK cell-expressed 4-1BB with 4-1BBL expressed by CLL cells, but also by preventing 4-1BB upregulation on NK cells via neutralization of TNF in patient serum with Infliximab. Our data indicate that 4-1BBL mediates NK-cell immunosubversion in CLL, and thus might contribute to the reportedly compromised efficacy of Rituximab to induce NK-cell reactivity in the disease, and that TNF neutralization may serve to enhance the efficacy of Rituximab treatment in CLL.</p></div>]]></content:encoded><description>NK cells play an important role in tumor immunosurveillance and largely contribute to the therapeutic success of anti-tumor antibodies like Rituximab. Here, we studied the role of the TNF family member 4-1BB ligand (4-1BBL) during the interaction of NK cells with chronic lymphocytic leukemia (CLL) cells. 4-1BBL was highly expressed on patient B-CLL cells in all 56 investigated cases. Signaling via 4-1BBL following interaction with 4-1BB, which was detected on NK cells of CLL patients but not healthy individuals, led to the release of immunoregulatory cytokines including TNF by CLL cells. CLL patient sera contained elevated levels of TNF and induced 4-1BB upregulation on NK cells, which in turn impaired direct and Rituximab-induced NK-cell reactivity against 4-1BBL-expressing targets. NK-cell reactivity was not only enhanced by blocking the interaction of NK cell-expressed 4-1BB with 4-1BBL expressed by CLL cells, but also by preventing 4-1BB upregulation on NK cells via neutralization of TNF in patient serum with Infliximab. Our data indicate that 4-1BBL mediates NK-cell immunosubversion in CLL, and thus might contribute to the reportedly compromised efficacy of Rituximab to induce NK-cell reactivity in the disease, and that TNF neutralization may serve to enhance the efficacy of Rituximab treatment in CLL.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141798" xmlns="http://purl.org/rss/1.0/"><title>Half of the T-cell repertoire combinatorial diversity is genetically determined in humans and humanized mice</title><link>http://dx.doi.org/10.1002%2Feji.201141798</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Half of the T-cell repertoire combinatorial diversity is genetically determined in humans and humanized mice</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hang-Phuong Pham</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Manuarii Manuel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nicolas Petit</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David Klatzmann</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sylvia Cohen-Kaminsky</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Adrien Six</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gilles Marodon</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-11-22T06:31:12.23121-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141798</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141798</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141798</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Molecular immunology</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>In humanized mice, the T-cell repertoire is derived from genetically identical human progenitors in distinct animals. Thus, careful comparison of the T-cell repertoires of humanized mice with those of humans may reveal the contribution of genetic determinism on T-cell repertoire formation. Here, we performed a comprehensive assessment of the distribution of V-J combinations of the human β chain of the T-cell receptor (hTRBV) in NOD.SCID.γc<sup>−/−</sup> (NSG) humanized mice. We observed that numerous V-J combinations were equally distributed in the thymus and in the periphery of humanized mice compared with human references. A global analysis of the data, comparing repertoire perturbation indices in humanized NSG mice and unrelated human PBMCs, reveals that 50% of the hTRBV families significantly overlapped. Using multivariate ranking and bootstrap analyses, we found that 18% of all possible V-J combinations contributed close to 50% of the expressed diversity, with significant over-representation of BV5-J1.1+1.2 and BV6-J1.1+1.2 rearrangements. Finally, comparison of CD3<sup>−</sup> and CD3<sup>+</sup> thymocyte repertoires indicated that the observed V-J combination overlap was already present before TCR-MHC selection in the thymus. Altogether, our results show that half of the T-cell repertoire combinatorial diversity in humans is genetically determined.</p></div>]]></content:encoded><description>In humanized mice, the T-cell repertoire is derived from genetically identical human progenitors in distinct animals. Thus, careful comparison of the T-cell repertoires of humanized mice with those of humans may reveal the contribution of genetic determinism on T-cell repertoire formation. Here, we performed a comprehensive assessment of the distribution of V-J combinations of the human β chain of the T-cell receptor (hTRBV) in NOD.SCID.γc−/− (NSG) humanized mice. We observed that numerous V-J combinations were equally distributed in the thymus and in the periphery of humanized mice compared with human references. A global analysis of the data, comparing repertoire perturbation indices in humanized NSG mice and unrelated human PBMCs, reveals that 50% of the hTRBV families significantly overlapped. Using multivariate ranking and bootstrap analyses, we found that 18% of all possible V-J combinations contributed close to 50% of the expressed diversity, with significant over-representation of BV5-J1.1+1.2 and BV6-J1.1+1.2 rearrangements. Finally, comparison of CD3− and CD3+ thymocyte repertoires indicated that the observed V-J combination overlap was already present before TCR-MHC selection in the thymus. Altogether, our results show that half of the T-cell repertoire combinatorial diversity in humans is genetically determined.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141702" xmlns="http://purl.org/rss/1.0/"><title>Differential effects of inhibition of bone morphogenic protein (BMP) signalling on T-cell activation and differentiation</title><link>http://dx.doi.org/10.1002%2Feji.201141702</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Differential effects of inhibition of bone morphogenic protein (BMP) signalling on T-cell activation and differentiation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yumiko Yoshioka</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Masahiro Ono</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Motonao Osaki</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ikuo Konishi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shimon Sakaguchi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-05T06:31:05.01129-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141702</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141702</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141702</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Molecular immunology</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Bone morphogenetic proteins (BMPs) are involved in patterning and cellular fate in various organs including the thymus. However, the redundancy of BMPs and their receptors have made it difficult to analyse their physiological roles. Here, we investigated the role of BMP signalling in peripheral CD4<sup>+</sup> T cells by analysing the effects of an inhibitor of BMP signalling, dorsomorphin. Dorsomorphin suppressed phosphorylation of SMAD1/5/8, suggesting that BMP signalling naturally occurs in T cells. At high doses, dorsomorphin suppressed proliferation of T cells in a dose-dependent manner, inducing G1 arrest. Also, dorsomorphin suppressed Th17 and induced Treg-cell differentiation, while preserving Th2 differentiation. Dorsomorphin efficiently suppressed IL-2 production even at low doses in mouse CD4<sup>+</sup> T cells, suggesting that the BMP-Smad signalling physiologically regulates IL-2 transcription in these cells. In addition, recombinant BMP2 induced a dose-dependent multiphasic pattern of IL-2 production, while Noggin suppressed IL-2 production at higher doses in Jurkat cells. Notably, BMP signalling controlled the phosphorylation of RUNX1, revealing the molecular nature of its effect. Collectively, we describe multiple effects of dorsomorphin and Noggin on T-cell activation and differentiation, demonstrating a physiological role for BMP signalling in these processes.</p></div>]]></content:encoded><description>Bone morphogenetic proteins (BMPs) are involved in patterning and cellular fate in various organs including the thymus. However, the redundancy of BMPs and their receptors have made it difficult to analyse their physiological roles. Here, we investigated the role of BMP signalling in peripheral CD4+ T cells by analysing the effects of an inhibitor of BMP signalling, dorsomorphin. Dorsomorphin suppressed phosphorylation of SMAD1/5/8, suggesting that BMP signalling naturally occurs in T cells. At high doses, dorsomorphin suppressed proliferation of T cells in a dose-dependent manner, inducing G1 arrest. Also, dorsomorphin suppressed Th17 and induced Treg-cell differentiation, while preserving Th2 differentiation. Dorsomorphin efficiently suppressed IL-2 production even at low doses in mouse CD4+ T cells, suggesting that the BMP-Smad signalling physiologically regulates IL-2 transcription in these cells. In addition, recombinant BMP2 induced a dose-dependent multiphasic pattern of IL-2 production, while Noggin suppressed IL-2 production at higher doses in Jurkat cells. Notably, BMP signalling controlled the phosphorylation of RUNX1, revealing the molecular nature of its effect. Collectively, we describe multiple effects of dorsomorphin and Noggin on T-cell activation and differentiation, demonstrating a physiological role for BMP signalling in these processes.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.200939117" xmlns="http://purl.org/rss/1.0/"><title>Critical role for the immunoproteasome subunit LMP7 in the resistance of mice to Toxoplasma gondii infection</title><link>http://dx.doi.org/10.1002%2Feji.200939117</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Critical role for the immunoproteasome subunit LMP7 in the resistance of mice to Toxoplasma gondii infection</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Liping Tu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chikako Moriya</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Takashi Imai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hidekazu Ishida</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kohhei Tetsutani</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xuefeng Duan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shigeo Murata</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Keiji Tanaka</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chikako Shimokawa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hajime Hisaeda</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kunisuke Himeno</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2009-11-04T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.200939117</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.200939117</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.200939117</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunity to infection</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Proteasome-mediated proteolysis is responsible for the generation of immunogenic epitopes presented by MHC class I molecules, which activate antigen-specific CD8<sup>+</sup> T cells. Immunoproteasomes, defined by the presence of the three catalytic subunits LMP2, MECL-1, and LMP7, have been hypothesized to optimize MHC class I antigen processing. In this study, we demonstrate that the infection of mice with a protozoan parasite, <em>Toxoplasma gondii</em>, induced the expression of LMP7 mRNA in APC and increased the capacity of APC to induce the production of IFN-γ by antigen-specific CD8<sup>+</sup> T cells. <em>In vitro</em> infection of a DC cell line with <em>T. gondii</em> also induced the expression of LMP7 and resulted in enhanced proteasome proteolytic activity. Finally, mice lacking LMP7 were highly susceptible to infection with <em>T. gondii</em> and showed a reduced number of functional CD8<sup>+</sup> T cells. These results demonstrate that proteasomes containing LMP7 play an indispensable role in the survival of mice infected with <em>T. gondii</em>, presumably due to the efficient generation of CTL epitopes required for the functional development of CD8<sup>+</sup> T cells.</p></div>]]></content:encoded><description>Proteasome-mediated proteolysis is responsible for the generation of immunogenic epitopes presented by MHC class I molecules, which activate antigen-specific CD8+ T cells. Immunoproteasomes, defined by the presence of the three catalytic subunits LMP2, MECL-1, and LMP7, have been hypothesized to optimize MHC class I antigen processing. In this study, we demonstrate that the infection of mice with a protozoan parasite, Toxoplasma gondii, induced the expression of LMP7 mRNA in APC and increased the capacity of APC to induce the production of IFN-γ by antigen-specific CD8+ T cells. In vitro infection of a DC cell line with T. gondii also induced the expression of LMP7 and resulted in enhanced proteasome proteolytic activity. Finally, mice lacking LMP7 were highly susceptible to infection with T. gondii and showed a reduced number of functional CD8+ T cells. These results demonstrate that proteasomes containing LMP7 play an indispensable role in the survival of mice infected with T. gondii, presumably due to the efficient generation of CTL epitopes required for the functional development of CD8+ T cells.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201290004" xmlns="http://purl.org/rss/1.0/"><title>Cover Picture: Eur. J. Immunol. 2/12</title><link>http://dx.doi.org/10.1002%2Feji.201290004</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cover Picture: Eur. J. Immunol. 2/12</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Niki Tsakiri</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dimitrios Papadopoulos</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maria C. Denis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dimos-Dimitrios Mitsikostas</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">George Kollias</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201290004</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201290004</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201290004</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cover Picture</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The cover is based on a spinal cord histology section taken from a TNFR2<sup>−/−</sup> mouse adoptively transferred with TNFR2<sup>−/−</sup> Treg cells prior to immunization with MOG<sub>35–55</sub> to induce EAE. The section is stained with Luxol Fast blue to detect demyelination; Luxol Fast Red, which detects inflammatory infiltration, is the counterstain. The image is taken from the article by Tsakiri et al. (<em>pp</em>. 403–412) in which it is shown that TNFR2 on non-haematopoietic cells is necessary for Treg-cell suppressive activity and repression of EAE development. The colour of the image has been digitally altered for the cover.</p></div>]]></content:encoded><description>The cover is based on a spinal cord histology section taken from a TNFR2−/− mouse adoptively transferred with TNFR2−/− Treg cells prior to immunization with MOG35–55 to induce EAE. The section is stained with Luxol Fast blue to detect demyelination; Luxol Fast Red, which detects inflammatory infiltration, is the counterstain. The image is taken from the article by Tsakiri et al. (pp. 403–412) in which it is shown that TNFR2 on non-haematopoietic cells is necessary for Treg-cell suppressive activity and repression of EAE development. The colour of the image has been digitally altered for the cover.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201290005" xmlns="http://purl.org/rss/1.0/"><title>Editorial Board: Eur. J. Immunol. 2/12</title><link>http://dx.doi.org/10.1002%2Feji.201290005</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Editorial Board: Eur. J. Immunol. 2/12</dc:title><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201290005</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201290005</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201290005</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Editorial Board</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201290000" xmlns="http://purl.org/rss/1.0/"><title>Contents – Eur. J. Immunol. 2/12</title><link>http://dx.doi.org/10.1002%2Feji.201290000</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Contents – Eur. J. Immunol. 2/12</dc:title><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201290000</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201290000</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201290000</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Contents</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">269</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">273</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201290001" xmlns="http://purl.org/rss/1.0/"><title>In this issue</title><link>http://dx.doi.org/10.1002%2Feji.201290001</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">In this issue</dc:title><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201290001</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201290001</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201290001</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">In this issue</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">274</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">275</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Cover image</h3><div class="para"><p>The cover is based on a spinal cord histology section taken from a TNFR2<sup>−/−</sup> mouse adoptively transferred with TNFR2<sup>−/−</sup> Treg cells prior to immunization with MOG<sub>35–55</sub> to induce EAE. The section is stained with Luxol Fast blue to detect demyelination; Luxol Fast Red, which detects inflammatory infiltration, is the counterstain. The image is taken from the article by Tsakiri et al. (<em>pp</em>. 403–412) in which it is shown that TNFR2 on non-haematopoietic cells is necessary for Treg-cell suppressive activity and repression of EAE development. The colour of the image has been digitally altered for the cover.</p></div><div class="para"><p><img alt="inline image" src="http://onlinelibrary.wiley.com/store/10.1002/eji.201290001/asset/image_n/ngra001.jpg?v=1&amp;t=gyn77jl2&amp;s=2c62f52e42316ad6cd52dd024957f4fb8013c189" class="inlineGraphic"/></p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">CMV: Fine tuning the NK-cell response during chronic hepatitis infection</h3><div class="para"><p>Two recent studies reported on the expansion of NKG2C<sup>+</sup> NK cells during chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. In this issue, Béziat et al. show that the expansion of NKG2C<sup>+</sup>CD56<sup>dim</sup> NK cells observed in the blood and liver of HBV- or HCV-infected patients is dependent on infection with human cytomegalovirus (HCMV). The expanded NKG2C<sup>+</sup> NK cells display a terminally differentiated phenotype with strong functional responses against HLA-E-expressing targets and antibody-coated targets but not to IL-12/IL-18 stimulation. Interestingly, these NKG2C<sup>+</sup> NK cells clonally or oligoclonally express self-specific KIRs that block NKG2C-mediated activation, possibly explaining the limited immune pathology associated with the presence/expansion of this highly cytotoxic subset. Together, these findings shed new light on how the human NK-cell compartment adjusts to HCMV infection, resulting in the clonal expansion and differentiation of polyfunctional NK cells expressing self-specific inhibitory KIRs.</p></div><div class="para"><p><img alt="inline image" src="http://onlinelibrary.wiley.com/store/10.1002/eji.201290001/asset/image_n/ngra002.jpg?v=1&amp;t=gyn77jl6&amp;s=9ba60a70026dc0de59918bc915981c6776705a51" class="inlineGraphic"/></p></div><div class="para"><p><a class="accessionId" href="http://dx.doi.org/10.1002/eji.201141826" title="Link to external resource: pp. 447–457">pp. 447–457</a></p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Keep that thymus! Affinity maturation of antibodies requires an intact thymus in the adult</h3><div class="para"><p>The thymus generates T cells, which in turn provide help to B cells to produce antibodies, which constitute the only means of protection against some microbial organisms and their toxins. Whether the thymus contributes other functions to promote antibody responses is not known. In this issue, AbuAttieh et al. show that thymus integrity enables the selection of B cells producing high-affinity antibodies, but is dispensable for the generation of long-lived antibody secreting cells. The defective affinity maturation of antibodies occurs in spite of normal T-cell repertoires in mice with disrupted thymuses, which suggests a novel thymic-dependent mechanism for producing high-affinity antibodies. This finding also explains the deficient responses to vaccination in pediatric cardiac transplantation patients who had their thymus removed at the time of surgery. Finding the molecular mechanisms by which the thymus controls antibody affinity maturation will inspire new approaches to manipulating immunity for the purpose of enhancing or suppressing antigen-specific responses.</p></div><div class="para"><p><img alt="inline image" src="http://onlinelibrary.wiley.com/store/10.1002/eji.201290001/asset/image_n/ngra003.jpg?v=1&amp;t=gyn77jl9&amp;s=b5983000dfc8666de81396496390a97106942bc9" class="inlineGraphic"/></p></div><div class="para"><p><a class="accessionId" href="http://dx.doi.org/10.1002/eji.201141889" title="Link to external resource: pp. 500–510">pp. 500–510</a></p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">All roads lead to Rome: IL-17 drives Th1 immunity following BCG vaccination</h3><div class="para"><p><em>Mycobacterium bovis</em> Bacille Calmette Guerin (BCG) is the only available vaccine against tuberculosis. The generation of effective type 1 T-helper (Th1) cell responses is required for immunity against tuberculosis, but the factors that drive effective generation of vaccine-induced Th1 responses are not completely understood. In this issue, Gopal et al. show that following BCG vaccination, the production of interleukin (IL)-17 by Th17 cells overcomes the inhibitory effects of IL-10 on the generation of vaccine-induced Th1 responses. Following exposure to BCG, mediators such as prostaglandin-E2 (PGE2) promote IL-10 production, limit IL-12 production and Th1 host responses; however, PGE2 also induces IL-23 production and Th17-cell generation. The ability of IL-17 to down-regulate IL-10 and induce IL-12 production in DCs allows the subsequent generation of Th1 responses. These findings highlight how vaccine-induced Th17 cells can be targeted to induce optimal Th1 immunity and may be exploited to improve vaccine strategies against tuberculosis.</p></div><div class="para"><p><img alt="inline image" src="http://onlinelibrary.wiley.com/store/10.1002/eji.201290001/asset/image_n/ngra004.jpg?v=1&amp;t=gyn77jld&amp;s=ffd5795c94ed8c1c36271a9860a243bf9aadebf1" class="inlineGraphic"/></p></div><div class="para"><p><a class="accessionId" href="http://dx.doi.org/10.1002/eji.201141569" title="Link to external resource: pp. 364–373">pp. 364–373</a></p></div></div><div class="section" id="abs1-5" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Constraints for monocyte-derived dendritic cell differentiation</h3><div class="para"><p>The chronic activation of Toll-like receptors (TLRs) leads to persistently impaired macrophage or DC functionality. TLR signals trigger several negative feedback mechanisms but it is not known which of these lead to long-lasting tolerance to further stimulatory signals. It is also not yet understood how monocyte-derived DCs (MoDCs) develop in inflamed tissues in spite of the constant stimulation received during their differentiation. In this issue, Fekete et al. examine the role of several DC inhibitory mechanisms in a robust model of MoDC inactivation induced by early TLR signals during differentiation. The authors find that the activation-induced SOCS1, IL-10, STAT-3, miR146a and CD150 molecules have short-term inhibitory effects on cytokine production, and that IRAK-1 downregulation is linked with persistent MoDC inactivation. Early activation of developing MoDCs allows transient cytokine production that is followed by persistent MoDC inactivation and the preservation of a tissue-resident, non-migratory phenotype.</p></div><div class="para"><p><img alt="inline image" src="http://onlinelibrary.wiley.com/store/10.1002/eji.201290001/asset/image_n/ngra005.jpg?v=1&amp;t=gyn77jlg&amp;s=27cf9a1c72cc013c44a00580c7b53ea1c1eb9fd6" class="inlineGraphic"/></p></div><div class="para"><p><a class="accessionId" href="http://dx.doi.org/10.1002/eji.201141924" title="Link to external resource: pp. 458–469">pp. 458–469</a></p></div></div><div class="section" id="abs1-6" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">From our sister journals – a screening tool for therapeutic antibodies</h3><div class="para"><p>The development of bio-therapeutics is a long and winding road that is dependent on many variables along the way. One of these factors is the stability of a protein and its propensity for forming aggregates. Aggregates, however small the amount present, are highly undesirable due to decreased biological activity of the protein, and the potential to trigger unintended immune responses. A current standard method of analyzing protein stability and aggregate formation is size-exclusion chromatography (SEC). SEC however, has several drawbacks such as its inability to detect conformational differences. In this issue, Trout and colleagues report a novel screening tool based on dye (i.e. thioflavin T (ThT))-binding properties. ThT binds nonspecifically to the β-sheet-rich amyloid-type protein aggregates. The major advantage of ThT binding is the short duration of testing compared to SEC – results can be obtained within days as opposed to months.</p></div><div class="para"><p><img alt="inline image" src="http://onlinelibrary.wiley.com/store/10.1002/eji.201290001/asset/image_n/ngra006.jpg?v=1&amp;t=gyn77jlk&amp;s=146ec8b6d5ed57e96c5d6312ec9f59c0c7e1ad99" class="inlineGraphic"/></p></div><div class="para"><p><a class="accessionId" href="http://dx.doi.org/10.1002/bies.201100366" title="Link to external resource: pp. 127–132">pp. 127–132</a></p></div></div>]]></content:encoded><description>Cover imageThe cover is based on a spinal cord histology section taken from a TNFR2−/− mouse adoptively transferred with TNFR2−/− Treg cells prior to immunization with MOG35–55 to induce EAE. The section is stained with Luxol Fast blue to detect demyelination; Luxol Fast Red, which detects inflammatory infiltration, is the counterstain. The image is taken from the article by Tsakiri et al. (pp. 403–412) in which it is shown that TNFR2 on non-haematopoietic cells is necessary for Treg-cell suppressive activity and repression of EAE development. The colour of the image has been digitally altered for the cover.CMV: Fine tuning the NK-cell response during chronic hepatitis infectionTwo recent studies reported on the expansion of NKG2C+ NK cells during chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. In this issue, Béziat et al. show that the expansion of NKG2C+CD56dim NK cells observed in the blood and liver of HBV- or HCV-infected patients is dependent on infection with human cytomegalovirus (HCMV). The expanded NKG2C+ NK cells display a terminally differentiated phenotype with strong functional responses against HLA-E-expressing targets and antibody-coated targets but not to IL-12/IL-18 stimulation. Interestingly, these NKG2C+ NK cells clonally or oligoclonally express self-specific KIRs that block NKG2C-mediated activation, possibly explaining the limited immune pathology associated with the presence/expansion of this highly cytotoxic subset. Together, these findings shed new light on how the human NK-cell compartment adjusts to HCMV infection, resulting in the clonal expansion and differentiation of polyfunctional NK cells expressing self-specific inhibitory KIRs.pp. 447–457Keep that thymus! Affinity maturation of antibodies requires an intact thymus in the adultThe thymus generates T cells, which in turn provide help to B cells to produce antibodies, which constitute the only means of protection against some microbial organisms and their toxins. Whether the thymus contributes other functions to promote antibody responses is not known. In this issue, AbuAttieh et al. show that thymus integrity enables the selection of B cells producing high-affinity antibodies, but is dispensable for the generation of long-lived antibody secreting cells. The defective affinity maturation of antibodies occurs in spite of normal T-cell repertoires in mice with disrupted thymuses, which suggests a novel thymic-dependent mechanism for producing high-affinity antibodies. This finding also explains the deficient responses to vaccination in pediatric cardiac transplantation patients who had their thymus removed at the time of surgery. Finding the molecular mechanisms by which the thymus controls antibody affinity maturation will inspire new approaches to manipulating immunity for the purpose of enhancing or suppressing antigen-specific responses.pp. 500–510All roads lead to Rome: IL-17 drives Th1 immunity following BCG vaccinationMycobacterium bovis Bacille Calmette Guerin (BCG) is the only available vaccine against tuberculosis. The generation of effective type 1 T-helper (Th1) cell responses is required for immunity against tuberculosis, but the factors that drive effective generation of vaccine-induced Th1 responses are not completely understood. In this issue, Gopal et al. show that following BCG vaccination, the production of interleukin (IL)-17 by Th17 cells overcomes the inhibitory effects of IL-10 on the generation of vaccine-induced Th1 responses. Following exposure to BCG, mediators such as prostaglandin-E2 (PGE2) promote IL-10 production, limit IL-12 production and Th1 host responses; however, PGE2 also induces IL-23 production and Th17-cell generation. The ability of IL-17 to down-regulate IL-10 and induce IL-12 production in DCs allows the subsequent generation of Th1 responses. These findings highlight how vaccine-induced Th17 cells can be targeted to induce optimal Th1 immunity and may be exploited to improve vaccine strategies against tuberculosis.pp. 364–373Constraints for monocyte-derived dendritic cell differentiationThe chronic activation of Toll-like receptors (TLRs) leads to persistently impaired macrophage or DC functionality. TLR signals trigger several negative feedback mechanisms but it is not known which of these lead to long-lasting tolerance to further stimulatory signals. It is also not yet understood how monocyte-derived DCs (MoDCs) develop in inflamed tissues in spite of the constant stimulation received during their differentiation. In this issue, Fekete et al. examine the role of several DC inhibitory mechanisms in a robust model of MoDC inactivation induced by early TLR signals during differentiation. The authors find that the activation-induced SOCS1, IL-10, STAT-3, miR146a and CD150 molecules have short-term inhibitory effects on cytokine production, and that IRAK-1 downregulation is linked with persistent MoDC inactivation. Early activation of developing MoDCs allows transient cytokine production that is followed by persistent MoDC inactivation and the preservation of a tissue-resident, non-migratory phenotype.pp. 458–469From our sister journals – a screening tool for therapeutic antibodiesThe development of bio-therapeutics is a long and winding road that is dependent on many variables along the way. One of these factors is the stability of a protein and its propensity for forming aggregates. Aggregates, however small the amount present, are highly undesirable due to decreased biological activity of the protein, and the potential to trigger unintended immune responses. A current standard method of analyzing protein stability and aggregate formation is size-exclusion chromatography (SEC). SEC however, has several drawbacks such as its inability to detect conformational differences. In this issue, Trout and colleagues report a novel screening tool based on dye (i.e. thioflavin T (ThT))-binding properties. ThT binds nonspecifically to the β-sheet-rich amyloid-type protein aggregates. The major advantage of ThT binding is the short duration of testing compared to SEC – results can be obtained within days as opposed to months.pp. 127–132</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201290002" xmlns="http://purl.org/rss/1.0/"><title>ECI 2012 Focuses On Innovation</title><link>http://dx.doi.org/10.1002%2Feji.201290002</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">ECI 2012 Focuses On Innovation</dc:title><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201290002</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201290002</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201290002</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">News and EFIS</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">276</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">277</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201290003" xmlns="http://purl.org/rss/1.0/"><title>Latest immunology books</title><link>http://dx.doi.org/10.1002%2Feji.201290003</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Latest immunology books</dc:title><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201290003</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201290003</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201290003</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">News and EFIS</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">277</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">277</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142231" xmlns="http://purl.org/rss/1.0/"><title>Neutrophil-active chemokines in in vivo imaging of neutrophil trafficking</title><link>http://dx.doi.org/10.1002%2Feji.201142231</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Neutrophil-active chemokines in in vivo imaging of neutrophil trafficking</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maria-Jesus Sanz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paul Kubes</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142231</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142231</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142231</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Highlights</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">278</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">283</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Chemokines are proinflammatory mediators that regulate leukocyte trafficking at different steps of the leukocyte recruitment cascade. Studies using new imaging approaches and new mouse models are giving new insights into the role of chemokines in neutrophil migration at sites of inflammation. Conventional rolling and adhesion paradigms as well as previously unappreciated functions of signaling pathways triggering leukocyte adhesion, intralumenal crawling and transendothelial migration are compiled and described here. In this review we will summarize recent work in this field, highlighting in vivo imaging studies that examine the behavior of neutrophils in response to chemokines.</p></div>]]></content:encoded><description>Chemokines are proinflammatory mediators that regulate leukocyte trafficking at different steps of the leukocyte recruitment cascade. Studies using new imaging approaches and new mouse models are giving new insights into the role of chemokines in neutrophil migration at sites of inflammation. Conventional rolling and adhesion paradigms as well as previously unappreciated functions of signaling pathways triggering leukocyte adhesion, intralumenal crawling and transendothelial migration are compiled and described here. In this review we will summarize recent work in this field, highlighting in vivo imaging studies that examine the behavior of neutrophils in response to chemokines.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142223" xmlns="http://purl.org/rss/1.0/"><title>Ectoenzymes controlling leukocyte traffic</title><link>http://dx.doi.org/10.1002%2Feji.201142223</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Ectoenzymes controlling leukocyte traffic</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marko Salmi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sirpa Jalkanen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142223</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142223</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142223</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Highlights</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">284</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">292</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Ectoenzymes are a diverse group of membrane proteins that have their catalytic sites outside the plasma membrane. Many of them are found on leukocytes and endothelial cells, and they are multifunctional in nature. Collectively, different ectoenzymes can modulate each step of leukocyte–endothelial contacts, as well as subsequent cell migration in tissues. Here, we review how ectoenzymes belonging to the oxidase, NAD-metabolizing enzyme, nucleotidase and peptidase/protease families regulate and fine-tune leukocyte trafficking, and how ectoenzymes have been targeted both in preclinical and clinical trials.</p></div>]]></content:encoded><description>Ectoenzymes are a diverse group of membrane proteins that have their catalytic sites outside the plasma membrane. Many of them are found on leukocytes and endothelial cells, and they are multifunctional in nature. Collectively, different ectoenzymes can modulate each step of leukocyte–endothelial contacts, as well as subsequent cell migration in tissues. Here, we review how ectoenzymes belonging to the oxidase, NAD-metabolizing enzyme, nucleotidase and peptidase/protease families regulate and fine-tune leukocyte trafficking, and how ectoenzymes have been targeted both in preclinical and clinical trials.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142337" xmlns="http://purl.org/rss/1.0/"><title>TSLP: From allergy to vaccine adjuvant
</title><link>http://dx.doi.org/10.1002%2Feji.201142337</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">TSLP: From allergy to vaccine adjuvant
</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vassili Soumelis</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142337</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142337</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142337</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Highlights</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">293</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">295</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The field of vaccine adjuvants has been an area of active research and development because of the need to improve the generation of protective immunity to a large number of pathogens, as well as in diseases such as cancer. Adjuvants can also help induce stronger immune responses with fewer injections, and consequently improve both the feasibility and success rate of large-scale population vaccine campaigns in developing countries. A current challenge is to identify vaccine adjuvants of various classes (cytokines, toll-like receptor ligands, etc.) with specific immune-modulating properties in order to tailor the immune response to certain pathological situations. In this issue, Van Roey et al. <a class="accessionId" href="http://dx.doi.org/10.1002/eji.201141787" title="Link to external resource: [Eur. J. Immunol. 2012. 42: 353–363]">[Eur. J. Immunol. 2012. 42: 353–363]</a> explore one of these challenges, namely to identify novel mucosal adjuvants. Van Roey et al. show that the pro-allergic cytokine thymic stromal lymphopoietin (TSLP) promotes a strong B-cell response with production of secretory IgA at mucosal sites. Here, we discuss the importance and limits of these findings within the broader field of vaccine adjuvants, and the potential development of TSLP as a mucosal and B-cell adjuvant in humans.</p></div>]]></content:encoded><description>The field of vaccine adjuvants has been an area of active research and development because of the need to improve the generation of protective immunity to a large number of pathogens, as well as in diseases such as cancer. Adjuvants can also help induce stronger immune responses with fewer injections, and consequently improve both the feasibility and success rate of large-scale population vaccine campaigns in developing countries. A current challenge is to identify vaccine adjuvants of various classes (cytokines, toll-like receptor ligands, etc.) with specific immune-modulating properties in order to tailor the immune response to certain pathological situations. In this issue, Van Roey et al. [Eur. J. Immunol. 2012. 42: 353–363] explore one of these challenges, namely to identify novel mucosal adjuvants. Van Roey et al. show that the pro-allergic cytokine thymic stromal lymphopoietin (TSLP) promotes a strong B-cell response with production of secretory IgA at mucosal sites. Here, we discuss the importance and limits of these findings within the broader field of vaccine adjuvants, and the potential development of TSLP as a mucosal and B-cell adjuvant in humans.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142342" xmlns="http://purl.org/rss/1.0/"><title>FAK and PAX-illin get involved in leukocyte diapedesis</title><link>http://dx.doi.org/10.1002%2Feji.201142342</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">FAK and PAX-illin get involved in leukocyte diapedesis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Francis W. Luscinskas</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142342</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142342</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142342</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Highlights</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">296</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">298</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>A major focus of researchers studying leukocyte recruitment has been to identify and understand how cell surface endothelial adhesion molecules, cell-to-cell junctional protein complexes, secreted chemokines and chemoattractants, and the vessel basement membrane structure organization coordinate the process of leukocyte recruitment. As research expands beyond the components initially identified as being necessary for leukocyte recruitment, attention has turned to the structures that regulate endothelial cell-to-matrix adhesion. In this issue of the <em>European Journal of Immunology</em>, Parsons et al. <a class="accessionId" href="http://dx.doi.org/10.1002/eji.201041303" title="Link to external resource: [Eur. J. Immunol. 2012. 42: 436–446]">[Eur. J. Immunol. 2012. 42: 436–446]</a> identify new players in the regulation of neutrophil diapedesis (transendothelial migration), namely the focal adhesion proteins, paxillin and focal adhesion kinase (FAK). While understudied, and indeed previously underappreciated, in leukocyte diapedesis, this <em>Commentary</em> discusses how the work by Parsons et al. implicates FAK and paxillin in the proximal (leukocyte rolling) and distal (diapedesis) steps of the multistep adhesion cascade of leukocyte recruitment.</p></div>]]></content:encoded><description>A major focus of researchers studying leukocyte recruitment has been to identify and understand how cell surface endothelial adhesion molecules, cell-to-cell junctional protein complexes, secreted chemokines and chemoattractants, and the vessel basement membrane structure organization coordinate the process of leukocyte recruitment. As research expands beyond the components initially identified as being necessary for leukocyte recruitment, attention has turned to the structures that regulate endothelial cell-to-matrix adhesion. In this issue of the European Journal of Immunology, Parsons et al. [Eur. J. Immunol. 2012. 42: 436–446] identify new players in the regulation of neutrophil diapedesis (transendothelial migration), namely the focal adhesion proteins, paxillin and focal adhesion kinase (FAK). While understudied, and indeed previously underappreciated, in leukocyte diapedesis, this Commentary discusses how the work by Parsons et al. implicates FAK and paxillin in the proximal (leukocyte rolling) and distal (diapedesis) steps of the multistep adhesion cascade of leukocyte recruitment.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141801" xmlns="http://purl.org/rss/1.0/"><title>NHERF1 regulates gp120-induced internalization and signaling by CCR5, and HIV-1 production</title><link>http://dx.doi.org/10.1002%2Feji.201141801</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">NHERF1 regulates gp120-induced internalization and signaling by CCR5, and HIV-1 production</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yi-Qun Kuang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wei Pang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yong-Tang Zheng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Denis J. Dupré</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141801</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141801</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141801</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Highlights</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">299</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">310</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The scaffolding protein Na<sup>+</sup>/H<sup>+</sup> exchanger regulator factor 1 (NHERF1) plays an important role in the trafficking of G protein-coupled receptors. We previously demonstrated that NHERF1 is involved in chemokine receptor CCR5 homodimer internalization and signal transduction. Given the importance of CCR5 internalization during HIV-1 infection, we evaluated NHERF1's contribution in HIV-1 infection. We challenged human osteosarcoma cells coexpressing CD4 and CCR5 cells expressing either NHERF1 fragment domains or WT NHERF1 with an HIV-1 strain to examine the effects of NHERF1 on HIV-1 entry and replication. WT NHERF1 potentiates HIV-1 envelope gp120-induced CCR5 internalization, and promotes the replication of HIV-1. In order to better understand how NHERF1 affects signal transduction, different domains of NHERF1 were overexpressed in cells to analyze their effect on the different signaling pathways. Here, we show that NHERF1 can associate with CCR5, and promote activation of the gp120-induced MAPK/ERK, focal adhesion kinase and RhoA (Ras homolog gene family member A) signaling pathways. NHERF1 overexpression also increases HIV-1 host cell migration triggered by gp120 via focal adhesion kinase (FAK) signaling. Finally, NHERF1 enhanced actin filament rearrangement in host cells, an important step in post-entry HIV-1 replication events. While postsynaptic density 95/disk-large/zonula occludens 2 (PDZ2) appears to be the major contributor in those events, other domains also participate in the regulation of gp120-induced signaling pathways. Altogether, our results suggest a very important role of the scaffold NHERF1 in the regulation of HIV-1 entry and replication.</p></div>]]></content:encoded><description>The scaffolding protein Na+/H+ exchanger regulator factor 1 (NHERF1) plays an important role in the trafficking of G protein-coupled receptors. We previously demonstrated that NHERF1 is involved in chemokine receptor CCR5 homodimer internalization and signal transduction. Given the importance of CCR5 internalization during HIV-1 infection, we evaluated NHERF1's contribution in HIV-1 infection. We challenged human osteosarcoma cells coexpressing CD4 and CCR5 cells expressing either NHERF1 fragment domains or WT NHERF1 with an HIV-1 strain to examine the effects of NHERF1 on HIV-1 entry and replication. WT NHERF1 potentiates HIV-1 envelope gp120-induced CCR5 internalization, and promotes the replication of HIV-1. In order to better understand how NHERF1 affects signal transduction, different domains of NHERF1 were overexpressed in cells to analyze their effect on the different signaling pathways. Here, we show that NHERF1 can associate with CCR5, and promote activation of the gp120-induced MAPK/ERK, focal adhesion kinase and RhoA (Ras homolog gene family member A) signaling pathways. NHERF1 overexpression also increases HIV-1 host cell migration triggered by gp120 via focal adhesion kinase (FAK) signaling. Finally, NHERF1 enhanced actin filament rearrangement in host cells, an important step in post-entry HIV-1 replication events. While postsynaptic density 95/disk-large/zonula occludens 2 (PDZ2) appears to be the major contributor in those events, other domains also participate in the regulation of gp120-induced signaling pathways. Altogether, our results suggest a very important role of the scaffold NHERF1 in the regulation of HIV-1 entry and replication.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141847" xmlns="http://purl.org/rss/1.0/"><title>Developmental regulation of Th17-cell capacity in human neonates</title><link>http://dx.doi.org/10.1002%2Feji.201141847</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Developmental regulation of Th17-cell capacity in human neonates</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Allison Black</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Suniti Bhaumik</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Richard L. Kirkman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Casey T. Weaver</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David A. Randolph</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141847</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141847</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141847</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cellular immune response</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">311</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">319</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Human neonates are at significantly greater risk of serious infection than immunocompetent adults. In particular, very low birth weight infants in the neonatal intensive care nursery are at high risk of developing life-threatening bacterial and fungal infections. Recent studies have identified Th17 cells as critical mediators of immunity to bacterial and fungal infections at epithelial barriers. Little is known, however, about the ontogeny of Th17-cell responses in humans. The frequency of serious bacterial infections in preterm infants and the importance of Th17 cells in providing protection against such infections in animal studies prompted us to study Th17-cell development in human neonates. Naïve CD4<sup>+</sup> T cells from extremely preterm infants, term infants, and adults were assayed for their capacity to develop into Th17 effector cells. Surprisingly, Th17-cell capacity was inversely related to developmental age. Neonates expressed higher levels of <em>IL-23R</em>, <em>ROR</em>γ<em>t</em>, and <em>STAT3</em> prior to activation and showed a significant Th17-cell bias after activation. In contrast, adult cells expressed more <em>TBX21</em> with a corresponding Th1-cell bias. CD161 expression on Th17-cell precursors was also developmentally regulated. Our results suggest there is significant developmental regulation of CD4<sup>+</sup> effector lineages with a strong bias toward Th17-cell development early in life.</p></div>]]></content:encoded><description>Human neonates are at significantly greater risk of serious infection than immunocompetent adults. In particular, very low birth weight infants in the neonatal intensive care nursery are at high risk of developing life-threatening bacterial and fungal infections. Recent studies have identified Th17 cells as critical mediators of immunity to bacterial and fungal infections at epithelial barriers. Little is known, however, about the ontogeny of Th17-cell responses in humans. The frequency of serious bacterial infections in preterm infants and the importance of Th17 cells in providing protection against such infections in animal studies prompted us to study Th17-cell development in human neonates. Naïve CD4+ T cells from extremely preterm infants, term infants, and adults were assayed for their capacity to develop into Th17 effector cells. Surprisingly, Th17-cell capacity was inversely related to developmental age. Neonates expressed higher levels of IL-23R, RORγt, and STAT3 prior to activation and showed a significant Th17-cell bias after activation. In contrast, adult cells expressed more TBX21 with a corresponding Th1-cell bias. CD161 expression on Th17-cell precursors was also developmentally regulated. Our results suggest there is significant developmental regulation of CD4+ effector lineages with a strong bias toward Th17-cell development early in life.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142091" xmlns="http://purl.org/rss/1.0/"><title>Type-I IFN drives the differentiation of short-lived effector CD8+ T cells in vivo</title><link>http://dx.doi.org/10.1002%2Feji.201142091</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Type-I IFN drives the differentiation of short-lived effector CD8+ T cells in vivo</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Melanie Wiesel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Josh Crouse</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gregor Bedenikovic</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrew Sutherland</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nicole Joller</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Annette Oxenius</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142091</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142091</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142091</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cellular immune response</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">320</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">329</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Two subsets of CD8<sup>+</sup> T cells are generated early during an immune response; one of these subsets forms the memory pool, known as memory precursor effector cells (MPECs), identified by high expression of CD127 and low expression of KLRG1, whereas the other subset forms short-lived effector cells (SLECs) identified by low expression of CD127 and high expression of KLRG1. Here, we studied in vivo the role of type-I IFN in this fate decision. We found that under priming conditions dominated by type-I IFN, as observed in lymphocytic choriomeningitis virus (LCMV) infection, type-I IFN signaling directly impacted the regulation of T-bet and thus the early fate decision of CD8<sup>+</sup> T cells. In the absence of type-I IFN signaling, CD8<sup>+</sup> T cells failed to form SLECs but could form MPECs that give rise to functional memory CD8<sup>+</sup> T cells. Together, these findings identify type-I IFN as an important factor driving SLEC differentiation and thus instructing the early division between the effector and memory precursor CD8<sup>+</sup> T-cell pool.</p></div>]]></content:encoded><description>Two subsets of CD8+ T cells are generated early during an immune response; one of these subsets forms the memory pool, known as memory precursor effector cells (MPECs), identified by high expression of CD127 and low expression of KLRG1, whereas the other subset forms short-lived effector cells (SLECs) identified by low expression of CD127 and high expression of KLRG1. Here, we studied in vivo the role of type-I IFN in this fate decision. We found that under priming conditions dominated by type-I IFN, as observed in lymphocytic choriomeningitis virus (LCMV) infection, type-I IFN signaling directly impacted the regulation of T-bet and thus the early fate decision of CD8+ T cells. In the absence of type-I IFN signaling, CD8+ T cells failed to form SLECs but could form MPECs that give rise to functional memory CD8+ T cells. Together, these findings identify type-I IFN as an important factor driving SLEC differentiation and thus instructing the early division between the effector and memory precursor CD8+ T-cell pool.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201142064" xmlns="http://purl.org/rss/1.0/"><title>Virus-like particles induce robust human T-helper cell responses</title><link>http://dx.doi.org/10.1002%2Feji.201142064</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Virus-like particles induce robust human T-helper cell responses</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marion Braun</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Camilla Jandus</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Patrik Maurer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anya Hammann-Haenni</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Katrin Schwarz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Martin F. Bachmann</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniel E. Speiser</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pedro Romero</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201142064</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201142064</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201142064</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cellular immune response</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">330</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">340</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Among synthetic vaccines, virus-like particles (VLPs) are used for their ability to induce strong humoral responses. Very little is reported on VLP-based-vaccine-induced CD4<sup>+</sup> T-cell responses, despite the requirement of helper T cells for antibody isotype switching. Further knowledge on helper T cells is also needed for optimization of CD8<sup>+</sup> T-cell vaccination. Here, we analysed human CD4<sup>+</sup> T-cell responses to vaccination with MelQbG10, which is a Qβ-VLP covalently linked to a long peptide derived from the melanoma self-antigen Melan-A. In all analysed patients, we found strong antibody responses of mainly IgG1 and IgG3 isotypes, and concomitant Th1-biased CD4<sup>+</sup> T-cell responses specific for Qβ. Although less strong, comparable B- and CD4<sup>+</sup> T-cell responses were also found specific for the Melan-A cargo peptide. Further optimization is required to shift the response more towards the cargo peptide. Nevertheless, the data demonstrate the high potential of VLPs for inducing humoral and cellular immune responses by mounting powerful CD4<sup>+</sup> T-cell help.</p></div>]]></content:encoded><description>Among synthetic vaccines, virus-like particles (VLPs) are used for their ability to induce strong humoral responses. Very little is reported on VLP-based-vaccine-induced CD4+ T-cell responses, despite the requirement of helper T cells for antibody isotype switching. Further knowledge on helper T cells is also needed for optimization of CD8+ T-cell vaccination. Here, we analysed human CD4+ T-cell responses to vaccination with MelQbG10, which is a Qβ-VLP covalently linked to a long peptide derived from the melanoma self-antigen Melan-A. In all analysed patients, we found strong antibody responses of mainly IgG1 and IgG3 isotypes, and concomitant Th1-biased CD4+ T-cell responses specific for Qβ. Although less strong, comparable B- and CD4+ T-cell responses were also found specific for the Melan-A cargo peptide. Further optimization is required to shift the response more towards the cargo peptide. Nevertheless, the data demonstrate the high potential of VLPs for inducing humoral and cellular immune responses by mounting powerful CD4+ T-cell help.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141692" xmlns="http://purl.org/rss/1.0/"><title>Sepsis leads to a reduced antigen-specific primary antibody response</title><link>http://dx.doi.org/10.1002%2Feji.201141692</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Sepsis leads to a reduced antigen-specific primary antibody response</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Arno Mohr</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Johannes Polz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elisabeth M. Martin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sybille Grießl</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anja Kammler</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christian Pötschke</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anja Lechner</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Barbara M. Bröker</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sven Mostböck</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniela N. Männel</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141692</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141692</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141692</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cellular immune response</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">341</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">352</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Immunosuppression, impaired cytokine production and high susceptibility to secondary infections are characteristic for septic patients, and for mice after induction of polymicrobial septic peritonitis by sublethal cecal ligation and puncture (CLP). Here, we demonstrate that CLP markedly altered subsequent B-cell responses. Total IgG and IgM levels, as well as the memory B-cell response, were increased in septic mice, but antigen-specific primary antibody production was strongly impaired. We found that two days after CLP, CD11b<sup>+</sup> splenocytes were activated as demonstrated by the increased expression of activation markers, expression of arginase and production of NO by immature myeloid cells. The in vivo clearance of a bacterial infection was not impaired. DCs demonstrated reduced IL-12 production and altered antigen presentation, resulting in decreased proliferation but enhanced IFN-γ production by CD4<sup>+</sup> cells. CD4<sup>+</sup> T cells from mice immunized on day 2 after CLP showed reduced Th1 and Th2 cytokine production. In addition, there was an increase in Treg cells. Interestingly, levels of immature B cells decreased but levels of mature B cells increased two days after CLP. However, adoptive transfer of naïve CD4<sup>+</sup> T cells, naïve B cells, or naïve DCs did not rescue the antigen-specific antibody response.</p></div>]]></content:encoded><description>Immunosuppression, impaired cytokine production and high susceptibility to secondary infections are characteristic for septic patients, and for mice after induction of polymicrobial septic peritonitis by sublethal cecal ligation and puncture (CLP). Here, we demonstrate that CLP markedly altered subsequent B-cell responses. Total IgG and IgM levels, as well as the memory B-cell response, were increased in septic mice, but antigen-specific primary antibody production was strongly impaired. We found that two days after CLP, CD11b+ splenocytes were activated as demonstrated by the increased expression of activation markers, expression of arginase and production of NO by immature myeloid cells. The in vivo clearance of a bacterial infection was not impaired. DCs demonstrated reduced IL-12 production and altered antigen presentation, resulting in decreased proliferation but enhanced IFN-γ production by CD4+ cells. CD4+ T cells from mice immunized on day 2 after CLP showed reduced Th1 and Th2 cytokine production. In addition, there was an increase in Treg cells. Interestingly, levels of immature B cells decreased but levels of mature B cells increased two days after CLP. However, adoptive transfer of naïve CD4+ T cells, naïve B cells, or naïve DCs did not rescue the antigen-specific antibody response.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141787" xmlns="http://purl.org/rss/1.0/"><title>Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice</title><link>http://dx.doi.org/10.1002%2Feji.201141787</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Griet A. Van Roey</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mauricio A. Arias</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John S. Tregoning</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">George Rowe</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robin J. Shattock</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141787</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141787</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141787</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunity to infection</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">353</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">363</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The development of a successful vaccine against HIV is likely to require the induction of strong and long-lasting humoral immune responses at the mucosal portal of virus entry. Hence, the design of a vaccine strategy able to induce mucosal antibodies and in particular specific IgA, may be crucial to providing immune protection. Nasal immunisation is known to induce specific IgG and IgA responses in the cervicovaginal mucosa; however, there is an urgent need for the development of safe, effective and accessible mucosal adjuvants for nasal application in humans. To reduce the potential for adverse events associated with some nasal adjuvants, we have assessed whether the B-cell-activating cytokines APRIL, BAFF and TSLP enhance humoral immune responses to HIV-1 gp140. Following intranasal immunisation, TSLP but not APRIL or BAFF induced strong humoral responses both in serum and mucosa. The adjuvant effect of TSLP on humoral responses was similar to that of cholera toxin (CT). The use of TSLP as an adjuvant skewed both the cellular and humoral immune responses towards Th2 cells. This is the first time that TSLP has been demonstrated to have a positive effect as a mucosal adjuvant, and specifically to promote mucosal and systemic responses to HIV gp140.</p></div>]]></content:encoded><description>The development of a successful vaccine against HIV is likely to require the induction of strong and long-lasting humoral immune responses at the mucosal portal of virus entry. Hence, the design of a vaccine strategy able to induce mucosal antibodies and in particular specific IgA, may be crucial to providing immune protection. Nasal immunisation is known to induce specific IgG and IgA responses in the cervicovaginal mucosa; however, there is an urgent need for the development of safe, effective and accessible mucosal adjuvants for nasal application in humans. To reduce the potential for adverse events associated with some nasal adjuvants, we have assessed whether the B-cell-activating cytokines APRIL, BAFF and TSLP enhance humoral immune responses to HIV-1 gp140. Following intranasal immunisation, TSLP but not APRIL or BAFF induced strong humoral responses both in serum and mucosa. The adjuvant effect of TSLP on humoral responses was similar to that of cholera toxin (CT). The use of TSLP as an adjuvant skewed both the cellular and humoral immune responses towards Th2 cells. This is the first time that TSLP has been demonstrated to have a positive effect as a mucosal adjuvant, and specifically to promote mucosal and systemic responses to HIV gp140.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141569" xmlns="http://purl.org/rss/1.0/"><title>IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination</title><link>http://dx.doi.org/10.1002%2Feji.201141569</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Radha Gopal</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yinyao Lin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nataša Obermajer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Samantha Slight</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nikhil Nuthalapati</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mushtaq Ahmed</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pawel Kalinski</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shabaana A. Khader</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141569</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141569</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141569</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cellular immune response</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">364</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">373</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The generation of effective type 1 T helper (Th1)-cell responses is required for immunity against intracellular bacteria. However, some intracellular bacteria require interleukin (IL)-17 to drive Th1-cell immunity and subsequent protective host immunity. Here, in a model of <em>Mycobacterium bovis</em> Bacille Calmette–Guerin (BCG) vaccination in mice, we demonstrate that the dependence on IL-17 to drive Th1-cell responses is a host mechanism to overcome bacteria-induced IL-10 inhibitory effects. We show that BCG-induced prostaglandin-E2 (PGE2) promotes the production of IL-10 which limits Th1-cell responses, while simultaneously inducing IL-23 and Th17-cell differentiation. The ability of IL-17 to downregulate IL-10 and induce IL-12 production allows the generation of subsequent Th1-cell responses. Accordingly, BCG-induced Th17-cell responses precede the generation of Th1-cell responses in vivo, whereas the absence of the IL-23 pathway decreases BCG vaccine-induced Th17 and Th1-cell immunity and subsequent vaccine-induced protection upon <em>M. tuberculosis</em> challenge. Importantly, in the absence of IL-10, BCG-induced Th1-cell responses occur in an IL-17-independent manner. These novel data demonstrate a role for the IL-23/IL-17 pathway in driving Th1-cell responses, specifically to overcome IL-10-mediated inhibition and, furthermore, show that in the absence of IL-10, the generation of BCG-induced Th1-cell immunity is IL-17 independent.</p></div>]]></content:encoded><description>The generation of effective type 1 T helper (Th1)-cell responses is required for immunity against intracellular bacteria. However, some intracellular bacteria require interleukin (IL)-17 to drive Th1-cell immunity and subsequent protective host immunity. Here, in a model of Mycobacterium bovis Bacille Calmette–Guerin (BCG) vaccination in mice, we demonstrate that the dependence on IL-17 to drive Th1-cell responses is a host mechanism to overcome bacteria-induced IL-10 inhibitory effects. We show that BCG-induced prostaglandin-E2 (PGE2) promotes the production of IL-10 which limits Th1-cell responses, while simultaneously inducing IL-23 and Th17-cell differentiation. The ability of IL-17 to downregulate IL-10 and induce IL-12 production allows the generation of subsequent Th1-cell responses. Accordingly, BCG-induced Th17-cell responses precede the generation of Th1-cell responses in vivo, whereas the absence of the IL-23 pathway decreases BCG vaccine-induced Th17 and Th1-cell immunity and subsequent vaccine-induced protection upon M. tuberculosis challenge. Importantly, in the absence of IL-10, BCG-induced Th1-cell responses occur in an IL-17-independent manner. These novel data demonstrate a role for the IL-23/IL-17 pathway in driving Th1-cell responses, specifically to overcome IL-10-mediated inhibition and, furthermore, show that in the absence of IL-10, the generation of BCG-induced Th1-cell immunity is IL-17 independent.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141548" xmlns="http://purl.org/rss/1.0/"><title>Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis</title><link>http://dx.doi.org/10.1002%2Feji.201141548</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anca Dorhoi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Geraldine Nouailles</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sabine Jörg</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kristine Hagens</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ellen Heinemann</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lydia Pradl</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dagmar Oberbeck-Müller</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maria Adelaida Duque-Correa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stephen T. Reece</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jürgen Ruland</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Roland Brosch</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jürg Tschopp</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Olaf Gross</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stefan H. E. Kaufmann</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141548</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141548</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141548</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunity to infection</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">374</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">384</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>As a hallmark of tuberculosis (TB), <em>Mycobacterium tuberculosis</em> (MTB) induces granulomatous lung lesions and systemic inflammatory responses during active disease. Molecular regulation of inflammation is associated with inflammasome assembly. We determined the extent to which MTB triggers inflammasome activation and how this impacts on the severity of TB in a mouse model. MTB stimulated release of mature IL-1β in macrophages while attenuated <em>M. bovis</em> BCG failed to do so. Tubercle bacilli specifically activated the NLRP3 inflammasome and this propensity was strictly controlled by the virulence-associated RD1 locus of MTB. However, <em>Nlrp3</em>-deficient mice controlled pulmonary TB, a feature correlated with NLRP3-independent production of IL-1β in infected lungs. Our studies demonstrate that MTB activates the NLRP3 inflammasome in macrophages in an ESX-1-dependent manner. However, during TB, MTB promotes NLRP3- and caspase-1-independent IL-1β release in myeloid cells recruited to lung parenchyma and thus overcomes NLRP3 deficiency in vivo in experimental models.</p></div>]]></content:encoded><description>As a hallmark of tuberculosis (TB), Mycobacterium tuberculosis (MTB) induces granulomatous lung lesions and systemic inflammatory responses during active disease. Molecular regulation of inflammation is associated with inflammasome assembly. We determined the extent to which MTB triggers inflammasome activation and how this impacts on the severity of TB in a mouse model. MTB stimulated release of mature IL-1β in macrophages while attenuated M. bovis BCG failed to do so. Tubercle bacilli specifically activated the NLRP3 inflammasome and this propensity was strictly controlled by the virulence-associated RD1 locus of MTB. However, Nlrp3-deficient mice controlled pulmonary TB, a feature correlated with NLRP3-independent production of IL-1β in infected lungs. Our studies demonstrate that MTB activates the NLRP3 inflammasome in macrophages in an ESX-1-dependent manner. However, during TB, MTB promotes NLRP3- and caspase-1-independent IL-1β release in myeloid cells recruited to lung parenchyma and thus overcomes NLRP3 deficiency in vivo in experimental models.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141903" xmlns="http://purl.org/rss/1.0/"><title>Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory</title><link>http://dx.doi.org/10.1002%2Feji.201141903</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jonathan K. Nambiar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rachel Pinto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Juan I. Aguilo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kiyoshi Takatsu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carlos Martin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Warwick J. Britton</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James A. Triccas</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141903</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141903</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141903</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunity to infection</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">385</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">392</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Definition of protective immunity induced by effective vaccines is important for the design of new pathogen control strategies. Inactivation of the PhoP response-regulator in <em>Mycobacterium tuberculosis</em> results in a highly attenuated strain that demonstrates impressive protective efficacy in pre-clinical models of tuberculosis. In this report we demonstrate that the protection afforded by the <em>M. tuberculosis phoP</em> mutant strain is associated with the long-term maintenance of CD4<sup>+</sup> T-cell memory. Immunization of mice with SO2 resulted in enhanced expansion of <em>M. tuberculosis</em>-specific CD4<sup>+</sup> T cells compared with vaccination with the BCG vaccine, with an increased frequency of these cells persisting at extended time-points after vaccination. Strikingly, vaccination with SO2 resulted in sustained generation of CD4<sup>+</sup> T cells displaying a central memory phenotype, a property not shared by BCG. Further, SO2 vaccination markedly improved the generation of polyfunctional cytokine-secreting CD4<sup>+</sup> T cells compared with BCG vaccination. The improved generation of functionally competent memory T cells by SO2 correlated with augmented recall responses in SO2-vaccinated animals after challenge with virulent <em>M. tuberculosis</em>. This study defines a mechanism for the protective effect of the SO2 vaccine and suggests that deletion of defined virulence networks may provide vaccine strains with potent immuno-stimulatory properties.</p></div>]]></content:encoded><description>Definition of protective immunity induced by effective vaccines is important for the design of new pathogen control strategies. Inactivation of the PhoP response-regulator in Mycobacterium tuberculosis results in a highly attenuated strain that demonstrates impressive protective efficacy in pre-clinical models of tuberculosis. In this report we demonstrate that the protection afforded by the M. tuberculosis phoP mutant strain is associated with the long-term maintenance of CD4+ T-cell memory. Immunization of mice with SO2 resulted in enhanced expansion of M. tuberculosis-specific CD4+ T cells compared with vaccination with the BCG vaccine, with an increased frequency of these cells persisting at extended time-points after vaccination. Strikingly, vaccination with SO2 resulted in sustained generation of CD4+ T cells displaying a central memory phenotype, a property not shared by BCG. Further, SO2 vaccination markedly improved the generation of polyfunctional cytokine-secreting CD4+ T cells compared with BCG vaccination. The improved generation of functionally competent memory T cells by SO2 correlated with augmented recall responses in SO2-vaccinated animals after challenge with virulent M. tuberculosis. This study defines a mechanism for the protective effect of the SO2 vaccine and suggests that deletion of defined virulence networks may provide vaccine strains with potent immuno-stimulatory properties.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141845" xmlns="http://purl.org/rss/1.0/"><title>IFN-γ elevates airway hyper-responsiveness via up-regulation of neurokinin A/neurokinin-2 receptor signaling in a severe asthma model</title><link>http://dx.doi.org/10.1002%2Feji.201141845</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">IFN-γ elevates airway hyper-responsiveness via up-regulation of neurokinin A/neurokinin-2 receptor signaling in a severe asthma model</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Minoru Kobayashi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shigeru Ashino</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yasuo Shiohama</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daiko Wakita</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hidemitsu Kitamura</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Takashi Nishimura</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141845</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141845</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141845</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunomodulation</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">393</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">402</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The adoptive transfer of OVA-specific Th1 cells into WT mice followed by OVA inhalation induces a significant elevation of airway hyper-responsiveness (AHR) with neutrophilia but not mucus hypersecretion. Here, we demonstrate that the airway inflammation model, pathogenically characterized as severe asthma, was partly mimicked by i.n. administration of IFN-γ. The administration of IFN-γ instead of Th1 cells caused AHR elevation but not neutrophilia, and remarkably induced neurokinin-2 receptor (NK2R) expression along with neurokinin A (NKA) production in the lung. To evaluate whether NKA/NK2R was involved in airway inflammation, we first investigated the role of NKA/NK2R-signaling in airway smooth muscle cells (ASMCs) in vitro. NK2R mRNA expression was significantly augmented in tracheal tube-derived ASMCs of WT mice but not STAT-1<sup>−/−</sup> mice after stimulation with IFN-γ. In addition, methacholine-mediated Ca<sup>2+</sup> influx into the ASMCs was significantly reduced in the presence of NK2R antagonist. Moreover, the NK2R antagonist strongly inhibited IFN-γ-dependent AHR elevation in vivo. Thus, these results demonstrated that IFN-γ directly acts on ASMCs to elevate AHR via the NKA/NK2R-signaling cascade. Our present findings suggested that NK2R-mediated neuro-immuno crosstalk would be a promising target for developing novel drugs in Th1-cell-mediated airway inflammation, including severe asthma.</p></div>]]></content:encoded><description>The adoptive transfer of OVA-specific Th1 cells into WT mice followed by OVA inhalation induces a significant elevation of airway hyper-responsiveness (AHR) with neutrophilia but not mucus hypersecretion. Here, we demonstrate that the airway inflammation model, pathogenically characterized as severe asthma, was partly mimicked by i.n. administration of IFN-γ. The administration of IFN-γ instead of Th1 cells caused AHR elevation but not neutrophilia, and remarkably induced neurokinin-2 receptor (NK2R) expression along with neurokinin A (NKA) production in the lung. To evaluate whether NKA/NK2R was involved in airway inflammation, we first investigated the role of NKA/NK2R-signaling in airway smooth muscle cells (ASMCs) in vitro. NK2R mRNA expression was significantly augmented in tracheal tube-derived ASMCs of WT mice but not STAT-1−/− mice after stimulation with IFN-γ. In addition, methacholine-mediated Ca2+ influx into the ASMCs was significantly reduced in the presence of NK2R antagonist. Moreover, the NK2R antagonist strongly inhibited IFN-γ-dependent AHR elevation in vivo. Thus, these results demonstrated that IFN-γ directly acts on ASMCs to elevate AHR via the NKA/NK2R-signaling cascade. Our present findings suggested that NK2R-mediated neuro-immuno crosstalk would be a promising target for developing novel drugs in Th1-cell-mediated airway inflammation, including severe asthma.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141659" xmlns="http://purl.org/rss/1.0/"><title>TNFR2 on non-haematopoietic cells is required for Foxp3+ Treg-cell function and disease suppression in EAE</title><link>http://dx.doi.org/10.1002%2Feji.201141659</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">TNFR2 on non-haematopoietic cells is required for Foxp3+ Treg-cell function and disease suppression in EAE</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Niki Tsakiri</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dimitrios Papadopoulos</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maria C. Denis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dimos-Dimitrios Mitsikostas</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">George Kollias</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141659</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141659</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141659</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunomodulation</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">403</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">412</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The TNF/TNFR system exerts multiple proinflammatory and immunosuppressive functions in the pathogenesis of chronic inflammation and autoimmunity. In EAE, the experimental model of Multiple Sclerosis (MS), genetic ablation of TNFR2, results in exacerbated immune reactivity and chronic disease course. The underlying mechanism driving this immunosuppressive function of TNFR2 remains unclear. We show here that chronic exacerbated EAE in TNFR2 KO mice is associated with increased Th17-cell responses and reduced numbers of Foxp3<sup>+</sup> Treg cells both in the spinal cord and peripheral lymphoid organs. Treg cells from TNFR2-deficient animals developing EAE show decreased proliferative and suppressive functions, both ex vivo and in vivo, and appear responsible for the exacerbated non-remitting disease, as evidenced by phenotypic rescue following adoptive transfer of Treg cells from WT but not TNFR2<sup>−/−</sup> donors. Reciprocal BM transplantation experiments between WT and TNFR2-deficient mice demonstrated that the capacity of TNFR2 to support Treg-cell expansion and function during EAE is non-intrinsic to Treg or other haematopoietic cells but requires expression of TNFR2 in radiation-resistant cells of the host. These results reveal a previously unsuspected role for non-haematopoietic TNFR2 in modulating Treg-cell expansion and immune suppression during development of autoimmunity and suggest that a similar mechanism may affect chronicity and relapses characterizing human autoimmune disease, including MS.</p></div>]]></content:encoded><description>The TNF/TNFR system exerts multiple proinflammatory and immunosuppressive functions in the pathogenesis of chronic inflammation and autoimmunity. In EAE, the experimental model of Multiple Sclerosis (MS), genetic ablation of TNFR2, results in exacerbated immune reactivity and chronic disease course. The underlying mechanism driving this immunosuppressive function of TNFR2 remains unclear. We show here that chronic exacerbated EAE in TNFR2 KO mice is associated with increased Th17-cell responses and reduced numbers of Foxp3+ Treg cells both in the spinal cord and peripheral lymphoid organs. Treg cells from TNFR2-deficient animals developing EAE show decreased proliferative and suppressive functions, both ex vivo and in vivo, and appear responsible for the exacerbated non-remitting disease, as evidenced by phenotypic rescue following adoptive transfer of Treg cells from WT but not TNFR2−/− donors. Reciprocal BM transplantation experiments between WT and TNFR2-deficient mice demonstrated that the capacity of TNFR2 to support Treg-cell expansion and function during EAE is non-intrinsic to Treg or other haematopoietic cells but requires expression of TNFR2 in radiation-resistant cells of the host. These results reveal a previously unsuspected role for non-haematopoietic TNFR2 in modulating Treg-cell expansion and immune suppression during development of autoimmunity and suggest that a similar mechanism may affect chronicity and relapses characterizing human autoimmune disease, including MS.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141871" xmlns="http://purl.org/rss/1.0/"><title>Anti IL-17A therapy inhibits bone loss in TNF-α-mediated murine arthritis by modulation of the T-cell balance</title><link>http://dx.doi.org/10.1002%2Feji.201141871</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Anti IL-17A therapy inhibits bone loss in TNF-α-mediated murine arthritis by modulation of the T-cell balance</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Karin Zwerina</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marije Koenders</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Axel Hueber</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Renoud J. Marijnissen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wolfgang Baum</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gisela Ruiz Heiland</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mario Zaiss</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Iain Mclnnes</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Leo Joosten</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wim van den Berg</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jochen Zwerina</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Georg Schett</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141871</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141871</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141871</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunomodulation</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">413</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">423</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Tumour necrosis factor alpha (TNF-α) is a major inducer for inflammation and bone loss. Here, we investigated whether interleukin (IL)-17 plays a role in TNF-α-mediated inflammation and bone resorption. Human TNF-α transgenic (hTNFtg) mice were treated with a neutralizing anti-IL-17A antibody and assessed for inflammation, cartilage and bone damage. T-cell transcription factors and lymphokine patterns were measured in the LNs. IL-17A inhibition in the absence of IL-1 was also evaluated by treating hTNFtg/IL-1<sup>−/−</sup> mice with an IL-17A neutralizing antibody. IL-17A neutralization had only minor effects on TNF-α-induced inflammation but effectively reduced local and systemic bone loss by blocking osteoclast differentiation in vivo. Effects were based on a shift to bone-protective T-cell responses such as enhanced Th2 differentiation, IL-4 and IL-12 expression and Treg cell numbers. Whereas inflammation in hTNFtg/IL-1<sup>−/−</sup> mice was highly sensitive to IL-17A blockade, no shift in the T-cell lineages and no additional benefit on bone mass were observed in response to IL-17A neutralization. We thus conclude that IL-17A is a key mediator of TNF-α-induced bone loss by closely interacting with IL-1 in blocking bone protective T-cell responses.</p></div>]]></content:encoded><description>Tumour necrosis factor alpha (TNF-α) is a major inducer for inflammation and bone loss. Here, we investigated whether interleukin (IL)-17 plays a role in TNF-α-mediated inflammation and bone resorption. Human TNF-α transgenic (hTNFtg) mice were treated with a neutralizing anti-IL-17A antibody and assessed for inflammation, cartilage and bone damage. T-cell transcription factors and lymphokine patterns were measured in the LNs. IL-17A inhibition in the absence of IL-1 was also evaluated by treating hTNFtg/IL-1−/− mice with an IL-17A neutralizing antibody. IL-17A neutralization had only minor effects on TNF-α-induced inflammation but effectively reduced local and systemic bone loss by blocking osteoclast differentiation in vivo. Effects were based on a shift to bone-protective T-cell responses such as enhanced Th2 differentiation, IL-4 and IL-12 expression and Treg cell numbers. Whereas inflammation in hTNFtg/IL-1−/− mice was highly sensitive to IL-17A blockade, no shift in the T-cell lineages and no additional benefit on bone mass were observed in response to IL-17A neutralization. We thus conclude that IL-17A is a key mediator of TNF-α-induced bone loss by closely interacting with IL-1 in blocking bone protective T-cell responses.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141880" xmlns="http://purl.org/rss/1.0/"><title>CD40 engagement of CD4+CD40+ T cells in a neo-self antigen disease model ablates CTLA-4 expression and indirectly impacts tolerance</title><link>http://dx.doi.org/10.1002%2Feji.201141880</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">CD40 engagement of CD4+CD40+ T cells in a neo-self antigen disease model ablates CTLA-4 expression and indirectly impacts tolerance</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jessica Carter</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gisela M. Vaitaitis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dan M. Waid</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David H. Wagner</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141880</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141880</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141880</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Immunomodulation</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">424</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">435</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Biomarkers defining pathogenic effector T (Teff) cells slowly have been forthcoming and towards this we identified CD4<sup>+</sup> T cells that express CD40 (CD4<sup>+</sup>CD40<sup>+</sup>) as pathogenic in the NOD type 1 diabetes (T1D) model. CD4<sup>+</sup>CD40<sup>+</sup> T cells rapidly and efficiently transfer T1D to NOD.scid recipients. To study the origin of CD4<sup>+</sup>CD40<sup>+</sup> T cells and disease pathogenesis, we employed a dual transgenic model expressing OVA<sub>323–339</sub> peptide as a neo-self antigen on islet β cells and medullary thymic epithelial cells (mTECs) and a transgenic TCR recognizing the OVA<sub>323–339</sub> peptide. CD4<sup>+</sup>CD40<sup>+</sup> T cells and Treg cells each recognizing the cognate neo-antigen, rather than being deleted through central tolerance, drastically expanded in the thymus. In pancreatic lymph nodes of DO11.RIPmOVA mice, CD4<sup>+</sup>CD40<sup>+</sup> T cells and Treg cells are expanded in number compared with DO11 mice and importantly, Treg cells remain functional throughout the disease process. When exposed to neo-self antigen, CD4<sup>+</sup>CD40<sup>+</sup> T cells do not express the auto-regulatory CTLA-4 molecule while naïve CD4<sup>+</sup>CD40<sup>+</sup> T cells do. DO11.RIPmOVA mice develop autoimmune-type diabetes. CD40 engagement has been shown to prevent CTLA-4 expression and injecting anti-CD40 in DO11.RIPmOVA mice significantly exacerbates disease. These data suggest a unique means by which CD4<sup>+</sup>CD40<sup>+</sup> T cells thwart tolerance.</p></div>]]></content:encoded><description>Biomarkers defining pathogenic effector T (Teff) cells slowly have been forthcoming and towards this we identified CD4+ T cells that express CD40 (CD4+CD40+) as pathogenic in the NOD type 1 diabetes (T1D) model. CD4+CD40+ T cells rapidly and efficiently transfer T1D to NOD.scid recipients. To study the origin of CD4+CD40+ T cells and disease pathogenesis, we employed a dual transgenic model expressing OVA323–339 peptide as a neo-self antigen on islet β cells and medullary thymic epithelial cells (mTECs) and a transgenic TCR recognizing the OVA323–339 peptide. CD4+CD40+ T cells and Treg cells each recognizing the cognate neo-antigen, rather than being deleted through central tolerance, drastically expanded in the thymus. In pancreatic lymph nodes of DO11.RIPmOVA mice, CD4+CD40+ T cells and Treg cells are expanded in number compared with DO11 mice and importantly, Treg cells remain functional throughout the disease process. When exposed to neo-self antigen, CD4+CD40+ T cells do not express the auto-regulatory CTLA-4 molecule while naïve CD4+CD40+ T cells do. DO11.RIPmOVA mice develop autoimmune-type diabetes. CD40 engagement has been shown to prevent CTLA-4 expression and injecting anti-CD40 in DO11.RIPmOVA mice significantly exacerbates disease. These data suggest a unique means by which CD4+CD40+ T cells thwart tolerance.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201041303" xmlns="http://purl.org/rss/1.0/"><title>Endothelial paxillin and focal adhesion kinase (FAK) play a critical role in neutrophil transmigration</title><link>http://dx.doi.org/10.1002%2Feji.201041303</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Endothelial paxillin and focal adhesion kinase (FAK) play a critical role in neutrophil transmigration</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sean A. Parsons</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ritu Sharma</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dawn L. Roccamatisi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hong Zhang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Björn Petri</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paul Kubes</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pina Colarusso</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kamala D. Patel</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201041303</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201041303</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201041303</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Innate immunity</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">436</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">446</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>During an inflammatory response, endothelial cells undergo morphological changes to allow for the passage of neutrophils from the blood vessel to the site of injury or infection. Although endothelial cell junctions and the cytoskeleton undergo reorganization during inflammation, little is known about another class of cellular structures, the focal adhesions. In this study, we examined several focal adhesion proteins during an inflammatory response. We found that there was selective loss of paxillin and focal adhesion kinase (FAK) from focal adhesions in proximity to transmigrating neutrophils; in contrast the levels of the focal adhesion proteins β1-integrin and vinculin were unaffected. Paxillin was lost from focal adhesions during neutrophil transmigration both under static and flow conditions. Down-regulating endothelial paxillin with siRNA blocked neutrophil transmigration while having no effect on rolling or adhesion. As paxillin dynamics are regulated partly by FAK, the role of FAK in neutrophil transmigration was examined using two complementary methods. siRNA was used to down-regulate total FAK protein while dominant-negative, kinase-deficient FAK was expressed to block FAK signaling. Disruption of the FAK protein or FAK signaling decreased neutrophil transmigration. Collectively, these findings reveal a novel role for endothelial focal adhesion proteins paxillin and FAK in regulating neutrophil transmigration.</p></div>]]></content:encoded><description>During an inflammatory response, endothelial cells undergo morphological changes to allow for the passage of neutrophils from the blood vessel to the site of injury or infection. Although endothelial cell junctions and the cytoskeleton undergo reorganization during inflammation, little is known about another class of cellular structures, the focal adhesions. In this study, we examined several focal adhesion proteins during an inflammatory response. We found that there was selective loss of paxillin and focal adhesion kinase (FAK) from focal adhesions in proximity to transmigrating neutrophils; in contrast the levels of the focal adhesion proteins β1-integrin and vinculin were unaffected. Paxillin was lost from focal adhesions during neutrophil transmigration both under static and flow conditions. Down-regulating endothelial paxillin with siRNA blocked neutrophil transmigration while having no effect on rolling or adhesion. As paxillin dynamics are regulated partly by FAK, the role of FAK in neutrophil transmigration was examined using two complementary methods. siRNA was used to down-regulate total FAK protein while dominant-negative, kinase-deficient FAK was expressed to block FAK signaling. Disruption of the FAK protein or FAK signaling decreased neutrophil transmigration. Collectively, these findings reveal a novel role for endothelial focal adhesion proteins paxillin and FAK in regulating neutrophil transmigration.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141826" xmlns="http://purl.org/rss/1.0/"><title>CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients</title><link>http://dx.doi.org/10.1002%2Feji.201141826</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vivien Béziat</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Olav Dalgard</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tarik Asselah</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Philippe Halfon</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pierre Bedossa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ali Boudifa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Baptiste Hervier</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ioannis Theodorou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michelle Martinot</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Patrice Debré</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Niklas K. Björkström</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Karl-Johan Malmberg</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Patrick Marcellin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vincent Vieillard</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141826</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141826</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141826</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Innate immunity</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">447</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">457</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Natural killer (NK) cells are affected by infection with human cytomegalovirus (HCMV) manifested by increased expression of the HLA-E binding activating receptor NKG2C. We here show that HCMV seropositivity was associated with a profound expansion of NKG2C<sup>+</sup>CD56<sup>dim</sup> NK cells in patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Multi-color flow cytometry revealed that the expanded NKG2C<sup>+</sup>CD56<sup>dim</sup> NK cells displayed a highly differentiated phenotype, expressed high amounts of granzyme B and exhibited polyfunctional responses (CD107a, IFN-γ, and TNF-α) to stimulation with antibody-coated as well as HLA-E expressing target cells but not when stimulated with IL-12/IL-18. More importantly, NKG2C<sup>+</sup>CD56<sup>dim</sup> NK cells had a clonal expression pattern of inhibitory killer cell immunoglobulin-like receptors (KIRs) specific for self-HLA class I molecules, with predominant usage of KIR2DL2/3. KIR engagement dampened NKG2C-mediated activation suggesting that such biased expression of self-specific KIRs may preserve self-tolerance and limit immune-pathology during viral infection. Together, these findings shed new light on how the human NK-cell compartment adjusts to HCMV infection resulting in clonal expansion and differentiation of educated and polyfunctional NK cells.</p></div>]]></content:encoded><description>Natural killer (NK) cells are affected by infection with human cytomegalovirus (HCMV) manifested by increased expression of the HLA-E binding activating receptor NKG2C. We here show that HCMV seropositivity was associated with a profound expansion of NKG2C+CD56dim NK cells in patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Multi-color flow cytometry revealed that the expanded NKG2C+CD56dim NK cells displayed a highly differentiated phenotype, expressed high amounts of granzyme B and exhibited polyfunctional responses (CD107a, IFN-γ, and TNF-α) to stimulation with antibody-coated as well as HLA-E expressing target cells but not when stimulated with IL-12/IL-18. More importantly, NKG2C+CD56dim NK cells had a clonal expression pattern of inhibitory killer cell immunoglobulin-like receptors (KIRs) specific for self-HLA class I molecules, with predominant usage of KIR2DL2/3. KIR engagement dampened NKG2C-mediated activation suggesting that such biased expression of self-specific KIRs may preserve self-tolerance and limit immune-pathology during viral infection. Together, these findings shed new light on how the human NK-cell compartment adjusts to HCMV infection resulting in clonal expansion and differentiation of educated and polyfunctional NK cells.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141924" xmlns="http://purl.org/rss/1.0/"><title>Constraints for monocyte-derived dendritic cell functions under inflammatory conditions</title><link>http://dx.doi.org/10.1002%2Feji.201141924</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Constraints for monocyte-derived dendritic cell functions under inflammatory conditions</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tünde Fekete</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Attila Szabo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luca Beltrame</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nancy Vivar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andor Pivarcsi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Arpad Lanyi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Duccio Cavalieri</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eva Rajnavölgyi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bence Rethi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141924</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141924</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141924</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Leukocyte signaling</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">458</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">469</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The activation of TLRs expressed by macrophages or DCs, in the long run, leads to persistently impaired functionality. TLR signals activate a wide range of negative feedback mechanisms; it is not known, however, which of these can lead to long-lasting tolerance for further stimulatory signals. In addition, it is not yet understood how the functionality of monocyte-derived DCs (MoDCs) is influenced in inflamed tissues by the continuous presence of stimulatory signals during their differentiation. Here we studied the role of a wide range of DC-inhibitory mechanisms in a simple and robust model of MoDC inactivation induced by early TLR signals during differentiation. We show that the activation-induced suppressor of cytokine signaling 1 (SOCS1), IL-10, STAT3, miR146a and CD150 (SLAM) molecules possessed short-term inhibitory effects on cytokine production but did not induce persistent DC inactivation. On the contrary, the LPS-induced IRAK-1 downregulation could alone lead to persistent MoDC inactivation. Studying cellular functions in line with the activation-induced negative feedback mechanisms, we show that early activation of developing MoDCs allowed only a transient cytokine production that was followed by the downregulation of effector functions and the preservation of a tissue-resident non-migratory phenotype.</p></div>]]></content:encoded><description>The activation of TLRs expressed by macrophages or DCs, in the long run, leads to persistently impaired functionality. TLR signals activate a wide range of negative feedback mechanisms; it is not known, however, which of these can lead to long-lasting tolerance for further stimulatory signals. In addition, it is not yet understood how the functionality of monocyte-derived DCs (MoDCs) is influenced in inflamed tissues by the continuous presence of stimulatory signals during their differentiation. Here we studied the role of a wide range of DC-inhibitory mechanisms in a simple and robust model of MoDC inactivation induced by early TLR signals during differentiation. We show that the activation-induced suppressor of cytokine signaling 1 (SOCS1), IL-10, STAT3, miR146a and CD150 (SLAM) molecules possessed short-term inhibitory effects on cytokine production but did not induce persistent DC inactivation. On the contrary, the LPS-induced IRAK-1 downregulation could alone lead to persistent MoDC inactivation. Studying cellular functions in line with the activation-induced negative feedback mechanisms, we show that early activation of developing MoDCs allowed only a transient cytokine production that was followed by the downregulation of effector functions and the preservation of a tissue-resident non-migratory phenotype.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141915" xmlns="http://purl.org/rss/1.0/"><title>SNARE protein expression and localization in human cytotoxic T lymphocytes</title><link>http://dx.doi.org/10.1002%2Feji.201141915</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">SNARE protein expression and localization in human cytotoxic T lymphocytes</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Varsha Pattu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bin Qu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eva C. Schwarz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bettina Strauβ</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lisa Weins</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shruthi S. Bhat</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mahantappa Halimani</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Misty Marshall</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jens Rettig</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Markus Hoth</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141915</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141915</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141915</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Molecular immunology</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">470</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">475</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The major function of cytotoxic T lymphocytes (CTLs) is to eliminate pathogen-infected and tumorigenic cells. This is mediated mainly through the exocytosis of lytic granules (LGs) containing cytotoxic components, such as perforin and granzymes at the immunological synapse (IS). The soluble NSF attachment receptor (SNARE) protein isoforms are well known to be required for vesicle exocytosis in neuronal synapses, but their potential function in CTLs is only partly understood. Here, we examined the expression of SNARE proteins before and after the activation of primary human CD8<sup>+</sup> T cells and determined their co-localization with LGs and CD3 after IS formation with target cells. We found that several key SNARE proteins in neuronal cells were not expressed in CTLs, such as syntaxin1B2 and SNAP-25. Vti1b, Stx8 and Stx16 had the highest degrees of co-localization with LGs while Stx3, Stx4, Stx6, Stx7, Stx8, Stx13, Vti1b, VAMP3 and VAMP4 co-localized with CD3. Our data provide the first complete expression profile and localization of SNAREs in primary human CD8<sup>+</sup> T cells, laying the groundwork for further understanding their potential role in T-cell function.</p></div>]]></content:encoded><description>The major function of cytotoxic T lymphocytes (CTLs) is to eliminate pathogen-infected and tumorigenic cells. This is mediated mainly through the exocytosis of lytic granules (LGs) containing cytotoxic components, such as perforin and granzymes at the immunological synapse (IS). The soluble NSF attachment receptor (SNARE) protein isoforms are well known to be required for vesicle exocytosis in neuronal synapses, but their potential function in CTLs is only partly understood. Here, we examined the expression of SNARE proteins before and after the activation of primary human CD8+ T cells and determined their co-localization with LGs and CD3 after IS formation with target cells. We found that several key SNARE proteins in neuronal cells were not expressed in CTLs, such as syntaxin1B2 and SNAP-25. Vti1b, Stx8 and Stx16 had the highest degrees of co-localization with LGs while Stx3, Stx4, Stx6, Stx7, Stx8, Stx13, Vti1b, VAMP3 and VAMP4 co-localized with CD3. Our data provide the first complete expression profile and localization of SNAREs in primary human CD8+ T cells, laying the groundwork for further understanding their potential role in T-cell function.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201041295" xmlns="http://purl.org/rss/1.0/"><title>DUSP4 deficiency enhances CD25 expression and CD4+ T-cell proliferation without impeding T-cell development</title><link>http://dx.doi.org/10.1002%2Feji.201041295</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">DUSP4 deficiency enhances CD25 expression and CD4+ T-cell proliferation without impeding T-cell development</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ching-Yu Huang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yu-Chun Lin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wan-Yi Hsiao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fang-Hsuean Liao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pau-Yi Huang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tse-Hua Tan</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201041295</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201041295</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201041295</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Molecular immunology</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">476</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">488</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The differentiation and activation of T cells are critically modulated by MAP kinases, which are in turn feed-back regulated by dual-specificity phosphatases (DUSPs) to determine the duration and magnitude of MAP kinase activation. DUSP4 (also known as MKP2) is a MAP kinase-induced DUSP member that is dynamically expressed during thymocyte differentiation. We generated DUSP4-deficient mice to study the function of DUSP4 in T-cell development and activation. Our results show that thymocyte differentiation and activation-induced MAP kinase phosphorylation were comparable between DUSP4-deficient and WT mice. Interestingly, activated DUSP4<sup>−/−</sup> CD4<sup>+</sup> T cells were hyperproliferative while DUSP4<sup>−/−</sup> CD8<sup>+</sup> T cells proliferated normally. Further mechanistic studies suggested that the hyperproliferation of DUSP4<sup>−/−</sup> CD4<sup>+</sup> T cells resulted from enhanced CD25 expression and IL-2 signaling through increased STAT5 phosphorylation. Immunization of DUSP4<sup>−/−</sup> mice recapitulated the T-cell hyperproliferation phenotype in antigen recall responses, while the profile of Th1/Th2-polarized antibody production was not altered. Overall, these results suggest that other DUSPs may compensate for DUSP4 deficiency in T-cell development, MAP kinase regulation, and Th1/Th2-mediated antibody responses. More importantly, our data indicate that DUSP4 suppresses CD4<sup>+</sup> T-cell proliferation through novel regulations in STAT5 phosphorylation and IL-2 signaling.</p></div>]]></content:encoded><description>The differentiation and activation of T cells are critically modulated by MAP kinases, which are in turn feed-back regulated by dual-specificity phosphatases (DUSPs) to determine the duration and magnitude of MAP kinase activation. DUSP4 (also known as MKP2) is a MAP kinase-induced DUSP member that is dynamically expressed during thymocyte differentiation. We generated DUSP4-deficient mice to study the function of DUSP4 in T-cell development and activation. Our results show that thymocyte differentiation and activation-induced MAP kinase phosphorylation were comparable between DUSP4-deficient and WT mice. Interestingly, activated DUSP4−/− CD4+ T cells were hyperproliferative while DUSP4−/− CD8+ T cells proliferated normally. Further mechanistic studies suggested that the hyperproliferation of DUSP4−/− CD4+ T cells resulted from enhanced CD25 expression and IL-2 signaling through increased STAT5 phosphorylation. Immunization of DUSP4−/− mice recapitulated the T-cell hyperproliferation phenotype in antigen recall responses, while the profile of Th1/Th2-polarized antibody production was not altered. Overall, these results suggest that other DUSPs may compensate for DUSP4 deficiency in T-cell development, MAP kinase regulation, and Th1/Th2-mediated antibody responses. More importantly, our data indicate that DUSP4 suppresses CD4+ T-cell proliferation through novel regulations in STAT5 phosphorylation and IL-2 signaling.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141758" xmlns="http://purl.org/rss/1.0/"><title>Role of Hedgehog signalling at the transition from double-positive to single-positive thymocyte</title><link>http://dx.doi.org/10.1002%2Feji.201141758</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Role of Hedgehog signalling at the transition from double-positive to single-positive thymocyte</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anna L. Furmanski</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jose Ignacio Saldana</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nicola J. Rowbotham</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Susan E. Ross</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tessa Crompton</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141758</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141758</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141758</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Molecular immunology</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">489</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">499</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>In the thymus, developing T cells receive signals that determine lineage choice, specificity, MHC restriction and tolerance to self-antigen. One way in which thymocytes receive instruction is by secretion of Sonic hedgehog (Shh) from thymic epithelial cells. We have previously shown that Hedgehog (Hh) signalling in the thymus decreases the CD4:CD8 single-positive (SP) thymocyte ratio. Here, we present data indicating that double-positive (DP) thymocytes are Hh-responsive and that thymocyte-intrinsic Hh signalling plays a role in modulating the production of CD4<sup>+</sup> (SP4), CD8<sup>+</sup> (SP8) and unconventional T-cell subsets. Repression of physiological Hh signalling in thymocytes altered the proportions of DP and SP4 cells. Thymocyte-intrinsic Hh-dependent transcription also attenuated both the production of mature SP4 and SP8 cells, and the establishment of peripheral T-cell compartments in TCR-transgenic mice. Additionally, stimulation or withdrawal of Hh signals in the WT foetal thymus impaired or enhanced upregulation of the CD4 lineage-specific transcription factor Gata3 respectively. These data together suggest that Hh signalling may play a role in influencing the later stages of thymocyte development.</p></div>]]></content:encoded><description>In the thymus, developing T cells receive signals that determine lineage choice, specificity, MHC restriction and tolerance to self-antigen. One way in which thymocytes receive instruction is by secretion of Sonic hedgehog (Shh) from thymic epithelial cells. We have previously shown that Hedgehog (Hh) signalling in the thymus decreases the CD4:CD8 single-positive (SP) thymocyte ratio. Here, we present data indicating that double-positive (DP) thymocytes are Hh-responsive and that thymocyte-intrinsic Hh signalling plays a role in modulating the production of CD4+ (SP4), CD8+ (SP8) and unconventional T-cell subsets. Repression of physiological Hh signalling in thymocytes altered the proportions of DP and SP4 cells. Thymocyte-intrinsic Hh-dependent transcription also attenuated both the production of mature SP4 and SP8 cells, and the establishment of peripheral T-cell compartments in TCR-transgenic mice. Additionally, stimulation or withdrawal of Hh signals in the WT foetal thymus impaired or enhanced upregulation of the CD4 lineage-specific transcription factor Gata3 respectively. These data together suggest that Hh signalling may play a role in influencing the later stages of thymocyte development.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141889" xmlns="http://purl.org/rss/1.0/"><title>Affinity maturation of antibodies requires integrity of the adult thymus</title><link>http://dx.doi.org/10.1002%2Feji.201141889</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Affinity maturation of antibodies requires integrity of the adult thymus</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mouhammed AbuAttieh</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Diane Bender</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Esther Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Peter Wettstein</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeffrey L. Platt</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marilia Cascalho</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141889</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141889</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141889</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Molecular immunology</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">500</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">510</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The generation of B-cell responses to proteins requires a functional thymus to produce CD4<sup>+</sup> T cells which helps in the activation and differentiation of B cells. Because the mature T-cell repertoire has abundant cells with the helper phenotype, one might predict that in mature individuals, the generation of B-cell memory would proceed independently of the thymus. Contrary to that prediction, we show here that the removal of the thymus after the establishment of the T-cell compartment or sham surgery without removal of the thymus impairs the affinity maturation of antibodies. Because removal or manipulation of the thymus did not decrease the frequency of mutation of the Ig variable heavy chain exons encoding antigen-specific antibodies, we conclude that the thymus controls affinity maturation of antibodies in the mature individual by facilitating the selection of B cells with high-affinity antibodies.</p></div>]]></content:encoded><description>The generation of B-cell responses to proteins requires a functional thymus to produce CD4+ T cells which helps in the activation and differentiation of B cells. Because the mature T-cell repertoire has abundant cells with the helper phenotype, one might predict that in mature individuals, the generation of B-cell memory would proceed independently of the thymus. Contrary to that prediction, we show here that the removal of the thymus after the establishment of the T-cell compartment or sham surgery without removal of the thymus impairs the affinity maturation of antibodies. Because removal or manipulation of the thymus did not decrease the frequency of mutation of the Ig variable heavy chain exons encoding antigen-specific antibodies, we conclude that the thymus controls affinity maturation of antibodies in the mature individual by facilitating the selection of B cells with high-affinity antibodies.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141940" xmlns="http://purl.org/rss/1.0/"><title>Lyn deficiency affects B-cell maturation as well as survival</title><link>http://dx.doi.org/10.1002%2Feji.201141940</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Lyn deficiency affects B-cell maturation as well as survival</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gitit Shahaf</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrew J. Gross</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michal Sternberg-Simon</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Deborah Kaplan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anthony L. DeFranco</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ramit Mehr</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141940</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141940</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141940</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Molecular immunology</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">511</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">521</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Lyn, an Src-family protein tyrosine kinase expressed in B lymphocytes, contributes to initiation of BCR signaling and is also responsible for feedback inhibition of BCR signaling. Lyn-deficient mice have a decreased number of follicular B cells and also spontaneously develop a lupus-like autoimmunity. We used flow cytometric analysis, BrdU labeling and our mathematical models of B-cell population dynamics, to analyze how Lyn deficiency impacts B-cell maturation and survival. We found that Lyn-deficient transitional 1 (T1) cells develop normally, but T2 cells develop primarily from the T1 subset in the spleen and fail to also develop directly from BM immature B cells. Lyn-deficient T2 cells either mature to the follicular B-cell type at a close to normal rate, or die in this compartment rather than access the T3 anergic subset. The ∼40% of WT follicular cells that were short-lived exited primarily by joining the T3 anergic subset, whereas the ∼15% Lyn<sup>−/−</sup> follicular cells that were not long lived had a high death rate and died in this compartment rather than entering the T3 subset. We hypothesize that exaggerated BCR signaling resulting from weak interactions with self-antigens is largely responsible for these alterations in Lyn-deficient B cells.</p></div>]]></content:encoded><description>Lyn, an Src-family protein tyrosine kinase expressed in B lymphocytes, contributes to initiation of BCR signaling and is also responsible for feedback inhibition of BCR signaling. Lyn-deficient mice have a decreased number of follicular B cells and also spontaneously develop a lupus-like autoimmunity. We used flow cytometric analysis, BrdU labeling and our mathematical models of B-cell population dynamics, to analyze how Lyn deficiency impacts B-cell maturation and survival. We found that Lyn-deficient transitional 1 (T1) cells develop normally, but T2 cells develop primarily from the T1 subset in the spleen and fail to also develop directly from BM immature B cells. Lyn-deficient T2 cells either mature to the follicular B-cell type at a close to normal rate, or die in this compartment rather than access the T3 anergic subset. The ∼40% of WT follicular cells that were short-lived exited primarily by joining the T3 anergic subset, whereas the ∼15% Lyn−/− follicular cells that were not long lived had a high death rate and died in this compartment rather than entering the T3 subset. We hypothesize that exaggerated BCR signaling resulting from weak interactions with self-antigens is largely responsible for these alterations in Lyn-deficient B cells.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141987" xmlns="http://purl.org/rss/1.0/"><title>Pim1 and Myc reversibly transform murine precursor B lymphocytes but not mature B lymphocytes</title><link>http://dx.doi.org/10.1002%2Feji.201141987</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Pim1 and Myc reversibly transform murine precursor B lymphocytes but not mature B lymphocytes</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Corinne Bouquet</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fritz Melchers</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141987</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141987</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141987</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Molecular immunology</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">522</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">532</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The proto-oncogenes <em>Myc</em> and <em>Pim1</em>, which are deregulated in many types of cancers, are known to cooperate in B lymphoma development. Here we show that overexpression of retrovirally transduced, doxycycline-inducible Myc alone in IL-7-deprived, growth-arrested pre-B cells enhanced cell cycle entry without impairing apoptosis. Overexpression of Pim1 decreased apoptosis, but had no effect on cell cycle entry. Co-expression of Pim1 and Myc inhibited apoptosis and led to IL-7-independent proliferation of the transduced pre-B cells in vitro, while blocking their differentiation to IgM<sup>+</sup> immature cells. Transplantation of Pim1/Myc overexpressing pre-BI cells into B-cell-deficient mice expanded the pre-B-cell compartments up to 100-fold within 4–8 weeks. Transformation remained dependent on the expression of both oncogenes, as removal of doxycycline in vitro and in vivo terminated proliferation and induced differentiation to IgM<sup>+</sup> B cells. In contrast, <em>Pim1</em>/<em>Myc</em>-transduced mature B cells that developed from the oncogene-transduced pre-BI cells in the absence of oncogene overexpression in vivo were not capable of long-term proliferation after induction of Pim and Myc overexpression, neither in vivo nor in vitro, neither with nor without stimulation by polyclonal activators.</p></div>]]></content:encoded><description>The proto-oncogenes Myc and Pim1, which are deregulated in many types of cancers, are known to cooperate in B lymphoma development. Here we show that overexpression of retrovirally transduced, doxycycline-inducible Myc alone in IL-7-deprived, growth-arrested pre-B cells enhanced cell cycle entry without impairing apoptosis. Overexpression of Pim1 decreased apoptosis, but had no effect on cell cycle entry. Co-expression of Pim1 and Myc inhibited apoptosis and led to IL-7-independent proliferation of the transduced pre-B cells in vitro, while blocking their differentiation to IgM+ immature cells. Transplantation of Pim1/Myc overexpressing pre-BI cells into B-cell-deficient mice expanded the pre-B-cell compartments up to 100-fold within 4–8 weeks. Transformation remained dependent on the expression of both oncogenes, as removal of doxycycline in vitro and in vivo terminated proliferation and induced differentiation to IgM+ B cells. In contrast, Pim1/Myc-transduced mature B cells that developed from the oncogene-transduced pre-BI cells in the absence of oncogene overexpression in vivo were not capable of long-term proliferation after induction of Pim and Myc overexpression, neither in vivo nor in vitro, neither with nor without stimulation by polyclonal activators.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201041038" xmlns="http://purl.org/rss/1.0/"><title>Enhanced ovalbumin-induced airway inflammation in CD26−/− mice</title><link>http://dx.doi.org/10.1002%2Feji.201041038</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Enhanced ovalbumin-induced airway inflammation in CD26−/− mice</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shuling Yan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Reinhard Geßner</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Corinna Dietel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ulrike Schmiedek</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hua Fan</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201041038</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201041038</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201041038</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical immunology</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">533</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">540</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>In this study, we investigated the potential role of CD26 in ovalbumin (OVA)-induced airway inflammation using CD26 gene knockout mice. Compared with WT counterparts, CD26<sup>−/−</sup> mice showed an obviously enhanced tissue response and denser pulmonary infiltrates containing eosinophils around vessels and in the parenchyma after OVA sensitization and challenge. Serum IgG, including subclasses IgG1 and IgG2a, was greatly reduced in CD26<sup>−/−</sup> mice, but serum IgE remained unchanged. CD26<sup>−/−</sup> mice had increased mRNA expression of the Th2 cytokines IL-4, IL-5, and IL-13 in the lungs compared with WT mice, whereas the levels of the pro-Th1 cytokine IL-12p40 were similar in both strains. Consequently, enhanced protein secretion of IL-4, IL-5, and IL-13 was detected in bronchoalveolar lavage (BAL) fluid from CD26<sup>−/−</sup> mice. In agreement with overexpressed Th2 cytokines, both mRNA transcript and protein levels of chemokines eotaxin and RANTES, as well as their receptors CC chemokine receptor 3 (CCR3) and CCR5, were elevated in CD26<sup>−/−</sup> mice. These results suggest a protective role for CD26 in restricting OVA-induced airway inflammation.</p></div>]]></content:encoded><description>In this study, we investigated the potential role of CD26 in ovalbumin (OVA)-induced airway inflammation using CD26 gene knockout mice. Compared with WT counterparts, CD26−/− mice showed an obviously enhanced tissue response and denser pulmonary infiltrates containing eosinophils around vessels and in the parenchyma after OVA sensitization and challenge. Serum IgG, including subclasses IgG1 and IgG2a, was greatly reduced in CD26−/− mice, but serum IgE remained unchanged. CD26−/− mice had increased mRNA expression of the Th2 cytokines IL-4, IL-5, and IL-13 in the lungs compared with WT mice, whereas the levels of the pro-Th1 cytokine IL-12p40 were similar in both strains. Consequently, enhanced protein secretion of IL-4, IL-5, and IL-13 was detected in bronchoalveolar lavage (BAL) fluid from CD26−/− mice. In agreement with overexpressed Th2 cytokines, both mRNA transcript and protein levels of chemokines eotaxin and RANTES, as well as their receptors CC chemokine receptor 3 (CCR3) and CCR5, were elevated in CD26−/− mice. These results suggest a protective role for CD26 in restricting OVA-induced airway inflammation.</description></item><item rdf:about="http://dx.doi.org/10.1002%2Feji.201141832" xmlns="http://purl.org/rss/1.0/"><title>Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD</title><link>http://dx.doi.org/10.1002%2Feji.201141832</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Silke Wiesmayr</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Steven A. Webber</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Camila Macedo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Iulia Popescu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Louise Smith</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jane Luce</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Diana Metes</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-01T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/eji.201141832</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/eji.201141832</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Feji.201141832</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical immunology</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">541</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">550</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Post-transplantation lymphoproliferative disorders (PTLD) are life-threatening complications of organ transplantation caused by EBV infection and the use of chronic immunosuppression. While T-cell impairment is known to play a critical role in the immunopathogenesis of EBV complications post-transplantation, the role of NK cells is still under investigation. Here, we have characterized NK-cell phenotype and function in peripheral blood from asymptomatic pediatric thoracic transplant patients, patients with PTLD, and healthy controls. Overall, asymptomatic pediatric solid organ transplant (Tx) patients presented significant expansion of the CD56<sup>bright</sup>CD16<sup>±</sup> subset and displayed effective NK-cell function, while PTLD patients accumulated CD56<sup>dim</sup>CD16<sup>−</sup> and CD56<sup>−</sup>CD16<sup>+</sup> NK-cell subsets. In addition, NK cells from PTLD patients down-regulated NKp46 and NKG2D, and significantly up-regulated PD-1. These phenotypic changes were associated with NK functional impairment, resembling cellular exhaustion. Disrupting PD-1 inhibitory pathway improved IFN-γ release, but did not enhance cytotoxicity in PTLD patients, suggesting that these defects were partially PD-1 independent. Our results indicate the important role of NK cells during EBV surveillance post-transplantation, with implications for the immunopathogenesis of EBV complications, and suggest that monitoring NK cells in transplant patients may hold clinical value.</p></div>]]></content:encoded><description>Post-transplantation lymphoproliferative disorders (PTLD) are life-threatening complications of organ transplantation caused by EBV infection and the use of chronic immunosuppression. While T-cell impairment is known to play a critical role in the immunopathogenesis of EBV complications post-transplantation, the role of NK cells is still under investigation. Here, we have characterized NK-cell phenotype and function in peripheral blood from asymptomatic pediatric thoracic transplant patients, patients with PTLD, and healthy controls. Overall, asymptomatic pediatric solid organ transplant (Tx) patients presented significant expansion of the CD56brightCD16± subset and displayed effective NK-cell function, while PTLD patients accumulated CD56dimCD16− and CD56−CD16+ NK-cell subsets. In addition, NK cells from PTLD patients down-regulated NKp46 and NKG2D, and significantly up-regulated PD-1. These phenotypic changes were associated with NK functional impairment, resembling cellular exhaustion. Disrupting PD-1 inhibitory pathway improved IFN-γ release, but did not enhance cytotoxicity in PTLD patients, suggesting that these defects were partially PD-1 independent. Our results indicate the important role of NK cells during EBV surveillance post-transplantation, with implications for the immunopathogenesis of EBV complications, and suggest that monitoring NK cells in transplant patients may hold clinical value.</description></item></rdf:RDF>
